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Abstract 
Background: Malaria remains a serious threat in the Greater Mekong Sub-region (GMS), not 
just from the direct impact on human health, but also from the emergence and spread of 
resistance to artemisinin, the last remaining effective antimalarial. Malaria control in this 
region is therefore a high priority on a global as well as local scale. In the southern region of 
the Lao People's Democratic Republic (Lao PDR) as across much of the GMS malaria vectors 
are found biting outdoors in the early evening before people are protected by long-lasting 
insecticidal nets (LLlNs). Therefore there is a need for additional malaria control tools that can 
protect people during these evening hours. 
Methods: Human landing catches in a village setting in southern Lao PDR were used to 
evaluate the protection from evening biting given by repellent lotions containing 10-20% N,N-
diethyl-m-toluamide (DEET). A randomised controlled trial was designed to test the effect of 
15% DEET against malaria. A total of 1,597 households were recruited and randomised to 
either the repellent or a placebo lotion. All households were also provided with LLiNs. The 
acceptance and compliance with the repellent lotion was assessed through exit questionnaires 
and focus group discussions (FGDs). A meta-analysis was then carried out to put the results 
from the Lao PDR in context with other repellent trials. 
Findings: All DEET concentrations provided at least 96% protection from evening biting over 
five hours. However 15% DEET was determined to be the best choice of intervention over 10% 
DEET after also considering the results of other similar trials. Intention to treat analysis of the 
randomised controlled trial found no difference between treatment arms after accounting for 
gender and socio-economic status (incidence rate ratio 0.96, 95% confidence interval 0.54-
1.71, p=O.886). According to protocol analyses of participants who used the lotions over 90% 
of the time also found no effect from repellent use after other factors had been taken into 
account (incidence rate ratio 1.45, 95% confidence interval 0.53-3.99, p=0.467). The most 
important predictor of malaria incidence was socio-economic score which indicated that lower 
wealth was significantly associated with an increased malaria risk. Although the repellent was 
well received with over 90% of participants reporting that they liked using the lotions, 
compliance was still low with fewer than 60% of participants using the lotions more than 90% 
of the time. It emerged from FGDs that the assumption that local populations were protected 
from night biting if they were provided with LLiNs was not always true. Adult men and children 
reported spending time outdoors at night hunting and fishing. The protection from malaria by 
repellent use in this trial was lower than in other randomised controlled trials carried out in 
Bolivia, Pakistan and Tanzania. The meta-analysis found that repellent use was associated with 
a 33% reduction in P. !alciparum incidence (95% CI 0.42-1.09, p=O.l1) and a 35% reduction in 
P. vivax incidence (95% CI 0.18-2.34, p=0.51), however neither figure reach significance. 
Interpretation: Limitations of this trial include the compliance level which was lower than in 
other trials. In addition the variability inherent in topical repellents may make them unsuitable 
for use as an intervention. The outcome of this trial shows that topical insect repellent is not a 
suitable wide-scale intervention against malaria and does not provide significant protection 
over and above LLiNs in an area of outdoor biting. However, repellents do undoubtedly reduce 
biting and therefore their potential to be effective intervention tools remains. Future work 
should concentrate on forms of repellent that can be better standardised such as impregnated 
clothing. If successful then further research into mosquito response to repellent is 
recommended including, where best to apply and the potential for the development of 
resistance. 
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Chapter 1: A literature review examining the suitability of 
insect repellents for reducing malaria transmission in southern 
Lao PDR. 
1.1 Abstract 
Considerable reductions in malaria parasite rates have been recorded in Southeast Asia (SEA) 
over recent years. However the disease persists in remote, hilly and forested areas which 
present unique challenges to malaria control efforts. Here mosquito vectors tend to feed 
outdoors and early in the evening meaning conventional control methods that attack vectors 
that enter houses, such as long-lasting insecticidal nets (LLlNs), do not provide complete 
protection. Insect repellent used in the evening in combination with LLiNs may provide the 
additional protection required. Five studies of insect repellent, including three randomised 
controlled trials have previously been carried out in Asia and South America. Significant 
reductions in malaria rates were recorded in three of these studies meaning the intervention 
might be effective in the Lao PDR. The highest malaria rates in the Lao PDR are found in the 
south of the country and the local malaria vectors include Anopheles dirus and An. minimus. 
Both species are associated with forest environments and transmission of malaria during 
transitory forest visits is particularly difficult to control through LLiNs alone. Insect repellents 
are suitable to reduce outdoor biting in the forest and may be an effective control method in 
southern Lao PDR. 
1.2. The global malaria picture 
Malaria is a treatable and preventable disease, but remains a serious health burden across the 
tropiCS. The World Health Organization (WHO) estimates that approximately 3.3 billion people 
currently live in areas at risk of malaria transmission, and there were 216 million confirmed 
cases of malaria in 2010 [1]. The same source reports a decrease of 18% in malaria deaths from 
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800,000 in 2009 to 655,000 in 2010. However a recent review estimates mortality to be about 
twice as high, around 1.2 million in 2010, representing a 32% decrease since 2004 [2]. Both 
sources agree that the burden of disease falls most heavily in Africa where 81% of malaria 
cases and 91% of malaria deaths occurred. 
The Roll Back Malaria (RBM) Partnership was established in 1998 in an attempt to co-ordinate 
the malaria response on a global scale. Malaria control tools currently the focus of RBM 
activities include vector control through long-lasting insecticide nets (LLlNs) and indoor 
residual spraying (IRS); chemoprophylaxis for vulnerable groups such as pregnant women; 
parasitological diagnosis and appropriate treatment with antimalarials [3]. 
Although there are nine families of antimalarials including twenty-five different drugs still in 
use, antimalarial resistance is a growing threat to successful treatment and resistance has 
arisen to all of these drugs. The history of the spread of resistance makes it clear that the 
absence of effective antimalarials will increase the incidence of both malaria cases and deaths. 
Resistance to chloroquine, sulfadoxine-pyrimethamine and mefloquine arose within the 
Greater Mekong Subregion (GMS) before spreading through India and into Africa [4-6]. It has 
even been suggested that Plasmodium !alciparum from this South-east Asian region is 
particularly prone to genetic mutation that could result in drug resistance [7]. Antimalarial 
resistance results in straightforward increases in disease burden, including increases in hospital 
admissions, mortality and anaemia [8-11] as well as potentially more frequent malaria 
outbreaks [12]. There is also an economic cost from loss of working days to the cost of novel 
drug development [13, 14]. Other more subtle impacts that have been suggested include a loss 
of confidence in public sector health care leading to an increase in the use of unregulated 
private healthcare providers who might exacerbate the problem by providing monotherapies 
or substandard or counterfeit drugs [15]. 
Artemisinins (belonging to the sesquiterpene lactones chemical family) are currently the most 
powerful antimalarials available and artemisinin resistance is relatively recent. The first 
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indication of emerging drug resistance is treatment failure and therapeutic studies in 
Cambodia and Thailand showed the first indications of a slower clearance of parasites in 
patients treated with artemisinins [15). Treatment failure can also be caused by poor patient 
compliance, insufficient dosages, drug malabsorption or poor quality or counterfeit 
antimalarials [16). However, similar results have now been found on the Thai-Myanmar and 
Myanmar-China borders [15] and the threat of artemisinin resistance is both real and 
potentially devastating for global malaria control methods. 
1.3 Malaria in the Greater Mekong Sub-region 
The Greater Mekong Sub-region (GMS) consists of Cambodia, Lao PDR, Myanmar, Thailand, 
Vietnam and Yunnan Province in Southern China. These countries have much in common as far 
as their malaria ecology is concerned, but are spread between two World Health Organization 
(WHO) regions. Therefore the GMS Roll Back Malaria Partnership was formed in 1999 to create 
a coordinated malaria control strategy across the sub-region [17). Their main aim was to 
reduce malaria deaths by 50% from the 1998 levels by 2010 as well as further reducing malaria 
morbidity and the spread of multidrug resistance. By 2007 malaria deaths had fallen by 60% 
from 2.2 to 0.8 deaths per 100,000 population alongside a 25% reduction in overall malaria 
cases [18]. These impressive improvements have partly come about through the massive 
investments in control programmes initiated by the GMS-RBM Partnership, although 
background environmental changes such as deforestation, increased urbanisation and 
increasing economic development will also have had a considerable impact [19]. 
Malaria in the GMS is strongly associated with environment as the main vectors Anopheles 
dirus Peyton & Harrison, 1979 and An. minim us Theobald, 1901 are found in forest and forest 
fringe areas [19]. Therefore the population at risk are those who live and work in or near to 
forests including forestry workers, ethnic minorities and political or economic migrants. In 
Cambodia, Thailand and Vietnam forest work has been found to increase the risk of malaria 
[20-22]. Deforestation introduces a dynamic component to this system, conversion of land-use 
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from forest to rice cultivation or rubber plantation could result in a reduction in vector 
numbers as old habitats are destroyed, or increases in particular vector species favouring the 
new breeding sites. The process of deforestation also brings a greater number of people into a 
high-risk area and could lead to an increase in malaria cases [23]. A relatively recent change in 
land-use in the GMS has been the increase in rubber-plantations, particularly Lao PDR, 
Myanmar, Thailand and Vietnam [24]. This has lead to increases in vector populations in 
Malaysia and Thailand and resulting increases in malaria have been recorded in Malaysia [25]. 
Although Plasmodium !alciparum is the predominant parasite, P. vivax causes a significant 
proportion of malaria cases meaning parasite based diagnosis is very important for correct 
treatment [3]. As well as correct diagnosis, current malaria control strategy within the GMS 
relies on treatment with artemisinin-derived combination therapies, distribution of long-
lasting insecticidal nets (LLlNs) and indoor residual spraying (IRS) [26]. 
Malaria control in the GMS faces major challenges including multi-drug resistance, counterfeit 
or substandard antimalarials, widespread population movement and poor coverage of health 
care to ethnic minorities [18]. Antimalarial drug resistance is a particular concern in Southeast 
Asia (SEA) as alleles for resistance to chloroquine spread from SEA to Africa and South America 
in the 1960s [27] and this migration pattern was repeated with pyrimethamine-resistant 
malaria [5]. At present the most effective antimalarials are artemisinin-based, resistance to 
artemisinin has already been detected on the Thai-Cambodian border and is spreading into 
neighbouring areas [28, 29]. Even more concerning are the first signs of artemisinin resistance 
genes in Plasmodium parasites in Tanzania [30]. If artemisinin-resistance spreads there would 
be no effective or reliable antimalarials, and for this reason malaria control and elimination 
where possible in SEA is a high priority. Drug misuse and counterfeiting both contribute to the 
drug resistance threat in the region. Counterfeit artesunates have been found available 
commercially in Cambodia, Lao PDR, Myanmar, Thailand and Vietnam [31, 32]. Random 
sampling in Lao PDR found that 88% of pharmacies sold counterfeit artesunates, although it 
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should be noted that these collections were carried out in 2003 before the Lao Government 
had licensed the drug so legitimate sources may have been more difficult to access [33]. 
However, samples collected in Cambodia showed that fake antimalarials were available in 
licensed as well as unlicensed shops [34]. Counterfeit artesunates can contain low levels of 
artesunate or no artesunate at all, as well as a range of other ingredients including 
paracetamol, other antimalarials and antibiotics [35]. Counterfeit artesunates could endanger 
the patient taking them, but they can also increase the spread of drug resistance either 
because they contain low doses of real antimalarials or contain artesunate alone. Irrational 
drug use is also a problem in the area, monotherapy with artesunate creates a greater risk of 
resistance as does uncompleted treatment regimes, and these problems have been 
exacerbated by the increase in private sector penetration in malaria treatment [18]. In 
addition poor storage conditions could mean even genuine artesunates become degraded and 
ineffective potentially resulting in under-dosing [36]. Movement of people for both economic 
and political reasons has resulted in the spread of parasites to new areas and the exposure of 
non-immunes to infection in highly endemic areas [37-39]. Trans-border movement in 
particular has been a challenge to national control programmes and particular focus has been 
given by the WHO to the Thai-Myanmar border and Yunnan borders [18]. The scale of 
movement is huge, in 2003-2004 there were an estimated 2-3 million migrants within the 
GMS, a number that is expected to rise with improved highway crossings and visa-free 
arrangements between countries [40]. Ethnic minorities are also disproportionately affected 
by malaria in the GMS and unfortunately cultural and language barriers create an additional 
challenge for health service providers [3, 41]. These populations have often been pushed into 
hilly, forested areas where contact with An. dirus is greater and remote locations make access 
to health services a serious challenge. 
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The malaria situation in the GMS remains a serious problem despite recent improvements in 
morbidity and mortality. The populations at risk are particularly difficult for control 
programmes to reach and failure of control in this region could have global repercussions. 
1.4 Lao PDR 
1.4.1 Geography 
The Lao PDR shares borders all other GMS countries (Figure 1.1). The Mekong River forms 
much of the border with Thailand, whilst the Chinese, Vietnamese and Cambodian borders are 
all hilly forested areas. The Lao PDR has the smallest population within the GMS, only 5.8 
million in 2007 [42]. 
N 
China + 
Myanmar 
Thailand 
200 o 200 400 Miles 
Figure 1.1 The location of the Lao PDR and surrounding GMS countries. 
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1.4.2 The burden of malaria 
In 1998 the Lao PDR had the highest malaria incidence (7.9 cases per 1,000 population) and 
mortality rate (8.6 deaths per 100,000 population) in the GMS [18]. Although in 2007 the Lao 
PDR still had the second highest incidence, this represented a substantial improvement as 
malaria rates had more than halved to 3.3 cases per 1,000 population. Malaria mortality 
improved even more and the 2007 rate of 0.2 deaths per 100,000 was amongst the lowest in 
the GMS. Within the Lao PDR the highest malaria rates are found in the two south-
easternmost provinces Attapeu and Sekong. In 1998 there were 101 cases per 1,000 in Attapeu 
and 163 cases per 1,000 in Sekong compared the national average of 55 per 1,000 [43]. 
Malaria risk factors include non-use of bed nets, sleeping away from home, visiting the forest 
and living within 2km of a suspected mosquito breeding site [44,45]. No gender bias has been 
reported in infections, but children under ten years have a significantly higher risk of malaria 
[45-47]. Current policy in the Lao PDR is for the entire population at risk, estimated to be 70% 
of the country, to receive insecticide treated nets (ITNs) and to eventually replace these with 
LLiNs [41]. Early diagnosis using rapid diagnostic tests (RDTs, Paracheck) and treatment with 
artemisinin combined therapy (ACT, coartem: Artemether and Lumefantrine) has been 
implemented nationally following pilot trials in three provinces alongside monitoring of 
artemisinin resistance, which has yet to be detected in the Lao PDR [29,41]. 
1.4.3 Malaria parasites 
Plasmodium /alciparum is the most prevalent parasite in the Lao PDR and is confirmed in over 
95% of all cases [41, 48]. The remaining cases are mostly P. vivax, but P. malariae is also 
occasionally recorded [44,49]. 
1.4.4 Local malaria vectors 
Anopheles dirus, An. jeyporiensis James, 1902, An. maculatus Rattinarithikul & Green, 1987 and 
An. minimus have all been incriminated as malaria vectors in the Lao PDR with An. dirus and 
An. minimus likely to be the most important vectors [44, 49, 50]. Members of the An. dirus 
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complex are also major vectors in Thailand, Cambodia and Vietnam [51). The complex is 
closely associated with forest environments, traditionally found breeding in forest streams [52) 
although reports of An. dirus larvae in wells may represent a recent colonisation of urban areas 
[53). It is thought that dense forest provides dry season breeding sites that allow the An. dirus 
population to persist year round. Feeding times amongst the An. dirus complex vary with 
sibling species, An. dirus s.s. and An. baimaii bite mostly at night between 21.00h-02.00h but 
An. cracens and An. scanloni are early evening biters feeding from 18.00-22.00h [52, 54). 
Anopheles minimus is also found biting in the early evening, collections from across SEA record 
peak activity from 18.00h to midnight [50, 55, 56). Both An. dirus and An. minimus will readily 
feed outdoors as well as indoors [50, 52, 56). 
1.5. Long-lasting insecticidal nets 
There are two methods of manufacture of long-lasting insecticidal nets (LLlNs), one where the 
pyrethroid insecticide is factory applied to the netting material (e.g. PermaNet, Vestergaard 
Frandsen, deltamethrin coated on polyester) and the second where pyrethroid is impregnated 
into the fibres before being woven into a net (e.g. Olyset Net, Sumitomo Chemical Co. Ltd., 
permethrin incorporated into polyethylene) [57, 58). To be classified as long-lasting the 
insecticide needs to remain active after twenty washes in the laboratory and after three years 
standard use in the field [59). There are two main mechanisms through which LLiNs reduce 
malaria transmission. The first is direct protection of the person sleeping under the net from 
mosquito biting. Nets treated with pyrethroids provide better protection than untreated nets 
as the pyrethroid prevents many mosquitoes feeding through the net and reduces entry 
through holes in damaged nets [60, 61), but this effect is lessened by insecticide resistant 
vectors and the loss of insecticide through washing or damage to nets [62, 63). Treated nets 
can also be manufactured with a larger mesh size allowing greater air passage potentially 
making them more comfortable to use. The insecticide on the nets will also kill mosquitoes 
thereby reducing both the size and age of the local mosquito population. This should have the 
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effect of reducing malaria transmission for all people in the local area regardless of whether 
they are sleeping under an LLiN or not [64]. 
Long-lasting insecticidal nets are included in current malaria control strategies in all endemic 
areas and current policy in the GMS is free distribution to all ages in high-risk populations [48]. 
Data on LLiN ownership and use are difficult to find and different sources are inconsistent, but 
the general picture shows there is much more work to be done to reach a good level of 
coverage of the entire population at risk in the GMS (Table 1.1). 
Table 1.1. Current policy towards LLiN distribution in GMS countries and coverage data where available. 
No information could be found specific to the Yunnan Province of China. 
Country Current bed net distribution policy [1] Coverage [65,66] 
Cambodia ITNs/LLINs distributed free of charge 4% of children aged <5 years sleeping 
Lao PDR 
Myanmar 
Thailand 
Vietnam 
to all age groups from 2000 
ITNs/LLINs distributed free of charge 
to all age groups from 2003 
ITNs/LLINs to be distributed free of 
charge to all age groups (no 
information on year policy to be 
adopted) 
ITNs/LLINs distributed free of charge 
to all age groups from 2008 
ITNs/LLINs distributed free of charge 
to all age groups from 1992 
under ITNs in 2005. 75% of population 
sleeping under ITNs/LLINs in high risk 
areas in 2010 
18% of children aged <5 years sleeping 
under ITNs in 2000 
5.6% of population sleeping under 
ITNs/LLINs in high risk areas in 2008 
86% of population sleeping under 
ITNs/LLiNs in high risk areas in 2011 
5% of children aged <5 years sleeping 
under ITNs in 2006 
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The evidence base for the disease reduction effect of LLiNs is fairly strong, allowing a meta-
analysis of malaria health impacts from randomised controlled trials which found that LLiNs 
can reduce clinical cases of malaria by around 50% [67]. Regardless of transmission intensity, 
LLiNs are estimated to save 5.5 lives per 1000 children protected per year. However, there has 
been discussion about the efficacy of LLiNs where vectors are exophilic and zoophilic, as they 
are in Southeast Asia. Five randomised controlled trials of LLiNs in South and Southeast Asia 
were identified from the literature and their outcomes shown in Figure 1.2 [68-72]. An overall 
P. falciparum reduction of 60% was obtained from a meta-analysis of these trials weighted by 
sample size (rate ratio 0.41, 95% CI: 0.34-0.49, p<O.OOl). Heterogeneity was low so fixed 
effects were used to calculate confidence intervals (1 2=34%, l=6.10, p=0.19). Thus despite 
concerns about their efficacy in SEA the evidence shows that they are strongly protective. 
0.10 
India (2003) 
• 
India (2009) 
• 
Pakistan 
• 
Thai border 
• 
Thailand 
• 
Combined 0.41 
(0.34-0.49) 
• 
1.00 
P. /aldparum Risk Ratio 
10.00 
Figure 1.2 The outcomes of randomised controlled trials of LLiNs in Southeast Asian countries [68-72]. 
The combined figure shown is the result of a meta-analysis of the five trials weighted by sample size. 
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LLlNs work best when mosquito vectors bite indoors and at night. Unfortunately in the GM5 
none of the malaria vectors display these behaviours [56, 73]. When malaria transmission is 
away from the village, such as in forest habitats, this also shelters vector populations from the 
community effect of LLiNs. So although LLiNs are a powerful tool against malaria, in some 
areas they may not be sufficient as a sole prevention and there is a real need for additional 
tools. 
1.6. Insect Repellents 
An insect repellent was defined in 1960 by Dethier as a chemical that "causes insects to make 
oriented movement away from the chemical source" [74]. For the purposes of this review 
however insect repellents are defined more narrowly, conforming more to Dethier's definition 
of a deterrent as a chemical that prevents feeding when placed in a location where feeding 
would normally take place, and to the common modern use of the term which is a chemical 
that deters blood-feeding insects from biting. 
Repellents are commonly applied to the skin, but can also be burnt to produce repellent 
smoke deterring insects from a space or applied to clothing or bed nets combining the chemical 
repellent with a physical barrier [75, 76]. Ideally an insect repellent should be non-toxic to 
humans, non-irritating to the skin if applied topically and non-damaging to fabrics or plastics, 
whilst at the same time being active against a wide range of insects for several hours [77, 78]. 
Barnard gives fourteen groups of biting insects and arachnids that should be the focus of 
repellent research; mosquitoes (Family Culicidae), sandflies (Phlebotominae), blackflies 
(Simuliidae), biting midges (Ceratopogonidae), horseflies and deerflies (Tabanidae), stableflies 
(Muscidae), tsetse flies (Glossinidae), reduvid or kissing bugs (Reduviidae), bedbugs 
(Cimicidae), fleas (Pulicidae), lice (Anoplura), mites (Acarina), hard ticks (Ixodidae) and soft 
ticks (Argasidae). 
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Plant-based or natural repellents are mentioned by classical Greek and Roman sources, but are 
likely to have been used throughout prehistory [79]. The most important natural repellent is 
pyrethrum derived from Tanacetum (or Chrysanthemum) cinerariaejolium flowers. Pyrethrum 
is an insecticide as well as a repellent and is commonly used as a quick knock down indoor 
spray either for personal protection or for insect sampling [76]. As it is quickly broken down in 
sunlight it has almost no residual effect when used outdoors, so is often used in combination 
with a synthetic insecticide as its exicto-repeilent effect flushes out insects from their hiding 
places ensuring they receive a lethal dose of the synthetic residual insecticide [76]. Although 
synthetic pyrethroid insecticides were derived to improve on the short residual life of 
pyrethrum, modern pyrethroids have a very different chemical structure and molecular mode 
of action to pyrethrum [80]. Other plant-based insect repellents with proven repellent 
properties include citronella (oil derived from plants of the Cymbopogon genus), lemon 
eucalyptus (Eucalyptus maculata citriodon) and neem (leaves from Azidarachta indica) [76]. 
However, ethnobotanical studies have recorded more than 1200 plants that are traditionally 
used to reduce insect biting by human populations from all over the world and very few of 
these have been tested for their repellent or insecticidal properties [76]. One such study in the 
Lao PDR recorded 91 plant species and one insect species used as insect repellents by rural 
populations from all over the country, with the most commonly recorded repellent plants 
being Nicotiana tabacum (tobacco), Sapindus rarak (soapberry) and Tadehagi triquetrum (a 
legume subshrub commonly used for cattle feed) [81]. Plant-based repellents tend to be cheap 
and easily available but often do not last long so require frequent reapplication if applied 
topically, or require a lot of material if burnt as a torch or incense. 
Synthetic repellents were first manufactured in the twentieth century, the most successful 
being DEET (N,N-diethyl-m-toluamide) developed by the United States Department of 
Agriculture in the 1950s and still the most widely used repellent today with an estimated 200 
million annual applications [77]. There are now a number of synthetic and naturally derived 
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repellent compounds either already available to consumers or in development, but it is DEET 
that is used as the gold standard for comparison [82-84]. It is effective against a wide variety of 
blood-feeding organisms: from mosquitoes and blackflies to ticks, mites and even land leeches 
[85]. 
This review is concerned with chemical repellents, but a brief mention of sonic devices is 
included here for completeness. Electronic devices claiming to repel insects from an area by 
emitting a high pitched sound first appeared in 1970 and the first experiments showing them 
to be ineffective were published in 1974 [86]. A Cochrane review including ten studies carried 
out between 1974 and 2000 found that these devices had no effect on mosquito landing rate 
in a variety of field locations and conditions [87]. 
1.6.1 DEET safety and toxicity 
DEET has been registered for commercial use for over 50 years, and is used widely across the 
world [77]. Concerns over the safety of DEET first emerged after reports of encephalopathy 
following DEET exposure, by the mid-1980s there had been six reported cases of 
encephalopathy following exposure to DEET all in girls aged 1-8 years which had resulted in 
three deaths [88]. However the role of DEET in either the illness or deaths was speculative. Ten 
years later there had been a further eight cases of nervous system toxicity following DEET 
exposure; no gender bias was found across all fourteen cases, but all except one involved 
children under 8 years [89]. These cases prompted a number of reviews and investigations of 
DEET safety. 
Of 9,000 calls relating to DEET exposure that were made to American Poison Control Centres 
from 1985-9, almost 90% were treated solely at home and 80% of those referred to a health 
centre were discharged after initial examination suggesting mild or short-lived symptoms [90]. 
The severity of symptoms was found to be more closely related to the type of exposure 
(inhalation or contact with eyes caused greater symptoms) than the concentration of DEET, or 
the age or gender of the patient. Laboratory tests have found no reproductive, neurotoxic, 
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oncogenic or mutagenic effects from DEET use [91]. Animal testing helped establish a no-
observed-effect-Ievel for DEET of 200 mg per kg body weight for acute toxicity and 500 mg per 
kg body weight per day for chronic toxicity, both of which are much higher than estimated 
average exposures in people [92]. During a clinical trial of DEET for the prevention of malaria in 
pregnant women, no adverse neurological, gastrointestinal or dermatological effects were 
reported in the women and neither were there any adverse effects on survival or development 
of the babies at birth or one year [93]. As part of a re-registration decision The United States 
Environmental Protection Agency concluded that it was not possible to identify DEET as the 
cause of the seizures or encephalopathy and that there was no unreasonable risk to human 
health if used according to product instructions [94]. DEET is now considered very safe for 
topical use, although it would be prudent to protect younger children from overexposure 
bearing in mind the seizures that prompted the first safety concerns. 
1.6.2 DEET mode of action 
Despite its long history and widespread use, the precise mode of action of DEET is not well 
understood and a number of theories have been tested. Potential modes of action include the 
inhibition of host signal detection, direct detection activating avoidance behaviour, 
overloading sensory input so that host signals are lost, or changing host odours to confuse host 
recognition [95,96]. 
Olfactory receptors (OR) are found on the antennae and maxillary palps of mosquitoes [97]. 
Some are used to detect host odours such as two found in An. gambiae Patton, 1905 which 
detect indole and 1-octen-3-01, compounds found in human sweat [98]. The electrical response 
to 1-octen-3-01 OR is reduced when DEET is introduced alongside 1-octen-3-01 [99]. The same 
experiment with carbon dioxide sensitive olfactory neurones found no change in response. So 
it would appear that if DEET inhibits host detection, it only works to confuse certain host 
odours. An odorant receptor has been identified in Culex quinque!asciatus Say, 1823 that 
responds directly to DEET which supports the hypothesis that DEET directly induces avoidance 
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behaviour [96]. Also in support of this hypothesis, laboratory-reared DEET-insensitive 
Stegomyia aegypti (formerly Aedes aegypti, Linneaus, 1762) have been shown to have reduced 
electrical antennal responses to DEET with no interference with the response of the 1-octen-3-
01 olfactory receptor [100J. Antennal response does not allow direct prediction of behaviour 
response so bioassays are also required to determine whether the detection of DEET actually 
provokes a particular behaviour. Stegomyia aegypti respond to lactic acid, another component 
of human sweat, as an attractant and have no behavioural response to DEET alone, however a 
combination of DEET and lactic acid acts as a repellent rather than an attractant [101]. 
These results suggest that some mosquitoes can directly detect DEET and that it does affect 
the detection of some host odours. However mosquito species and genera differ in their 
behavioural response to DEET, so it is possible that the mode of action differs between 
species. Equally, the mode of actions of other repellents may be different from DEET [95]. 
1.6.3 Human-mosquito-Plasmodium interaction effects on repellency 
There is some evidence that DEET may break down faster when used by women compared to 
men. Anopheles stephensi Liston, 1901 were equally attracted to male and female volunteers, 
but 90% protection from a 32% DEET repellent lasted for significantly longer in men, 9 hours 
compared to 6 hours in women [102J. In a situation where women were at greater risk of 
malaria infection or malaria morbidity and mortality, an extremely stable DEET formulation 
would be desirable. In the GMS and the Lao PDR this is not the case [20-22,44, 46, 47] so a 
DEET repellent would be suitable for malaria control, although field test should include both 
men and women. 
Plasmodium-infected mosquitoes are more persistent biters than uninfected mosquitoes [103, 
104]. However infection status does not seem to affect response to DEET and the effective 
dose of DEET required to protect against P. falciparum-infected An. stephensi was similar to 
that required for uninfected mosquitoes [105]. The proportion of infective An. funestus Giles, 
1900 caught in Kenyan field trials was the same from collectors using 5% DEET and ethanol 
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controls, with a repellency of 49% over 10 hours [106]. Therefore the reduction in biting 
measured in field experiments is equally applicable to infected and uninfected mosquitoes, 
and an effective repellent is a suitable method of preventing biting from Plasmodium infected 
mosquitoes and reducing malaria transmission. 
The uptake of personal protection methods has been shown to be closely related to biting 
pressure. In The Gambia at least 30-49 mosquitoes per person per night were required to 
produce over SO% bed net coverage and the uptake of space repellents was also correlated 
with mosquito density although only amongst families that did not use bed nets [107]. 
Mosquito collections in villages in Lao PDR have not reported overall mosquito biting rates 
only anopheline biting rates, although a study covering sites in eight provinces found 50-S0% 
of collections were culicines [lOS]. Mosquito biting rates in the forest where malaria 
transmission occurs are also unavailable. Therefore even if topical repellent is acceptable to 
local people, close monitoring of patterns of use are desirable to determine whether people 
chose to use the repellent in high risk areas such as the forest where impact on malaria would 
be greatest. 
1.6.4 Laboratory testing of repellents 
The efficacy of a repellent is measured either by the complete protection time (CPT), the time 
between application of a repellent and first mosquito landing, or by effective dose, the dose 
required to protect from a percentage of mosquitoes (so EDso is the dose required to protect 
against 50% of biting and ED999 is the dose required for almost complete protection). The WHO 
Pesticide Evaluation Scheme (WHOPES) has provided guidelines for arm-in-cage evaluation of 
CPT and effective doses [S4], however a literature search found no experiments in which these 
conditions were rigidly followed (Table 1.1). A common deviation from WHOPES 
recommendations is the definition of treatment failure in CPT experiments. Treated arms are 
exposed to mosquito cages until a single bite is recorded, but experimenters have regularly 
used up to four bites to define treatment failure [109-113]. Both effective dose and CPT can be 
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affected by mosquito species, number of mosquitoes in the cage and cage size. According to 
WHOPES the number of mosquitoes in a cage can vary from 50-100 to estimate effective doses 
and 200-250 to estimate CPT. Experiments with s. aegypti and An. quadrimaculatus Say, 1824 
using 50-2,600 mosquitoes per cage found that higher mosquito numbers decreased CPT 
against An. quadrimaculatus but had little effect on protection from S. aegypti [109]. A larger 
cage size decreases protection time against S. aegypti biting, but in An. quadrimaculatus the 
longest protection time was recorded in medium sized cages [109]. Mosquito species can also 
have a huge impact on response to repellents. In a comparison of 18 mosquito species and 
strains the highest tolerance to DEET was recorded in An. albimanus Wiedemann, 1820 
(EDso=O.076 mg/cm2 ) and differing by almost seven times the lowest tolerance was ex. pipiens 
Linnaeus, 1758 (EDso=O.Ol1 mg/cm2) [114]. This comparative low sensitivity of anophelines to 
DEET compared to other genera is consistent with other studies [115-118]. 
Figure 1.3 shows the CPT from different concentrations of DEET using laboratory conditions 
similar to those described above and these tests suggest that a concentration of DEET above 
35% would be required to give at least two hours of complete protection against An. dirus 
biting [111, 112]. However the density of mosquitoes is much higher than that found in the 
field leading to an underestimate of real world protection. Laboratory evaluation of repellents 
allow standardised comparisons of different repellent compounds and formulation, but field 
trials are required to estimate protection. 
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Figure 1.3. Mean ± SE of complete protect ion t ime of 5-75% DEET formulations against An. dirus . 
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Table 1.2 Methods used during laboratory testing of repellents compared to WHO PES recommendations. 
Study Exposure time Rest interval Treatment failure Mosquitoes in cage Mosquito species Outcome (mean CPT, m inutes) 
WHOPES guidelines (84) 3 minutes 30-60 minutes 1 bite 200-250 mUltiple genera 
5-180+ (20% DEET) 
5-240+ (33% DEET) 
An. dirus 
Frances, 1993 (111) 5 30 3 200 40-240+ (35% DEET) 
S. albopicta 
>180 (50% DEET) 
>300 (75% DEET) 
<5-37.5 (5% DEET) 
Frances, 1996 (112) 5 30 3 25-200 An. dirus 7.5-172.5 (10% DEET) 
105-285 (20% DEET) 
Barnard, 1998 (109) 3 90 1 
An. quadrimaculatus 
100-1300 270-480 (25% DEET) 
S. aegypti 
An. dirus 
Cx. quinque!asciatus 
Thavara, 2001 (113) 3 30 2 250 348-870 (20% DEET) 
Cx. tritaeniorhynchus 
S. aegypti 
88.4 (4.75% DEET) 
112.4 (6.65% DEET) 
Fradin, 2002 (110) 1 5-15 1 10 S. aegypti 
234.4 (20% DEET) 
301.5 (23 .8% DEET) 
120 (10% DEET) 
Carroll, 2006 (119) 1 30 4 200 S. aegypti 
480 (30% DEET) 
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1.6.5 Field testing of topical repellents 
Field trials give a more useful measure of a repellent's efficacy when used in a real situation 
and usually measure percentage repellency compared to an untreated control using human 
landing catches [84]. Field trials can also give the duration of a repellent's effectiveness by 
comparing hourly repellency from application. Although DEET concentration is a factor in the 
duration of repellency the formulation can have a marked effect as well. A comparison of two 
commercial products of 34.6% and 40% DEET found that the lower concentration actually 
performed better over six hours most likely because it was in a more stable formulation [120]. 
A recurring design problem with field trials is the proximity of treatments and controls. If 
collectors are too close mosquitoes are diverted from treatment to control artificially 
distorting the difference between the catches. This diversion effect is recorded in pairs sitting 
1m apart but the limit of the effect has not yet been tested [121]. A separation distance of 
about 15m is recommended based on what is thought to be the limit of short range attraction 
for host-seeking mosquitoes and WHOPES guidelines say 20m [122, 123]. However as is clear 
from Table 1.3 most trials have used a smaller distance if they reported it at all. In field trials 
using a separation of treatment and control over Sm, DEET concentrations of over 15% have 
been sufficient to produce repellency rates over 85% [124, 125]. 
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Table 1.3. Locations, methods and repellency for field trials in GMS countries including DEET repellents. 
DEET Collection Distance from Hours post Repellency 
Country 
concentration period treatment to control application (%) 
21.00-01.00h 5m 8 77.6-98.9 Malaysia 
7.5% 
09.00-17.00h 5m 8 46.9-100 [124) * 
19.00-04.00h <1m ** 9 100 Thailand 
10% 
09.00-17.00h <1m ** 8 90.2-100 [85) 
21. 00-0 1. OOh 5m 8 91.5-100 Malaysia 
09.00-17.00h 5m 8 85.2-100 [124)* 
15% 
Vietnam 
18.00-06.00h 'near' 12 85 
[126) 
09.00-17 .00h 1m 8 94-100 Thailand 
20% 
19.00-24.00h 1m 5 94.2-100 [113) 
20% DEET and Thailand 
18.00-24.00h 10m 6 98.2-99.6 
0.5% permethrin [125) 
Thailand 
25% DEET 18.00-02.00h Not reported 7 58-93 
[112) 
Vietnam 
27% DEET 18.00-06.00h 'near' 12 93 
[126) 
Thailand 
33% DEET 18.00-24.00h Not reported 4-9 87.1-100 
[127) 
Thailand 
50% DEET 18.00-24.00h Not reported 4-9 80.8-100 
[127) 
Thailand 
75% DEET 18.00-24.00h Not reported 4-9 84.6-100 
[127) 
*DEET applied to one side of body only and another repellent to the other. 
.. DEET applied to one side of body and control was other side 
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1.6.6 Repellents as a malaria intervention 
There have been few randomised control trials of insect repellent used to reduce malaria. One 
of the first used a repellent soap containing 20% DEET and 0.5% permethrin randomised to 
matched pairs of communities in Ecuador and Peru [128). Self-reported malaria incidence 
decreased in both intervention and control communities in Ecuador and increased in both in 
Peru, with no statistical difference between treatment arms. In Thailand a local cosmetic, 
thanaka (Limonia acidissima), was combined with 20% DEET and used as a mosquito repellent 
by pregnant women in a Karen refugee camp [129). The incidence of actively detected P. 
jalciparum in women using DEET and thanaka was 28% lower than in those using only thanaka, 
but this was not statistically significant. The incidence of P. vivax was 9% lower in the repellent 
group, but again this did not reach statistical significance. Repellent soap (20% DEET and 0.5% 
permethrin) and a placebo lotion were randomised to households in an Afghan refugee camp 
in Pakistan. This trial found a 58% reduction in P. jalciparum incidence which did reach 
statistical significance [130]. No effect was demonstrated for P. vivax infections, although this 
may have been masked by relapsed cases. In a household randomised controlled trial in 
Bolivia, use of a repellent lotion containing 30% p-menthane-3,8-diol (PMD, a repellent 
compound found in lemon eucalyptus, Eucalyptus maculata citriodon) was associated with a 
statistically significant 80% in P. vivax incidence and a non-significant 82% reduction in P. 
jalciparum incidence compared to 0.1% clove oil controls [131]. Finally, a case-control study of 
repellent soap (20% DEET and 0.5% permethrin) in Afghanistan found a significant 92% 
reduction in the odds of malaria associated with repellent use in the ten days prior to an 
infection after accounting for use of bed nets and other factors [132). 
Low malaria rates in both Thailand and Bolivia mean that although reductions in malaria were 
recorded these did not reach statistical significance. In Peru and Ecuador there were problems 
with the formulation of the repellent used, in hot and humid climates it became difficult to use 
and compliance was even further reduced because only about 50-70% of the required amount 
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was provided to families each month. These trials show little overall statistically significant 
effect on malaria rates from repellent use (Fig. 1.3). However non-significant reductions in 
malaria are explainable by flaws in study design and small sample sizes so the effect of 
repellent on malaria is not fully explored. 
All of these trials used topical repellents, and there have been no published studies of the 
effectiveness of other forms of repellents such as space repellent or impregnated clothing. The 
most common use of repellent clothing is by the armed services, so there is a good data to 
show the effectiveness of these interventions at reducing biting from a range of biting insects 
[133, 134]. As troops tend to use chemoprophylaxis alongside other interventions, their 
efficacy at disease prevention in the field is not so well studied and failure often linked to non-
compliance [135]. Although the literature on the effectiveness of topical insect repellent is 
small, there is a huge gap in knowledge of the efficacy of these other repellent delivery 
systems. 
As disease control interventions, repellents have the advantage of being able to protect users 
outdoors while they are still active. However they have drawback in that the length of 
protection can be short, requiring reapplication. In addition when used to prevent disease 
transmission, they can divert biting to non-users thereby increasing disease risk for these 
people. If no humans are available diverted mosquitoes are likely to feed on animals, and this 
has been shown even in extremely anthropophilic mosquito species An. gambiae s.s. [136]. A 
mathematical model of repellents used to prevent malaria found compliance to be the most 
important variable in their success as an intervention [137]. 
1.7. Discussion 
The current malaria control strategy in the Lao PDR relies on free distribution of LLiNs 
alongside free diagnosis and treatment with ACTs [48]. The most important barrier to the use 
of repellents by people in malaria endemic areas is probably cost [79]. One of the first 
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attempts to produce a low cost and effective repellent formulation was 20% DEET and 0.5% 
permethrin soap, which is lathered and left to dry on the skin. Although early trials showed 
promising results, its efficacy is reduced by physical activity and sweating and many users 
found the formulation uncomfortable to wear [128, 138, 139]. At present insect repellents are 
only recommended and widely used by tourists and military personnel visiting endemic 
countries [140]. 
Although the numbers of cases and deaths caused by malaria in the GMS seems low when 
compared with the scale of the disease elsewhere, the threat of antimalarial resistance which 
would have global implications makes malaria control in this area a very high priority. The 
southern provinces of the Lao PDR have relatively high malaria rates and are geographically 
very close to the Thai-Cambodian border where antimalarial resistance has emerged before. 
Although researchers have struggled to demonstrate an impact on malaria transmission from 
repellent use, two recent randomised controlled trials have found major reductions in malaria 
associated with DEET and PMD. 
1.8 Study rationale 
Southeast Asian malaria vectors are known to bite outdoors and in the evening as well as 
indoors during the night, meaning LLiNs may only provide partial protection from malaria 
transmission. Repellents used during the evening could provide additional protection over that 
given by treated bed nets. Following the encouraging results of similar trials in Bolivia and 
Pakistan, this trial aims to establish whether Southeast Asian malaria vectors can also be 
prevented from transmitting malaria by the use of insect repellent. 
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1.9 Aims and objectives 
The overall aim of the study is to determine whether insect repellent are a suitable 
intervention against malaria in southern Lao PDR. The specific objectives are: 
1. To establish the most appropriate concentration of DEET for use during evening hours 
against local vector species in the Lao PDR. 
2. To design a household randomised controlled trial to test the effectiveness of 
repellent lotion to reduce malaria incidence. 
3. To compare baseline socio-economic data to ensure randomisation has been carried 
out fairly. 
4. To monitor compliance with repellent use throughout the trial. 
5. To monitor adverse reactions to repellent use throughout the trial 
6. To investigate acceptance of repellents as an intervention tool by local communities. 
1.10 Study Management 
The trial design, management, data collection and analysis was the work of a large team of 
collaborators, so this section aims to make clear the different roles of the people involved. The 
trial concept was developed by Nigel Hill and Ilona Carneiro at the London School of Hygiene & 
Tropical Medicine (LSHTM) following a repellent trial in Bolivia. PSI Laos are a social marketing 
organisation who joined with LSHTM to host the repellent project in the Lao PDR. The study 
protocol was developed by the Repellent Trial Manager, Vanessa Chen-Hussey (VCH), and 
approved by PSI Laos and the Lao Ministry of Health. Trial materials such as questionnaires and 
databases were developed by VCH and translated by Santi Sayarath (SS) the Project Co-
ordinator. Prior to the start of data collection, Dr Hongkham Keomanila (DH), a representative 
from the Lao Ministry of Health's Center for Malariology, Parasitology and Entomology was 
assigned to liaise with the project. Training of field staff was carried out by VCH, SS and DH. 
Data collection was largely carried out by district health staff and village health workers who 
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made monthly visits to perform rapid diagnostic tests, questionnaires and distribute repellent 
and placebo lotions. VCH, SS and DH visited each of the eight districts once each month to 
observe village surveys. Support for these visits was commonly supplied by Field Operations 
Officers from PSI Laos. Evening sniff checks were also carried out by VCH, SS and DH during 
these field visits. Entomological data collection was carried out by VCH, DH and two MSc 
students from LSHTM, Crystal Lee and Sarah Deraedt. All data were double entered, with the 
first set being completed by VCH and SS and the second by an independent data entry 
company, Viengkham Soomsaath. Data cleaning and analysis was carried out by VCH. Financial 
management and administrative support were provided throughout the two years of the trial 
by the finance and administration teams in PSI Laos. 
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Chapter 2: Entomological surveys to assess the efficacy of N,N-
diethyl-m-toluamide (DEET) to reduce malaria transmission in 
southern Lao PDR. 
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2.1 Abstract 
The main Southeast Asian malaria vector species bite outdoors and in the early evening before 
people are protected by long-lasting insecticidal nets. Insect repellent used in the evening 
could therefore help prevent malaria transmission. In order to support a clinical trial of N,N-
Diethyl-m-toluamide (DEET) used to prevent malaria transmission, we carried out 
entomological studies in southern Lao PDR to assess the effectiveness of DEET against local 
mosquito species. Routine entomological surveys using light traps and larval sampling were 
carried out in July 2009 to gather background information on the species found in the study 
area. In July 2010 human landing catches with 0%, 10%, 15% and 20% DEET were carried out 
over sixteen evenings from 17.00h to 22.00h in a Latin-square rotation to compare the efficacy 
of these concentrations. All DEET concentrations tested gave significant protection from biting 
compared to the placebo over the five hours of testing. After controlling for night and collector 
variation, 10% DEET gave 96.1% protection (95% CI. 92.4-99.0%), 15% DEET provided 98.9% 
protection (95% CI. 96.0-100%) and 20% DEET gave 98.1% protection (95% CI. 95.0-100%). 
The greater variation found in the protection from 10% DEET means that 15% would be a safer 
recommendation for use in the repellent trial, where environmental conditions were much 
more variable and repellent use was mostly unsupervised. 
2.2 Introduction 
Within the Greater Mekong Subregion (GMS) malaria is largely a rural disease, affecting poor 
and remote populations; it is highest in border regions which tend to be forest or forest fringe 
areas with low population densities [18, 141]. In the ten years since the Mekong Roll Back 
Malaria Initiative was created malaria cases have fallen by a quarter and malaria deaths by 
almost two thirds [18]. However it is possible that these improvements are more the 
consequence of deforestation, economic development and improved basic healthcare rather 
than malaria specific interventions [18]. Control is currently focused on parasite-based 
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diagnosis of cases, treatment with artemisinin-derived combination therapies, distribution of 
long-lasting insecticidal nets (LLlNs) and indoor residual spraying [3, 18]. The region faces 
major challenges to malaria control including multidrug resistance, counterfeit antimalarials, 
widespread population movement and poor health care coverage [18]. The malaria situation in 
the Lao PDR follows this pattern affecting poor, remote, rural populations, and is highest in 
southern provinces [141]. The main malaria vectors in southern Laos are Anopheles dirus, An. 
minimus and An. maculatus [44, 50, 142]. All three species bite outdoors, although An. 
maculatus is the only one to show a strong preference for exophagy [44, 50, 56, 143-149]. The 
peak biting time of An. minimus and An. maculatus can start as early as 18.00h [50, 144, 146, 
148, ISO, 151]; although An. dirus feeds later, peaking between 21.00h and 23.00h [44,49, 50, 
54]. Vector feeding outdoors and in the early evening means LLiNs would only provide partial 
protection from malaria transmission. Insect repellent could protect against mosquito biting 
during the evening hours when people are not yet protected by their bed nets. This is the 
rationale behind an intervention trial of 15% DEET in southern Lao PDR used to prevent 
malaria; the repellent is to be used in the evening alongside LLiNs at night (Chapter 3: Study 
protocol). 
Although field testing of repellents in GMS countries has been carried out before [85, 112, 124, 
125, 127], these tests were necessary to test the DEET formulation used in the trial under local 
conditions in Lao PDR. In addition most trials have been carried out at night or during the day, 
with little data from the early evening hours that are particularly relevant to the trial. As the 
repellent protection in the intervention trial would only be needed for a few hours, lower 
concentrations of repellent could be more appropriate. Although DEET is considered very safe 
and has been used by millions of people worldwide for over 50 years [77], concerns over its 
safety were raised in the 1990s after it was identified as a potential trigger of seizures in a 
small number of young children [88, 89]. Multiple studies found little risk from normal use 
(application to skin of commonly applied doses) of DEET [90-94]. However, as no other cause 
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was definitively identified for the seizures it is desirable to use the lowest effective 
concentration in an intervention trial involving long term DEET exposure. This study set out to 
determine whether low doses of DEET are effective against local vectors in the Lao PDR. 
2.3 Methods 
2.3.1 Study Location 
Collections were carried out in and around Gueng Makheua village (140 44' 32" N, 1060 58' 20" 
E) and a newer expansion to the village, Makheua Neua, in Attapeu province in southern Lao 
PDR (Figure 2.1). The village is the central point of four villages, so although its population is 
only around 900, it has a health clinic and a school. Mosquitoes were also collected from two 
houses surrounded by rice fields about 3km from Gueng Makheua. These houses allowed 
village residents to live near their crops throughout the planting and harvest seasons. The 
number of people in these two houses during surveys varied between two and eleven people. 
Both rice fields and village were surrounded by open canopy forest. 
Site of rice 
field survey 
lkrn 
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Figure 2.1 Mosquito sampling locations: Gueng Makheua and Makheua Neua villages and rice field site. 
2.3.2 Surveys of the local mosquito population 
In an attempt to help identify sites with high numbers of vectors, both larval and adult 
mosquito surveys were carried out. Larval surveys were carried out using larval dippers to 
sample all aquatic habitats within Gueng Makheua, in the forest surrounding the village and 
from the rice fields nearby. Ten dips were taken from each habitat identified: roadside ditches, 
temporary flood pools around the river, undisturbed buffalo wallows and the edges of small 
streams. CDC light traps were set in randomly selected houses throughout the village from 
19.00h to 07.00h from 3'd_29th July 2009 and th_21st July 2010. Traps were placed at a height of 
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l.sm and were O.sm from the foot end of an occupied bednet. Twelve all night human landing 
catches were carried out from the 10th to 21st July 2009. These catches aimed to ascertain 
biting density overnight to give a basis for sample size calculations for subsequent catches and 
to determine whether biting was higher in the village or rice field. Collections were carried out 
from 18.00h to 06.00h with a 15 minute break every hour, alternating each night between the 
village and rice field. 
2.3.3 Human Landing Catches 
Human landing catches were carried out from 5th_23'd July 2010 (no collections on the 20th_22"d 
July due to collector illness). Eight catchers were seated at 10m intervals along one of the 
roads in Makheua Neua (Figure 2.1) for sixteen nights. Collectors kept the same position each 
night. Three concentrations of DEET were tested as well as the control lotion. Previous 
repellent trials have used 20% DEET [129, 130, 132], so this concentration was tested alongside 
two lower concentrations 15% and 10% DEET. The control and 15% DEET concentrations from 
the repellent trial (formulated and supplied by SCJohnson, USA) were tested. The 10% and 20% 
DEET concentrations were mixed from a commercially available 50% DEET product (Boots 
Pharmaceuticals Repel Insect Repellent, Nottingham, UK) and moisturising lotion (E45 lotion, 
Reckitt Benckiser, Berkshire, UK). Two bottles of each of the four treatments were made up 
and randomly labelled A-H. The key to the code was kept in a sealed envelope in the field 
laboratory and not opened until after data analysis was complete. The eight collectors were 
randomly assigned to one of the eight treatments over the sixteen nights according to two 8x8 
Latin squares [152]. Each collector applied 10ml of lotion to their lower legs and arms at 
16.45h and wore shorts and shirts that covered them to the knee and elbow. Volunteers 
collected mosquitoes from their exposed skin from 17.00h to 22.00h with a ten minute break 
each hour. 
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2.3.4 Data Analysis 
The count data from landing catches were log transformed, and background biting estimated 
by geometric mean of control catches. A blinded analysis was performed first: the log 
transformed data were used to build a mixed effects model including date as random factor 
parameter, and collector (or location) and treatment A-H as fixed effects. Pairwise 
comparisons with Bonferroni corrections were used to determine whether there was 
substantial variation in catch size within each pair of treatments. To determine the effect of 
repellent concentration these analyses were repeated with the DEET concentration as another 
fixed effect. Percentage protection from biting was calculated from nightly counts and 
compared using Wald tests on the rate ratios of treatment to controls. Statistical analyses 
were performed on STATA 11 (Texas, USA). 
2.4 Results 
2.4.1 Local Mosquito Population 
Mosquitoes belonging to 13 genera were captured by light trap and landing catches. 
Anopheles, Culex and Stegomyia were identified to species by morphology, and there were 49 
species including 25 anopheline species in the catches. Twenty-two of these species are 
incriminated as disease vectors either in Laos or elsewhere (Table 2.1). Culex pseudovishnui 
Colless, 1957, Cx. vishnui Theobald, 1901 and ex. whitmorei (Giles, 1904), all vectors of 
Japanese Encephalitis (JE), accounted for almost three quarters of all mosquitoes collected. 
The major malaria vectors An. dirus, An. maculatus and An. minimus were also collected 
although in very low numbers and made up only 0.3% of mosquitoes biting humans. 
Although twice as many mosquitoes were caught by light traps in the rice field houses than in 
village houses (z=-17.67, p<O.OOl) the human landing collections found the opposite with 
almost three times as many mosquito caught in the village per man hour (z=2.61, p=0.009). 
Most mosquitoes were collected from outdoor catches in the village (Table 2.2, X2=17.5, 
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p<O.OOl). Although low catches meant the differences did not reach significance, it was 
decided that the repellency field trials should be carried out in an outdoor village setting. 
Table 2.1 Average catches of key vector species by CDC light trap (n = 301 trap-nights) and human 
landing collections (n = 784 man-hours). Full data for all species in Appendix C. 
Species CDC HLC Disease 
Anopheles barbirostris van der Wulp, 1884/ 
0.030 0.001 Malaria 
campestris Reid, 1962* 
An. cu/iei/aeies Giles, 1901 0.007 0.000 Malaria 
An. dirus Peyton & Harrison, 1979 0.007 0.000 Malaria ** 
An. jeyporiensis James, 1902 0.013 0.000 Malaria ** 
An. kochi Donitz, 1901 0.146 0.000 Malaria 
An. maculatus K / sawadwongporni 
0.053 0.003 Malaria ** 
Rattanarithikul & Green, 1987* 
An. minimus Theobald, 1901 0.033 0.000 Malaria ** 
An. subpictus Grassi, 1899 0.010 0.000 Malaria 
Armigeres spp. 0.907 0.056 Filariasis 
Culex bitaeniorhynchus Giles, 1901 0.010 0.000 JE 
Cx. /uscocephala Theobald, 1907 1.728 0.010 JE 
Cx. ge/idus Theobald, 1901 0.375 0.000 JE 
Cx. pseudovishnui Colless, 1957 10.179 0.042 JE 
Cx. quinque/aseiatus Say, 1823 0.532 0.046 JE, filariasis 
Cx. sitiens Wiedemann, 1828 3.601 0.089 JE 
Cx. tritaeniorhynchus Giles, 1901 2.203 0.001 JE 
Cx. vishnui Theobald, 1901 14.319 0.284 JE 
Cx. whitmorei (Giles, 1904) 13.987 0.023 JE 
Stegomyia albopicta (Skuse, 1895) 0.037 0.068 Dengue ** 
All Mosquitoes 50.595 0.749 
* Species not distinguishable by morphology 
Disease transmission shown for any SEA country, but ** indicates the species is a vector in 
the Lao PDR. 
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Table 2.2 Total number of mosquitoes caught indoors and outdoors in the village and rice field houses. 
Collections made over 3 nights per location, geometric mean for hourly biting rates and 95% confidence 
intervals shown in parentheses. 
Indoor 
Outdoor 
Village 
51 (GM: 1.89, 1.00-3.55) 
88 (GM: 3.78, 2.34-6.12) 
Rice field 
32 (GM: 1.19,0.53-2.63) 
12 (GM: 0.67, 0.18-2.45) 
2.4.2 Sample size for calculation for field trials 
Human landing catches during 2009 caught an average of 3.2 mosquitoes (standard deviation = 
1.9) per evening from 18.00h to 22.00h. Four treatments including the control were tested in a 
Latin square design would require a sample size of 30 man nights per arm to detect a 50% 
reduction in evening biting at the 95% significance level with 90% power (Table 2.3). To run the 
experiment over 16 nights would require two collectors per treatment arm per night. 
Table 2.3 Sample size calculations for repellent trial, numbers in bold show sample size collected. 
Mean no. mosquitoes per evening Intervention effect Man nights required 
3.2 50% 30 
3.2 70% 16 
3.2 90% 10 
3 50% 34 
2 50% 76 
4 50% 19 
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2.4.3 Time of biting 
All-night catches from the village showed clear peaks in activity in the morning and evening 
(Figure 2.2). Highest landing rates in were between 18.00-18.4Sh, the first hour of collection, 
therefore the repellent field trials were started an hour earlier to ensure good collections of 
evening biting mosquitoes. 
Collections during the repellent assays actually caught most mosquitoes between 21.00-
21.S0h. This is most likely explained by a difference in the collections of an early evening 
feeding genus Armigeres between the two years; either year on year variations or the change 
in location within the village could have caused the over 90% reduction in Armigeres numbers. 
There are clear differences between the feeding times of different genera (Figure 2.3), with 
Stegomyia and Armigeres feeding early evening and Culex starting later. Although Anophelines 
showed a biting peak mid-evening numbers were actually very low, they made up only 1.4% of 
all mosquitoes biting humans making any further analysis inappropriate. 
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Figure 2.3 Time of biting of different genera 17.00-21.S0h. Solid line shows the percentage of the total 
evening mosquito catch made at each hour. Dotted lines show the same data broken down by genera . 
2.4.4 Repellent Field Trial 
A total of 10 species were collected biting humans in the evening, 9 are incriminated disease 
vectors of malaria, JE and filariasis (Table 2.1). Almost half the catch were Cx. vishnui (46.8%), 
other common species included Stegomyia albopicta (12.4%), Cx. sitiens (12.1%) and 
Tripteroides spp. (11.6%). The repellent effect was high enough on all genera that no 
significant differences were found, but Stegomyia mosquitoes might show a reduced 
sensitivity to DEET compared to Tripteroides or Culex species (Table 2.5). 
Nightly mosquito catches on volunteers using blinded treatments A-H were significantly 
different (GLM allowing for variations in night and collector, p<O.OOl, Figure 2.4). The model 
showed that there was very little variation between collectors. Using collector 8 (who was 
closest to the geometric mean per night) as a comparison, mosquito catch varied by up to 20%, 
but the difference was significant in only two collectors. Pairwise comparisons between 
treatments A-H found that there were no significant differences between the catches using the 
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same DEET concentrations (Table 2.4) . After unblinding, bottles A and E were revealed to 
contain the control lotion and comparisons between the other treatments found that catches 
from all DEET concentrations were statistically similar. Controls caught 8.4 mosquitoes per 
evening (GM, 95% c.1. 6.4-11.0). After adjusting for variation due to night and collector, 
protection by 10% DEET was 96.1% (95% c.1. 92.4-99.0%, p<O.OOl), by 15% DEET was 98.9% 
(95% c.1. 96.0-100%, p<O.OOl) and by 20% DEET was 98.1% (95% c.1. 95.0-100%, p<O.OOl). 
Lowest repellency was recorded at the first hour of collection for all concentrations of DEET 
(Figure 2.5) possibly a sampling effect from the low background mosquito numbers, or 
alternatively because the predominant genera biting at this time, Stegomyia and Armigeres, do 
not respond as strongly to DEET. Some reduction was seen in repellency from the 10% and 
20% concentrations three hours after application. However protection never fell below 90% 
for the 15% and 20% formulations. 
Table 2.4 Pairwise comparisons of mosquito catches on volunteers using each blinded treatment. DEET 
concentrations are shown next to the bottle label in parentheses. Comparisons between the same DEET 
concentrations are shown in red and significant values indicated by *. 
A B (10%) C (20%) D (15%) E F (20%) G (15%) 
(control) (control) 
B (10%) -1.868* 
C (20%) -2.117* -0.249 
D (15%) -2 .124* -0.256 -0.007 
E (control) -0.026 1.843* 2.091* 2.099* 
F (20%) -2 .099* -0.231 0.018 0.025 -2.073* 
G (15%) -2.210* -0 .343 -0.094 -0.087 -2.185* -0.112 
H (10%) -2.067* -0.199 0.050 0.057 -2.041* 0.032 0.144 
[ntom%gv Survev~ ( ;6 
Table 2.5 Protection from different mosquito genera by the use of three topical DEET repellents. Total numbers caught on controls are shown as low catches for some genera, 
mean protection levels appear disproportionately high. 
Total number of mosquitoes % Protection (95% c.i.) 
Genera 
caught on controls 10% DEET 15% DEET 20% DEET 
Anopheles 
Including An. barbirostris / campestris 
5 100 80 (44.9-100) 100 
An. maculatus K / sawadwangpomi and 
An. philippinensis 
Armigeres spp. 8 100 87.5 (64.6-100) 100 
Culex spp. 
Including Cx. juscocephala, Cx. 
252 96 (93.6-98.4) 99.6 (98.8-100) 96.8 (94.7-99.0) 
hutchinsoni, Cx. quinquejasciatus, Cx. 
sitiens, Cx. vishnui and Cx. whitmorei 
Stegomyia spp. 
60 88.3 (80.2-96.5) 98.3 (95.1-100) 95.0 (89.5-100) 
Including Stegomyia albopicta 
Tripteroides spp. 45 97.8 (93.5-100) 100 97.8 (93.5-100) 
Total 370 95.1 (92.9-97.3) 98.9 (97.9-100) 96.8 (95.0-98.6) 
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Figure 2.5 Effectiveness of each repellent combination throughout the evening, bars show background 
level of biting. 
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2.5 Discussion 
Concentrations of DEET from 10-20% provided over 94% protection against mosquitoes biting 
in the early evening in the Lao PDR. It was not possible to measure protection against malaria 
vectors as catches of these species were very low. This is consistent with similar trials in 
Southeast Asia which have found 60-99% protection from 20-33% DEET [112, 125, 127]. The 
average biting rate on the collectors using the control lotion was 8.4 mosquitoes per person. 
This is very low when compared with some other field trials in Southeast Asia, where averages 
of 22-62 mosquitoes per person-night were recorded [85, 124, 127]. Performing repellency 
trials in areas with high mosquito numbers allows an accurate estimate of protective efficacy 
to be obtained although it is unlikely to represent the transmission levels experienced in 
Southeast Asian communities. By performing these tests within a village setting the protective 
efficacy found in our field trial is likely to reflect the degree of protection that would be 
obtained in community trials of the repellent. 
The repellent trial these tests are linked to is focused on malaria, and unfortunately malaria 
vectors were very rare in our collections. Anophelines appear to have a higher tolerance to 
DEET than other mosquitoes [114], so it is concerning that the effect of DEET could not be 
measured here. However, the fact that the repellent was very successful against general biting 
is not unimportant. In order to get people to accept and use repellents they have to be 
perceived to work (Chapter 6), therefore even reducing nuisance biting is an important factor. 
Although malaria vectors were rare, the mosquito species collected did contain many 
important disease vectors in the Lao PDR and other parts of Southeast Asia. Vectors of JE were 
actually the most abundant mosquitoes feeding on people in the study area: Cx. vishnui and 
Cx. sitiens accounted for 49.9% of the human landing collections, compared to malaria vectors 
which represented only 1.2%. The Japanese Encephalitis Virus is endemic to rural tropical 
areas of Eastern and Southern Asia, and causes epidemics in temperate areas [153]. It is a 
growing problem in countries such as the Lao PDR where there is currently no national 
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vaccination or diagnostic programme [154]. Therefore our results are likely to be relevant to 
other countries in the region such as Cambodia and Myanmar where JE is also on the increase. 
The use of insect repellents as a disease control tool is receiving increased interest, with a 
number of trials in recent years [130-132]. However, unlike LLlNs, where implementation is 
fairly straightforward, repellent use raises a number of questions: what concentration is best; 
when and where should the repellent be applied; who should use the repellent; and what form 
should the repellent take. As the necessity of these collections show, even the concentration 
of repellent may be difficult to decide on. Our intervention trial took place amongst 
agricultural workers including whole families including young children and we therefore 
wanted to identify a lowest effective concentration of DEET. But another important risk group 
in Southeast Asia are forestry workers [20,22, 155-157], who tend to be young males and who 
spend much longer periods of time in the forest. An intervention for this group may therefore 
involve a much higher repellent concentration in a formulation that is resistant to sweating, 
perhaps even applied to clothing. This means that repellent will never provide a one-size-fits-
all solution that policy makers may be looking for. But this does not mean it has no role to play: 
our results showed a near 100% reduction in biting, although demonstrating a reduction in 
disease transmission is a separate and more difficult challenge. 
All three DEET concentrations tested gave statistically equivalent protection, reducing biting by 
over 94% for five hours in the evening. Previous repellent trials have used 20% DEET [129, 130, 
132], but our results suggest that 15% or 10% would be just as effective in this rural Southeast 
Asia setting. Field trials of 10% DEET are very few; only one robust trial including 10% DEET was 
found by literature search and this was carried out in Australia [158]. Within Southeast Asia 
the only repellent trial involving a 10% DEET formulation used poor controls and it was 
therefore not possible to determine a protective effect [85]. In comparison there have been a 
number of field trials of 15% DEET in Southeast Asia [124, 126] and beyond [159-161] and our 
results are consistent with their findings. Therefore although 10% DEET performed as well as 
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20% DEET in these trials, it would be more prudent to use the 15% formulation in an 
intervention trial. 
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Chapter 3: Study protocol for a cluster-randomised controlled 
trial to assess whether the insect repellent N,N-diethyl-m-
toluamide (DEET) can provide additional protection against 
clinical malaria over current best practice in southern Lao 
PDR. 
3.1 Abstract 
Current malaria control efforts in many countries in Southeast Asia, including Lao PDR, focus 
on long-lasting insecticidal nets (LLlNs) and treatment with artemisinin-based combination 
therapy (ACTs). However, the main malaria vectors in the Lao PDR, Anopheles dirus and An. 
minim us, both feed outdoors in the evening before people might be under LLiNs and insect 
repellent could be used to prevent biting during this time. Field trials suggest that 15% N,N-
diethyl-m-toluamide (DEET) should be the lowest concentration effective over five hours. The 
study took place in Attapeu and Sekong Provinces in southern Lao PDR and was designed to 
detect whether the use of 15% DEET would result in a 50% reduction in clinical cases of malaria 
compared with the control group. The study aimed to recruit 800 households in each study 
arm. Participants were recruited primarily from rural agricultural populations who often work 
and sleep away from the village during the wet season. Either the 15% DEET or placebo lotion 
were provided for participants to use every evening. All participants were supplied with LLiNs 
which represents current best practice. Malaria cases were identified through active case 
detection using rapid diagnostic tests at baseline and at monthly intervals post-intervention. 
Data collection took place during June to December of 2009 and April to December of 2010. 
Few previous repellent trials have shown an effect on disease transmission, although in many 
cases this could be due to problems with trial design, sample sizes and repellent formulations, 
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but good promising results have come from trials in Bolivia and Pakistan. This trial aims to 
establish whether repellents could provide similar protection in a Southeast Asian setting. 
3.2 Background 
Malaria in Southeast Asia primarily affects poor, rural populations [141] and current control 
efforts focus on LLiNs and treatment with ACTs [162]. The main malaria vectors in the region 
are An. dirus and An. minimus, which both feed outdoors and in the evening before people 
might be under their bed nets [142] during which time insect repellent could be used to 
prevent biting. 
Laboratory and field trials of DEET varying in concentration from 5-75% have found that 
concentrations below 15% do not appear to give useful levels of protection against Southeast 
Asian mosquitoes [112, 113, 124, 125, 127, 132]. However, different mosquito densities and 
methodologies make comparisons between the studies difficult. 
Few trials have shown an effect on disease transmission from repellent use [128, 129, 132, 
159], although in many cases this could be due to problems with trial design, sample sizes and 
repellent formulations. A South American trial of repellent soap (20% DEET and 0.5% 
permethrin) found no significant differences between reported malaria cases in intervention 
and control groups [128]. Only 50-70% uptake of the intervention was estimated during this 
trial as the soap intervention was found to be unsuitable for active people. Repellent soap of 
the same formulation was also evaluated in Afghanistan where a 45% reduction in the odds of 
malaria infection was found in fever patients who used the soap ten days previously; this 
reduction was not statistically significant, possibly because of small sample size [132]. Similarly, 
in Thailand, a trial of 20% DEET in thanaka (a local plant-based cosmetic) against thanaka alone 
recorded a 28% reduction in Plasmodium !alciparum in the intervention group, but the trial 
was not sufficiently powered to detect a difference between this and the 15% reduction 
recorded in the control group [129]. A statistically significant 44% reduction in the odds of P. 
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falciparum infection in households given repellent soap (20% OEET and 0.5% permethrin) 
compared to a placebo lotion was recorded in Pakistan, although no effect was found for P. 
vivax infection [130]. An 80% reduction in P. vivax episodes amongst households given a 
repellent containing 30% PMO (derived from lemon eucalyptus, Eucalyptus maculata citriodon) 
compared to those given a clove oil control was found in Bolivia, but no significant effect was 
recorded for P. falciparum due to insufficient statistical power [131]. This study was designed 
to determine whether mosquito repellent applied daily to study subjects in the early evening 
can protect against malaria vectors that bite outdoors in the early evening before the subjects 
sleep under LLiNs. 
3.3 Methods 
3.3.1 Study area, house and participant eligibility 
Attapeu and Sekong are the most south-eastern provinces in the Lao POR, sharing borders with 
Vietnam and Cambodia (Figure 3.9). The Annamite mountains run along the eastern Vietnam 
border and 60% of Attapeu Province is classed as mountainous [163]. The mountainous areas 
contain dense rainforest, contrasting with the open canopy dry forest on the plains. River 
valleys are the most important areas in both provinces for agricultural production, although 
the regular floods that increase soil fertility can also destroy crops. The wet season runs from 
April to October, followed by a cool dry season from November to January and a hot dry 
season from February to March. Rice farming is the main economic activity in these two 
provinces; 57% of Attapeu's population are farmers and in Sekong the figure is even higher at 
71% [43]. 
Participants were recruited from primarily rural agricultural workers that often work and sleep 
overnight away from the village during the wet season. Participants were aged 6-60 years old 
and households had to enrol at least five eligible participants to enter the trial. In addition 
district health staff were responsible for ensuring that study houses contained at least five 
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eligible part icipants, and that study houses were distributed throughout the village, so that 
study houses were a minimum of 10m apart to prevent diversion of biting from repellent users 
to non-users [121]. 
China 
Vietnam 
Q 
Thailand 
Cambodia 
Figure 3.1. The Lao PDR with neighbouring GMS countries. Sekong and Attapeu Provinces indicated. 
3.3.2 Sample Size Rationale 
The only reliable epidemiological data from the study area prior to the start of the trial was 
32% prevalence of P. !alciparum from village surveys during September 2008 (PSI laos, 
unpublished data). Previous trials have shown an 80% reduction in clinical malaria due to P. 
vivax and a 44% reduction in P. !alciparum infection [130, 131]. It was considered that 30-50% 
reduction in cl inical malaria would represent a useful malaria intervention in this setting. An 
initial target of 500 households per arm was calculated to be able to detect a 50% reduction in 
Stu d y Pro t 0 col I 65 
clinical malaria associated with repellent use at 90% power and 95% significance. This was 
based on an estimated pre-trial incidence of 2-6%. However, a malaria incidence of only 0.7% 
was recorded in the first year of data collection. Therefore sample sizes were recalculated and 
a sample size of 633 households per arm was found necessary to detect a 50% intervention 
effect with 95% significance and 80% power. Less than 90% usage of the repellents and 
placebo lotions in the first year was around 20%, so the sample size was adjusted to 800 
households per arm, with 5 subjects in each household. 
3.3.3 Recruitment and randomisation 
Households were recruited through the village council who were consulted approximately a 
week prior to the baseline survey. Eligible households needed five volunteers aged 6-60 years. 
Only one quarter of the households in the village were recruited to reduce any potential 
increase in biting for non-repellent users (the number of households recruited = next whole 
number less than the number of households in village -;- 4 e.g. if there are 105 households in 
village, 104 -:- 4 = 26 households recruited). The village council identified potential households 
who then attended the village health centre or headman's house for the baseline survey. 
Randomisation was carried out at the household level and was stratified by village. District 
health workers who recruited and carried out the baseline survey labelled straws with the 
group codes, which the heads of households then picked. Group codes for treatments were 
"258" or "305" as provided by the manufacturer. 
3.3.4 Blinding 
The manufacturers held the key that identified the 3-digit code for each lotion, which was 
revealed after the end of the trial. Trial staff, local health staff carrying out randomisation and 
surveys, and participants were therefore blinded to the treatment arms. However, the 
possibility remains that participants were able to distinguish between the active repellent and 
the placebo, if the effects on biting were clearly different. 
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3.3.5 Interventions 
15% DEET or placebo lotion 
A 15% DEET lotion was provided to half the households the other half of households received a 
placebo lotion (both supplied by SOohnson, Racine, Wisconsin USA). Although previous 
repellent trials have used 20% DEET, a 15% DEET formulation was selected because this was 
the lowest concentration considered effective against Southeast Asian malaria vectors 
(Chapter 2 and [112, 113, 124, 125, 127, 132]). A low concentration was desirable to minimise 
the exposure of participants to DEET as the trial would require them to use the repellent for up 
to nine months. Adult participants were provided with three 100ml bottles of lotion to last one 
month (approximately 10ml per day). Children under 12 years were provided with two bottles 
per month, corresponding to approximately 7ml per day. This amount was considered 
sufficient to apply the treatments to arms and legs as directed by trial staff. District health staff 
demonstrated the amount of lotion to apply to arms and legs during the recruitment process. 
Participants were instructed to use the lotion every evening. Full USA compliant consumer 
product information [94] was given verbally in the local language and printed on the bottle 
labels in Lao (Appendix B). Any contraindications or side effects were recorded and reported at 
each monthly follow-up for appropriate action to local District Health departments. 
Long-lasting insecticide treated nets 
Study households were provided with sufficient LLiNs for the household (PermaNete2.0, 
deltamethrin 55mg/m2, mesh 25 holes/cm\ defined as one net for every 1.5 persons in the 
household, plus another for use away from home. Participants were instructed to sleep under 
a net every night, particularly when away from the village. 
3.3.6. Design 
Three hundred households were recruited from Attapeu province in May 2009, a further 1,297 
households were recruited from both Attapeu and Sekong provinces in April 2010. Participants 
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were recruited as volunteers from meetings with village members and local health team staff 
where the study was described in full with opportunity for questions. Individuals that wished 
to take part also received this information in writing and signed a consent form to confirm that 
they understood the trial, including the possibility that they might receive the placebo lotion. A 
maximum of 25% of households were recruited from any village to reduce the possibility that 
mosquitoes are diverted from repellent users to non-users. The baseline survey was carried 
out at the same time as recruitment. The questionnaire took 30 minutes and collected basic 
information on wealth indicators and current malaria prevention behaviour for the household, 
and individual information on malaria exposure. Households were randomly assigned to one of 
the treatment groups with equal numbers in each arm. Participants were supplied with a 
month's supply of lotion and sufficient LLiNs for the whole household. 
After the baseline, Village Health Workers (VHWs) and District Health Staff carried out follow-
up surveys at monthly intervals until December in both years, and provided an additional 
month's supply of lotion. A questionnaire collected data on compliance, acceptability of the 
lotion and malaria exposure that month. An RDT was carried out on all participants to actively 
detect malaria cases. Access to remote communities was anticipated to be a major challenge 
for data collection, particularly during the rainy season. The use of VHWs who are local 
community members with a few weeks of government medical training, enabled data 
collection to continue throughout these months. The monthly survey was designed to be as 
simple as possible to enable VHVs who sometimes have limited education to complete the 
form. District Health Staff carried out an exit survey during the final month of data collection, 
to assess the acceptability of the repellent lotion in more detail. VHWs were not used for the 
exit survey. 
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3.3.7 Monitoring of repellent and placebo use 
The use of the repellent and placebo lotions was monitored by self-reporting in the monthly 
questionnaires and by estimating the amount of lotion left in the bottles. Lotion use was also 
directly observed during evening 'sniff checks' carried out by trial staff. 
3.3.8. Clinical data collection and patient treatment 
Finger-prick blood spots do cause modest, brief discomfort but are common in use in this area 
and it is likely most individuals have already experienced this. Risk from this procedure is very 
low and antiseptic wipes were used to prevent infection. The RDTs used were CareStart™ 
Malaria Pfjpv Combo test (AccessBio, New Jersey, USA) which detect HRP2 antigen and pLDH 
and are able to detect both P. falciparum and P. vivax infections [164]. All positive cases were 
referred for immediate treatment following local guidelines through the District Health teams 
working on the study. National guidelines recommend ACT (coartem: artemether and 
lumefantrine) for the treatment of P. /alciparum infections in the Lao PDR, and coartem is free 
at the point of delivery. All positive RDTs and one age- and village- matched negative RDT for 
each positive were confirmed by polymerase chain reaction at the London School of Hygiene & 
Tropical Medicine. Use of repellent is common worldwide and presents an extremely low risk 
to the user. A commercial brand made, registered and sold in the USA by SCJohnson was used 
in the trial. The lowest effective dose of active 15% DEET was chosen and a consumer friendly 
gentle aqueous lotion formulation to minimise risk and discomfort. As young children have a 
lower body volume to skin surface ratio children under six years old were excluded from the 
trial. 
Only the consent forms contained personal information (names) and these were stored for the 
length of the trial in a locked filing cabinet in the project office in Vientiane. Number codes 
were used to identify participants during baseline and monthly surveys. Data were entered 
into a password protected Microsoft Access database. 
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3.3.9 Analysis 
Full details of the data analyses methods are presented separately in Chapter 4. The initial 
analysis was performed according to intention-to-treat. An additional per protocol analysis 
was carried out which will include only those participants who slept under a bed net and used 
the lotion in the evenings at least 90% of the month. Positive cases were subsequently 
excluded from the trial due to the possibility of them testing positive in later months from the 
same episode. Comparison of overall malaria, P. jalciparum and P. vivax incidence between 
the trial arms were carried out by a multi-level mixed effects Poisson regression adjusted for 
intracluster (household) variation by random effects methods. An assessment of compliance 
was carried out looking in particular at repellent and placebo use and LLiN use. Adverse events 
were also be assessed in each arm, separately for children under 12 years and participants 
over 12 years. 
3.4 Ethical approval 
Ethical Approval for this study was obtained from the Lao Ministry of Health and the Ethics 
Committee of the London School of Hygiene & Tropical Medicine (Appendix A). The DEET and 
placebo lotion were both donated by SCJohnson. The manufacturers did not contribute to the 
design or analysis of the trial. 
3.5 Discussion 
Randomised controlled trials minimise bias by keeping participants blinded to treatment 
allocation and are therefore seen as producing the most rigorous results to inform evidenced 
based medicine [165]. This trial design is double-blinded meaning that the treatment allocation 
was concealed from all investigators from data collection in the field to final data analysis. A 
cluster-randomised design was chosen to minimise potential treatment contamination and 
interaction. Three bottles of repellent or placebo lotion were provided each month to adults 
and there is a real risk of mix-up if individuals within the same household were to be given 
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different treatments. In addition it as been demonstrated that repellents have a diversion 
effect over short distances and having a mix of treatment within families could artificially 
increase biting and disease transmission for placebo users. 
The recruitment procedures used existing village hierarchy to identify potential households 
which aided acceptance of the trial at a local level. However, this does introduce potential bias 
in the households that were recruited. Village councils could preferentially recruit households 
they perceive as more likely to comply with repellent use; meaning the participants in the trials 
would be more open to behaviour change than otherwise. As randomisation was stratified by 
village this issue will not affect results within the trial, but may have some implications for the 
acceptability of the intervention across the region as a whole. 
Monthly RDTs were used to identify malaria cases during the trial. The lack of previous 
knowledge regarding malaria incidence in the study area made it difficult to judge how 
frequent testing should be to capture malaria infections in the study population. However, it 
was hoped that any infections that occurred in between monthly RDTs were picked up by the 
existing village health services. The same village health volunteers that were seconded for the 
trial each month also provided RDT testing and treatment as appropriate. Both positive and 
negative RDT results are entered into village ledgers which can be used to identify malaria 
cases in the study population that might otherwise be missed. These were used to confirm 
self-reported malaria in the previous month. 
Following the encouraging results of repellent trials in Bolivia and Pakistan [130, 131] this trial 
aimed to establish whether Southeast Asian malaria vectors could also be prevented from 
transmitting malaria by the use of insect repellent. 
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Chapter 4: Analytical pJan for a randomised pJacebo-controlled 
trial of N,N-diethyl-m-toluamide (DEET) to reduce malaria in 
southern Lao PDR. 
4.1 Abstract 
An initial intention to treat analysis was performed on all data, followed by per protocol 
analyses which excluded participants whose compliance with long-lasting insecticidal net 
(LLlN) and evening lotion use was less than 90%, 75% and 50% of the month. A principal 
component analysis (PCA) using data on education, house construction materials, type of 
electricity supply, ownership of motorbikes, tractors and televisions and animal ownership was 
carried out to develop overall socio-economic scores for each household. The PCA scores along 
with age, gender, nights slept under an LLlN, nights spent away from the village, self-reported 
lotion compliance and observed volume of lotion used were considered for inclusion in the 
regression. All variables except treatment group were first tested by non-parametric univariate 
methods and those with a significant association with the outcome at p<O.l were tested in a 
multi-level mixed effects Poisson regression model to adjusted for intra-cluster household 
variation by random effect methods. Variables maintaining their association in the 
multivariable model at p<0.05 were kept in the final model. 
Compliance with LLiN use and lotion use were first compared separately between treatment 
arms and then a chi-squared analysis of the relationship between compliance with each 
intervention was performed. Focus group discussions suggested that participants used their 
lotion more when away from the village, so a pairwise-correlation was used to examine the 
relationship between nights spent away from the village and lotion use. Reports of adverse 
events were compared between treatment groups using a chi-squared test. A logistic 
regression was run to examine treatment group, age and gender as predictors for the reports 
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of allergic reactions. The effect of LLiN use on malaria was estimated by comparison of malaria 
rates before and after baseline. 
4.2 The purpose of an analytical plan 
An analytical plan is a detailed description of how the study findings will be analysed. This plan 
was designed to address the primary objectives of the protocol and was agreed before the 
start of data analysis. This process reduces the number of different analyses that can be 
performed on a large data set and hence reduces the probability of a false positive finding. The 
analytical plan also enables potential design problems or bias to be anticipated as far as 
possible before the data is collected and analysed, for example with this study the clustering 
effect of households needed to be taken into account in the analysis method chosen. This 
process ensures that the results are analysed in an appropriate way and that the results are 
valid and credible. 
4.3 Objectives 
4.3.1 Primary Objective 
The primary objective of the trial was to detect a 50% reduction in the incidence of 
Plasmodium !alciparum infection among 6-60 year olds with 15% DEET repellent compared to 
a placebo applied topically in the evening, with 80% power at the 5% significance level. 
4.3.2 Secondary Objectives 
1. To detect a reduction in the incidence of at least one P. vivax infection among 6-60 year 
olds with 15% DEET repellent compared to a placebo applied topically in the evening, with 
80% power at the 5% significance level. 
2. To compare the incidence of adverse events (allergic reaction, itching or burning) in 
repellent and placebo users. 
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3. To compare other negative reports regarding DEET or placebo use such as an unpleasant 
smell. 
4.4 Outline of Study Design 
4.4.1 Type of Study 
The study was a household randomised, double-blind, placebo-controlled trial of 15% DEET 
applied topically every evening by rural populations in southern Lao PDR. 
4.4.2. Recruitment 
Villages with historically high malaria incidence were identified by district health staff using 
village health centre records (every health centre records RDTs performed and the outcome 
along with treatment) as potential study villages. Participants were aged from 6-60 years 
belonging to a household containing at least five eligible members. No more than 25% of the 
village were enrolled to the trial to reduce the risk of diversion of biting from repellent users to 
non-users. Trial households also had to be at least 10 metres apart to ensure they were 
distributed throughout the village. Eligible households were usually identified by the village 
council. 
4.4.3 Intervention 
Participants were given three 100ml bottles of either 15% DEET lotion or a placebo lotion (an 
identical formulation not containing DEET, both provided by SCJohnson) at the start of the trial 
and the same amount at monthly intervals during follow-up surveys. They were asked at the 
start of the trial to use the lotion every evening. Trial staff demonstrated how to apply the 
lotion to arms and legs. Participants were asked to apply the lotion every evening at 1S.00h. 
Each household was also provided with 1 long-lasting insecticidal net (LLlN: PermaNete2.0, 
deltamethrin 55mg/m2, mesh 25 holes/cm2) for every 1.5 persons in the household plus an 
extra for use away from the village, and participants were asked to sleep under them every 
night even when away from the village. 
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4.4.4 Randomisation 
Households were randomised to one of the trial arms by the head of the household choosing 
straws marked with the intervention codes (258 or 305). Randomisation was stratified by 
village to ensure that there were equal numbers in each treatment arm, and that village level 
effects would not influence the outcome of the trial. 
4.4.5 Clustering by household 
Households were randomly assigned to the repellent or placebo lotions, so all participants 
within the household received the same treatment. This approach was chosen to minimise the 
contamination of intervention effects, either through short range diversion of mosquitoes 
from repellent to placebo users or through confusion of self-administered treatment within 
the household. 
Clustering affects the sample size calculation as statistical power is reduced by the non-
independence of individuals. Therefore a cluster inflation factor must be used to produce a 
sample size. In analysis of cluster randomised trials, failure to control for the cluster effect can 
lead to a high Type I error rate, leading to rejection of a true null hypothesis. 
4.4.6 Measurement of outcomes 
All participants were asked to attend a monitoring survey at a local health centre were they 
are tested for the presence of malaria using a rapid diagnostic test (RDT: CareStart™ Malaria 
Pf/Pv Combo). The outcomes of interest are the incidence of P. fa/ciparum malaria infection, 
and the incidence of one or more P. vivax infections per person-month of observation. Adverse 
events from repellent use was measured as reported allergic reactions per person month. 
Allergic reactions were defined as a rash or any sensation of itching or burning on the skin 
during or after using the lotion. Other reported complaints (bad smell, no effect on biting) 
were also measured per person month. 
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4.4.7 Sample size rationale and calculation 
During a five month follow-up period in 2009 the incidence of P. falciparum infections was 
11/6950 = 0.0016 episodes per person-month, and 9/6950 = 0.0014 for P. vivax. There was one 
mixed infection giving an overall incidence of both species of malaria of 0.0029 cases per 
person month. A similar incidence in 2010 would give 0.024 cases per person over the eight 
months of follow-up, so a range of expected incidences from 0.015-0.025 cases per person was 
used in the calculation. 
In Pakistan a 44% reduction in the odds of a P. falciparum infection was found in households 
using a repellent soap (20% DEET and 0.5% permethrin) compared to those using a placebo 
lotion [130]. No effect was found on the odds of P. vivax infections in this trial. However, an 
80% reduction in the incidence of P. vivax was found in a trial of PMD (a repellent derived from 
lemon eucalyptus, Eucalyptus maculata citriodon) in Bolivia [131]. A conservative target of 50% 
reduction in malaria has been used here as the lowest reduction that would be considered 
useful as a public health intervention. 
The coefficient of variation (k) of the rate of cases between clusters (households) is measured 
as the standard deviation divided by the mean of each treatment group and is assumed to be 
similar in the two groups. A k of 0.25 suggests that true cluster rates are normally distributed, 
so that 95% of rates lie within two standard deviations of the mean [166]. A higher k would 
mean rates varied more, and a lower k would indicate less variation. In the 2009 data, malaria 
cases showed clustering at the village but not household level, suggesting that cases are not 
over-dispersed by household. Therefore the coefficient of variation (k) was set at 0.25. 
Non-compliance in the first year of the study was approximately 20% and samples were 
adjusted to take this into account. A sample size of 790 households per arm will be required to 
show a 50% intervention effect at 5% significance and 80% power [167] 
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Table 4.1 Sample size calculations for different scenarios of baseline incidence and intervention effect 
(with 80% power, 5% significance and co-efficient of variation = 0.25). 
Assumed incidence Intervention effect Households per arm Adjusted for 20% loss 
0.010 50% 948 1185 
0.015 50% 633 791 
0.020 50% 476 595 
0.010 40% 1579 1974 
0.015 40% 1054 1318 
0.020 40% 792 990 
0.010 30% 2982 3728 
0.015 30% 1991 2489 
0.020 30% 1495 1869 
4.5. Analysis of Baseline Data 
A principal component analysis (PCA) was used to develop an overall socia-economic score for 
each household [168]. Eighteen variables from the baseline survey were entered into the PCA 
(Table 4.2). Only surveys with complete responses can be entered into a PCA, therefore to 
avoid systematic bias any variables with more than 20% miSSing data were not be used in the 
analysis. 
Table 4.2 Variables from the baseline surveys that will be considered for entry into a peA. 
Subject Area 
Household Size 
Head of Household 
Housing 
possessions 
Animals 
Items from Baseline Survey 
Household size 
Occupation and education 
Roof and wall material 
Electricity and water supply 
Cooking fuel 
Motorcycle, tractor, radio and television ownership 
Insecticide treated bed net ownership 
Buffalo, pig, goat, chicken and dog ownership 
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Remaining baseline information on household-level (use of personal protection not including 
repellents or LLlNs) and individual-level characteristics (age, gender, visiting the fields or 
forest, and ROT results) were compared between treatment arms using chi-squared tests for 
categorical variables and t-tests for continuous variables. The socio-economic scores from the 
PCA were compared by non-parametric test. 
4.6. Analysis of incidence data 
4.6.1 Data Exclusions 
Oata were excluded from the analysis if the participants withdrew consent and discontinued 
with the trial. Concurrent infections in the same individual were also excluded in order to 
avoid counting recurring infections as new cases. 
4.6.2 Case Definition 
A P. !alciparum infection was defined as a P. /alciparum positive ROT detected at a monthly 
monitoring survey. A P. vivax infection was defined as a P. vivax positive ROT detected at a 
monthly monitoring survey. An adverse event was a report of an allergy from lotion use during 
a monthly monitoring survey. Other adverse reactions to the lotion that were reported at 
monthly monitoring surveys were; disliking the smell; or it not stopping insect bites; this was 
an open survey question so other reports may also be given. 
4.6.3 Person-time at risk 
Once a P. !alciparum infection was detected, the subsequent month of observation for that 
participant was excluded from the analysis to avoid double-counting the same infection. So as 
to avoid recording a relapse of P. vivax as a new infection, the analysis looked only at the 
incidence of at least one episode of P. vivax during the trial, but all qualifying months of 
observation were included in the denominator. If a participant misses a monitoring surveyor 
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does not have a supply of repellent for a particular month, then that month will be excluded 
from the analysis. 
4.6.4 Inclusion of observations 
The main analysis was an intention to treat (ITI) analysis, including all qualifying months of 
observation (see above). The secondary analysis was according to protocol (ATP) based on 90% 
compliance with application of the repellent or placebo as reported by the participants each 
month. For this analysis, a month of observation where the lotion was applied less than 90% of 
the time (e.g. <27/30 days) will be excluded from both the numerator (contributing cases) and 
the denominator (contributing person-time at risk). Subsidiary analyses were undertaken to 
look at the effect of the intervention with 75% and 50% compliance with product application 
per month. 
4.6.5 Regression analysis with random effect model 
The statistical test used to investigate the effect of the intervention was a multi-level mixed 
effects poisson regression model adjusted for intra-cluster variation by random effect 
methods. This model allows for repeated measures over time on each individual. Household 
clustering can be controlled for using random effects. The results of the model were presented 
as the incidence rate ratio of the outcome being considered in the intervention group 
compared with the placebo group. The co-variables to be considered for inclusion in the model 
were age, gender, socio-economic PCA scores, percentage of nights that a participant slept 
with a LLlN, percentage of nights slept away from the village at rice fields or the forest, self-
reported lotion use and observed volume of lotion used. All variables were tested in univariate 
models, and those with a significant association with the outcome at p<O.l, tested for 
inclusion in the final model. Variables maintaining their association in the multivariable model 
at p<0.05 will be kept in the final model. 
4.7. Analysis of co-variables 
4.7.1 Compliance with LLIN use 
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The proportion of self-reported fully compliant participants was compared between the two 
treatment arms using a chi-squared test. LLI N use was converted to proportion use per month 
to aid comparison with lotion use and considered for inclusion as a co-variable in the 
regression model. 
4.7.2 Compliance with lotion use 
Compliance with daily lotion use was not expected to be as high as with bed nets because there 
is not the same history of use in the study area. Compliance was first quantified as the number 
of evenings lotion was used per person per month. As lotion use might be affected by seasonal 
changes like temperature or mosquito density, the analysis was also adjusted for month. Focus 
groups discussions have also suggested that participants used the lotion more often when 
working in the forest or away from their village. Therefore, a multiple regression analysis was 
carried out to compare the mean number of evenings when lotion was used between 
treatment groups, adjusted for month and travel away from the village. 
4.8. Analysis of adverse events 
4.8.1 Allergic reactions to repellent and placebo lotions 
The analysis aimed to determine whether treatment group, age or gender had any effect on 
the reporting of allergic reactions. Allergies were expressed as present or absent for each 
participant each month and a logistic regression using random effects run to detect any 
association with the above variables. 
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4.8.2 Other negative reports from lotion use 
Any other negative effects from lotion use reported by participants - such as headaches, 
tingling sensations or an unpleasant smell - were recorded for each participant-month. They 
will also be compared across intervention groups, age and gender. 
4.9 Unblinding of the Trial 
The code for the repellent and placebo lotions was broken after all data had been cleaned and 
a 'frozen' blind data set sent to an independent statistician as an official record. 
4.10. Conclusions 
The Poisson regression was chosen because it models rare events, as the malaria rates were 
expected to be given the incidence in year one. The multi-level, mixed effects model allows for 
both repeated measures over time and household level clustering to be taken into account. 
Variables considered for inclusion in the model were informed by previous studies which 
identified age, net use and forest visits as risk factors for malaria [44, 46, 47, 169]. Although in 
the Lao PDR studies have found that malaria risk is similar between men and women, in other 
countries in the region men are significantly more likely to suffer malaria infection and this 
variable was therefore considered important enough to include in this analysis. The analytical 
plan provides an overall framework to approach the analysis ensuring fair and rigorous 
treatment of the data. 
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Chapter 5: A cluster-randomised placebo-controlled trial to 
assess whether the insect repellent N,N-diethyl-m-toluamide 
(DEET) can provide additional protection against clinical 
malaria over current best practice in southern Lao PDR. 
MALARIA 
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5.1 Abstract 
The main vectors of malaria in the Greater Mekong Subregion (GMS), An. dirus and An. 
minimus, bite outdoors in the early evening before people are under bed nets. Long-lasting 
insecticidal nets (LLlNs) are the first choice malaria prevention tool, and vector behaviour such 
as this enables mosquitoes to avoid contact with nets is therefore a concern. Insect repellent is 
a potential tool that could be paired with LLiNs in areas of outdoor and evening biting. A 
double blind, household randomised, placebo controlled trial of insect repellent to reduce 
malaria was carried out in southern Lao PDR to determine whether the use of repellent and 
long-lasting insecticidal nets (LLlNs) could reduce malaria more than LLiNs alone. Three 
hundred households were recruited in June 2009 and a further 1,297 in April 2010 giving a 
total of 1,597 households which included 7,979 participants. In total 795 households (3,972 
participants) were assigned to use a 15% DEET lotion and 802 households (4,007 participants) 
a placebo lotion. Randomisation was stratified by village and participants. Participants, field 
staff and data entry clerks were all blinded to the group assignment. All households received 
new LLiNs the current best practice for malaria control in Lao PDR. Participants were asked to 
apply their lotion to exposed skin every evening from 18.00h. Adults were provided with 
300ml per month and children under 12 years with 200ml of 15% DEET or the placebo. 
Plasmodium falciparum and P. vivax cases were actively identified by monthly rapid diagnostic 
tests. Five rounds of follow-up were completed in 2009 and eight in 2010. Intention to treat 
(In) analysis included 1,398 households and no effect from the use of repellent was found on 
malaria incidence (IRR: 0.97, 95% CI: 0.55-1.73, p=0.926). A higher general socio-economic 
score derived from principle components analysis (PCA) was significantly associated with a 
decreased risk of household malaria (p=0.005). According to protocol (ATP) analysis which 
excluded participants using the lotions less than 90%, 75% and 50% of the time included 1,311, 
1,342 and 1,368 households. No effect from the use of repellent was found, while lower socio-
economic score increased malaria risk. Therefore repellents are not a suitable intervention in 
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addition to LLiNs against malaria in agricultural populations in southern Lao PDR, and these 
results are likely to be applicable to much of the GMS. That topical repellents are very effective 
at reducing mosquito biting is not in question, but this trial provides no evidence that they are 
an effective intervention against malaria in Southern Lao PDR. Malaria rates were sufficiently 
high given the required sample size to detect an intervention effect of up to 50%. Potential 
reasons for the lack of effect include non-standard self-application of repellent that could 
result in under-treatment or non-compliance with the intervention. 
5.2 Introduction 
Malaria continues to be a major public health problem in the GMS which unites southern 
China, Cambodia, Lao PDR, Myanmar, Thailand and Vietnam [18]. These countries have 
common environmental conditions which create a similar malaria epidemiology across the 
region. Malaria in the GMS is highest in remote border areas where forest and low population 
densities create particular challenges to control efforts [21, 51, 157, 170]. The GMS Roll Back 
Malaria Partnership was set up in 1999 to reform control programmes across the region, 
including improving surveillance, increasing long-lasting insecticidal net (LLlN) coverage and 
targeting of risk groups [26]. Between 1998 and 2007 cases of malaria dropped by 25% and 
malaria mortality by 60% across the region [18]. Whilst effective malaria control has 
undoubtedly contributed to this reduction, it is suggested that the reductions in malaria may 
have been helped by other changes including deforestation, economic development and 
improved basic healthcare [19]. At present malaria control is focused on parasite-based 
diagnosis of cases, treatment with artemisinin-derived combination therapies, distribution of 
long-lasting insecticidal nets (LLlNs) and indoor residual spraying [3, 26]. 
The Lao PDR shares borders with all other GMS countries (Figure 5.1) and the highest malaria 
incidence rates are found in Attapeu and Sekong provinces along the southern borders with 
Cambodia and Vietnam [18]. Plasmodium /alciparum causes almost 97% of cases and P. vivax 
the remainder [162]. Village based surveys in Attapeu have found increased malaria risk to be 
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associated with sleeping without a bed net and visits to the forest [44, 45]. Unusually for the 
GMS where young men are most at risk of malaria infection, there is not a gender bias in the 
Lao PDR where young children are the group with the highest rates of malaria [44,45,47]. The 
main vector is Anopheles dirus which is strongly associated with forests and is frequently found 
biting outdoors [52, 142]. Biting time varies depending on sibling species, whilst for most peak 
biting occurs from 21.00-02.00h, other species start feeding at 18.00h [52, 54]. Anopheles 
minimus and An. maculatus are also important vectors and are similarly found biting outdoors 
in the early evening [44, 50, 56, 108, 171]. LLiNs protect from biting indoors at night and also 
reduce the local mosquito population, protecting even those in the community not using nets 
[172]. However in the GMS the efficacy of LLiNs may be reduced as vector contact is outdoors 
and the community effect may also be diluted by forest vectors found away from villages 
[173]. 
Insect repellents have the potential to reduce vector contact in this setting. Field trials in 
Thailand and Malaysia show DEET concentrations of 15-20% decrease biting by over 83% [124, 
125, 138]. However few trials have been able to demonstrate an effect on malaria 
transmission by the use of insect repellent. On the Thai-Myanmar border, pregnant women 
were given either thanaka (a traditional cosmetic derived from Limonia acidissima) mixed with 
DEET or thanaka alone. Although a 29% reduction in P. falciparum was observed, the 
transmission level was too low for this to be statistically significant [129]. Similarly, in 
Afghanistan low malaria rates meant a 45% reduction in malaria (96% of cases were P. vivax) 
observed in people using a repellent soap containing 20% DEET and 5% permethrin was non-
significant [132]. In Ecuador and Peru a village randomised trial of repellent soap found no 
reduction in malaria compared to untreated controls [128]. A 56% reduction in the odds of P. 
!alciparum infection was found in Pakistan amongst households using repellent soap 
compared to those using a placebo, no effect was found for P. vivax infections [130]. 
Households using 30% PMD (a repellent derived from lemon eucalyptus, Eucalyptus maculata 
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citriodon) in Bolivia had an 80% lower incidence of P. vivax [131]. There was also an 82% 
reduction in P. falciparum but case numbers were too low to reach significance. A number of 
common problems have affected the results of these trials. Lower than expected malaria rates 
have resulted in insufficient sample sizes and non-significant reductions. Compliance is also 
very important, since repellent requires application every few hours it is easy to forget, lose 
and even apply in insufficient doses. The inconsistency of these results means that it is not yet 
established whether the use of insect repellent can reduce malaria infection. The aim of this 
trial was to determine whether using a 15% DEET repellent, established by landing catches to 
reduce mosquito biting by 98.9% (Chapter 2) would reduce malaria incidence against 
exophagic vectors amongst rural populations in southern Lao PDR using LLiNs. 
5.3 Methods 
5.3.1 Trial Design 
Summary 
This was a double blind, household randomised, placebo controlled trial of insect repellent to 
reduce malaria, carried out in southern Lao PDR. Half the households were assigned to the 
repellent group and the other half to the placebo lotion (Figure 5.1). Reporting of methods, 
analysis and results has been according to CONSORT guidelines for the reporting of 
randomised controlled trials [174] 
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Figure S.l Flow chart of the process of recruitment and the planned progress of households through the 
trial. 
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Recruitment 
Households were recruited through the village council who were consulted approximately a 
week prior to the baseline survey. Eligible households needed five volunteers aged 6-60 years. 
The village council identified potential households who then attended a meeting with district 
health staff where the study was described in full with opportunity for questions. Individuals 
that wished to participate also received this information in writing and signed a consent form 
to confirm that they understood the trial, including the possibility that they might receive the 
placebo lotion (Appendix A). 
Baseline survey 
The baseline survey was carried out at the same time as recruitment. The questionnaire 
collected basic information on wealth indicators, current malaria prevention behaviour for the 
household, and individual information on malaria exposure (Appendix B). 
Follow-up surveys 
All participants were tested by rapid diagnostic test (RDT) every month during active case 
detection. Follow-up surveys finished in December in both years to ensure testing throughout 
the wet season and into the following transition/dry season when previous surveys had found 
high parasite rates [44]. The RDTs used were CareStart™ Malaria Pf/Pv Combo test (AccessBio, 
NJ) which detects HRP2 antigen and pLDH and are able to detect both P. /a/ciparum and P. 
vivax infections [164]. Follow-up surveys were conducted by field teams made up of village 
health workers (VHWs) and district health staff. The field teams gave the village council a list of 
the follow-uP dates at the beginning of the trial and these were confirmed one week in 
advance. The village council ensured all households were present in the village on the day of 
follow-uP. This process was necessary as many people do not live in their village houses during 
the wet season. If rice fields are a long distance from the village, households have another 
house next to their fields where the family lives during the rice planting and harvesting 
seasons. Participants who were missing on village follow-up visits would then be contacted by 
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VHWs who if necessary would visit that participant to carry out the RDT test. If an RDT could 
not be carried out within a week of the village follow-up visit the participant was deemed lost 
to follow-up. All positive cases were referred for immediate treatment following local 
guidelines through the district health teams working on the study. 
Access to remote communities was anticipated to be a major challenge for data collection, 
particularly during the rainy season. The use of VHWs who are local community members with 
a few weeks of medical training, enabled data collection to continue throughout these months. 
The monthly survey was designed to be as simple as possible to enable VHWs who sometimes 
have limited education to complete the form. A simple one-page questionnaire collected data 
on LLiN use, repellent use and time spent away from the village (Appendix B). This visit was 
also used to provide the next month's supply of lotion and record the amount of lotion 
returned. District health staff rather than VHWs carried out the exit survey during the final 
month of data collection, to assess the acceptability of the repellent lotion in more detail. 
Potential risk to participants 
Finger-prick blood spots can cause modest, brief discomfort but are commonly used in this 
area and it is likely most individuals have already experienced their use. Risk from this 
procedure is very low and antiseptic wipes were used to prevent infection. 
Use of repellent is universal worldwide and presents an extremely low risk to the user [94]. 
The DEET formulation used was a commercial brand made, registered and sold in the USA by 
SC Johnson Inc. The lowest effective dose of active 15% DEET (Chapter 2) was used, in a gentle 
aqueous lotion formulation to minimise risk and discomfort. 
Repellent use may divert mosquitoes to non-users increasing their disease risk [121]. 
Therefore to protect both the placebo users and non-participants in the study villages a 
maximum of 25% of any village were recruited to the trial. 
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Only the consent forms contained personal information (names) and these were stored for the 
length of the trial in a locked filing cabinet in the project office in Vientiane. Number codes 
were used to identify participants during baseline and monthly surveys. Data was entered into 
a password protected Microsoft Access database. 
5.3.2 Changes to trial design 
During the first year of the trial participants also provided bloodspots at baseline and exit 
intended for serological analysis for dengue, Japanese encephalitis and typhus antibodies. 
Lower than expected malaria rates during the first year of the trial led to a revision of the 
sample size required. Therefore 1300 households were recruited in the second year rather 
than the previously planned 700. This increase meant the sideline serological work on 
arbovirus infections had to be dropped due to insufficient funding, and the trial focused solely 
on malaria infections the major vector borne disease in the area. 
5.3.3 Participants 
Participants were recruited from primarily rural agricultural workers that often work and sleep 
overnight away from the village during the wet season. Participants were aged 6-60 years old 
and households had to enrol at least five eligible participants to enter the trial. Study 
households also had to be separated by at least 10m to prevent diversion of biting from 
repellent users to placebo users [121]. 
5.3.4 Study setting 
Households were recruited from 126 villages; 72 in Attapeu Province and 54 in Sekong 
Province. These are the most south-eastern provinces in the Lao PDR, sharing borders with 
Vietnam and Cambodia. The Annamite mountains run along the eastern Vietnam border and 
60% of Attapeu Province is classed as mountainous [42]. The mountainous areas contain dense 
rainforest, contrasting with the open canopy dry forest on the plains. River valleys are the 
most important areas in both provinces for agricultural production, although the regular floods 
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that increase soil fertility can also destroy crops (mostly rice with the addition of maize for 
animal feed in some areas). The wet season is usually from April to October, followed by a cool 
dry season from November to January and a hot dry season from February to March. Rice 
farming is the main economic activity in these two provinces; 57% of Attapeu's population are 
farmers and in Sekong the figure is even higher at 71% [43]. 
The malaria situation in the Lao PDR is similar to that across the GMS; low overall, but a severe 
problem in forested border areas [18]. Within the Lao PDR, it is the southern provinces that 
are most affected by malaria, with P. !alciparum parasite rate in Attapeu and Sekong about 
twice as high as the national average [43,48]. Plasmodium !alciparum is found in about 80% of 
cases, and P. vivax in most of the rest [44, 47, 142, 171]. The most important malaria vectors 
are An. dirus, An. minimus and An. maculatus [49, 50], and can all feed early and outside 
meaning they will be less affected by conventional control methods such as LLiNs [44, 50, 51, 
54, 56, 144, 146]. However although these behaviours may reduce the effectiveness of LLiNs in 
reducing malaria transmission, non-use of a bed net is still highly associated with malaria in 
Lao PDR [44,45]. Current policy in the Lao PDR is for the entire population at risk (estimated to 
be 70% of the country) to receive LLiNs [162]. In addition free diagnosis and treatment with 
artemisinin combined therapy (ACT) has been implemented to poor populations. Resistance to 
artemisinin has not yet been detected in Laos [29]. 
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Figure S.2. Location of study villages in Attapeu and Sekong provinces in Southern Lao PDR 
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5.3.5 Interventions 
15% DEET or placebo lotion 
A 15% DEET lotion was provided to half the households the other half of households received a 
placebo lotion (both supplied by SCJohnson, Racine, USA). Although previous repellent trials 
have used 20% DEET, a 15% DEET formulation was selected because this is the lowest 
concentration considered effective against Southeast Asian malaria vectors (Chapter 2, [124, 
125, 138]). A low concentration was desirable to minimise the possibility of adverse events in 
study subjects as the trial would require them to use the repellent for up to nine months. Adult 
participants were provided with three 100ml bottles of lotion to last one month 
(approximately 10ml per day). Children under 12 years were provided with two bottles per 
month, corresponding to approximately 7ml per day. This amount was considered sufficient to 
apply the treatments to arms and legs as directed by trial staff. District health staff 
demonstrated the amount of lotion to apply to arms and legs during the recruitment process. 
Participants were instructed to use the lotion every evening. Full USA compliant consumer 
product information [94] were given verbally and in the local language. Any contraindications 
or side effects were recorded and reported at each monthly follow-up for appropriate action 
to local District Health departments. 
Participants reported at each monthly follow-up visit how many evenings they had used the 
lotion. The amount of lotion returned was also recorded as a rough confirmation of the self-
reported usage data. In addition random checks were carried out by trial staff: these involved 
visiting a village at dusk and smelling the arms of participants to check lotion had been applied. 
Long-lasting insecticide treated nets 
Study households were provided with sufficient LLiNs (PermaNet®2.0, deltamethrin 55mg/m 2, 
mesh 25 holes/cm2), defined as one net for every 1.5 persons in the household, plus another 
for use away from home. PartiCipants were instructed to sleep under a net every night, 
particularly when away from the village. At monthly follow-up visits participants reported how 
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many nights they had slept under the nets in the village and also when sleeping in the forest or 
rice fields. 
5.3.6 Outcomes 
The primary outcome was household malaria incidence measured by monthly ROTs for P. 
!alciparum and P. vivax. Positive ROTs, paired with a negative ROT matched by age and village, 
were confirmed by polymerase chain reaction [175] at the London School of Hygiene and 
Tropical Medicine. To avoid the risk of including relapse infections, only the first P. vivax 
positive result for each participant was recorded. If a participant tested positive for P. 
!alciparum for two consecutive months the second result was also excluded in case of 
treatment failure. 
5.3.7 Changes to outcomes 
As mentioned above, at the start of the trial one of the secondary outcomes was changes in 
arbovirus antibodies in dried bloodspots, however they were dropped in the second year of 
the trial. All-cause fevers were also discarded during the interim analysis since these are not 
useful as proxy measure of malaria. 
5.3.8 Sample size 
The only reliable epidemiological data from the study area prior to the start of the trial was 
32% prevalence of P. !alciparum from village surveys during September 2008 (PSI Laos, 
unpublished data). Previous trials have shown an 80% reduction in clinical malaria due to P. 
vivax and a 44% reduction in P. !alciparum infection [130, 131]. A 30-50% reduction in clinical 
malaria was therefore considered to represent a useful malaria intervention in this setting. An 
initial target of 500 households per arm was calculated to be able to detect a 50% reduction in 
clinical malaria associated with repellent use at 90% power and 95% significance. This was 
based on an estimated pre-trial incidence of 2-6%. However, a malaria incidence of only 0.7% 
was recorded in the first year of data collection. Therefore sample sizes were recalculated and 
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a sample size of 633 households per arm was found necessary to detect a 50% reduction in 
malaria incidence with 95% level of significance at 80% power. Less than 90% compliance with 
repellent and placebo lotion usage was around 26% in the first year so the sample size was 
adjusted to 798 households per arm, with 5 subjects in each household, to adjust for loss of 
power in the according to protocol analysis. With 1,500 participants (300 households) followed 
up over 5 months and a further 6,480 (1,296 households) followed up over 8 months, at least 
74 malaria cases be would be required to measure a significant effect. 
5.3.9 Interim analyses and stopping guidelines 
The original sample size was based on weak survey data, so we recalculated the sample 
needed based on malaria incidence reported during the first year of the study. The trial 
manager was able to halt the trial at any point if the safety of participants was thought to be at 
risk, determined by any reports of severe reactions to or misuse of the lotions. 
5.3.10 Randomisation 
Households were randomised to one of the two treatment arms using equal groups allocation 
which was stratified by village. District health workers prepared labelled straws at a ratio of 1:1 
for each village. The straws were picked by the head of household to assign treatment groups. 
This method was not perfectly executed as some heads of household returned their straws 
after picking a group meaning that the actual ratio between the treatment arms was not 
exactly 1:1. 
5.3.11 Blinding 
The repellent and placebo lotions were identified by 3-digit codes '258' or '305' as provided by 
the repellent manufacturer. Participants, field staff carrying out randomisation and follow-up 
surveys and trial staff performing data entry and analysis were blinded for the length of the 
trial. The repellent and placebo codes were only revealed after data entry and analysis was 
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complete. However, the possibility remains that participants were able to distinguish between 
the active repellent and the placebo by the effect on biting insects. 
5.3.12 Similarity of interventions 
The repellent and placebo were in identical bottles (Figure 5.3) and identified by a code on the 
label. Therefore there was potential for mix-ups to occur when participants received their 
bottles each month. For th is reason the group codes were not only given to the heads of 
household on the ir ID cards, but the village council held a list as did the district health workers 
distributing lotions each month . 
Figure 5.3. Bottles of placebo and 15% DEET lotions used in the trial. 
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5.3.13 Statistical methods 
Analysis of this trial adhered as far as possible to a detailed analytical plan (Chapter 4) 
established before the investigators had access to the finalised data set. An initial intention-to-
treat analysis was performed on all data, followed by a per protocol analysis which excluded 
participants who slept under an LLiN and used the lotion in the evenings less than 90%, 75% 
and 50% of the month. A principal component analysis (PCA) using data on education, house 
construction materials, type of electricity supply, ownership of motorbikes, tractors and 
televisions and animal ownership was carried out to develop overall socio-economic scores for 
each household [168]. The PCA scores along with age, gender, nights slept under an LLlN, and 
nights spent away from the village were considered for inclusion in the regression. All variables 
except treatment group were first tested by non-parametric univariate methods and those 
with a significant association with the outcome at p<0.2 were considered for inclusion in the 
final model. Outcomes of overall malaria, P. falciparum and P. vivax infections were tested in a 
multi-level mixed effects Poisson regression model adjusted for intra-cluster household 
variation by random effect methods. Variables maintaining their association in the 
multivariable model at p<0.05 were kept in the final model. All analyses were carried out using 
STATA version 12 (Statcorp, Texas, USA). 
5.3.14 Additional analyses 
Self-reported and observed lotion use, self-reported LLI N use and treatment group were 
entered into linear regressions adjusted for household clustering. Focus group discussions 
(chapter 6) suggested that participants used their lotion more when away from the village, so a 
pairwise-correlation was used to examine the relationship between nights spent away from 
the village and lotion use. Reports of adverse events were compared between treatment 
groups using a chi-squared test. A logistic regression was run to examine treatment group, age 
and gender as predictors for the reports of allergic reactions. The effect of LLiN use on malaria 
was estimated by comparison of malaria rates before and after baseline. 
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5.4 Results 
5.4.1 Baseline data 
The first round of recruitment from 25th June to 4th July 2009 enrolled 300 households to the 
trial and a further 1,297 households were recruited between 24th April and 18th May 2010. A 
total of 7,980 participants were initially recruited but 40 (0.5%) were excluded after the 
baseline survey as they were outside the 6-60 years age limit. Almost half of households (795, 
49.8%) were randomised to the repellent arm and the remaining 802 allocated to the placebo 
lotion. 
The individual level baseline data were very similar between treatment groups indicating 
successful randomisation. Overall slightly more women were recruited than men, but this did 
not differ between the treatment arms (Table 5.1). The age structures of the two treatment 
arms were also similar (Table 5.1). Ethnicity was similar between treatment arms (Table 5.1). 
Participants came from 16 different ethnic groups, although no data were available for 19% of 
participants approximately 12% of those who gave information were from the ethnic majority 
Lao who make up about 66% of the national population. A further 22% were from six groups 
within the Katuic ethno-linguistic family and 66% came from nine groups within the Bahnaric-
Khmer ethno-linguistic family (Full data in Appendix E). 
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Table 5.1. Participant age, gender and ethnicities in each treatment arm. 
Treatment arm Repellent Placebo 
Total participants 3972 4008 
Female 2186 (55.3%) 2187 (54.9%) 
Median age (IQR) 19 (11-35) 20 (11-35) 
Ethnicity: Lao 396 (12.1%) 396 (12.3%) 
Katuic 712 (21.8%) 726 (22.5%) 
Bahnaric-Khmer 2154 (66.0%) 2106 (65.2%) 
Baseline household-level socioeconomic data on occupation and education of household 
heads, house construction, possessions and animals were all examined individually before 
being combined using a principal components analysis (PCA). Over 95% of all heads of 
household were farmers (Table 5.2). Although this result was expected given that the trial 
aimed to recruit agricultural workers, the homogeneity of the variable made it unsuitable to 
include in the PCA. About a quarter of household heads had never received any formal 
education, about 60% had attended school for 1-5 years and less than 4% had received over 9 
years of schooling. About two thirds of houses were made from wood rather than bamboo. 
Wooden stilts allow the house to be higher, which is generally an indication of greater wealth. 
A similar proportion had also managed to erect a metal roof over at least some part of their 
house, again an indicator of greater wealth. Sixty percent of households had no electricity 
supply and about half had access to a pump for water. Motorbike ownership was most 
frequent amongst the indicators used (televisions, radios, tractors and motorbikes), with about 
40% of households owning at least one. About 60% of households also owned buffalo or pigs. 
Along with occupation, cooking fuel, radio ownership and goat ownership were excluded from 
the PCA as they did not contain sufficient variation between the trial households. The PCA 
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therefore included the years of education of the head of household, housing materials, 
electricity and water supply, ownership of motorbikes, televisions and tractors, pre-trial 
ownership of bed nets and ownership of buffalo, pigs, chickens and dogs. 
Using the eigenvectors and standardised variables, two scores for each household were 
created, PCAl and PCA2. PCAl was created from almost all variables and provided a general 
socio-economic score. PCA2 was more heavily influenced by animal ownership. Due to missing 
data PCA scores could only be created for 1,402 (87.8%) households. Non-parametric 
comparison of these scores between the treatment groups showed no differences (PCA1: 
p=0.602; PCA2: p=0.699; Table 5.2). 
Baseline malaria rates were slightly higher in the placebo group, but not significantly so 
(Prevalence ratio: 0.82, 95% c.1. 0.5-1.37, p=0.454). Men had a slightly higher rate of malaria, 
but this did not reach significance (parasite rate in females: 0.61%, in males: 0.83%, p=0.263). 
Children aged 6-10 years were about twice as likely to have malaria as any other age group 
although the difference was only significant when compared to adults aged 31-40 years (Table 
5.3). 
Overall, the households in the two treatment groups were very similar despite wide variation 
between household, illustrating the success of the randomisation procedure. 
Ran d 0 m i sed Con t r 0 I led T ria I I 100 
Table 5.2 Household socio-economic data and resulting PCA scores per treatment arm. 
Socio-economic variable Repellent Placebo 
(n = 795) (n = 802) 
Heads of % gave main occupation as "farmer" 97.0 95.9 
household: Median (IQR) years of education 3 (1-5) 3 (1-5) 
Houses: % constructed from bamboo 34.3 35.5 
% constructed from wood 66.3 66.8 
% with a metal roof 68.6 68.7 
Household % with no electricity supply 59.0 61.7 
services: % with access to a water pump 51.6 52.1 
% using wood as main cooking fuel 97.5 97.0 
Household % that own at least one motorbike 38.7 41.3 
possessions: % that own a tractor 16.2 18.8 
% that own a radio 19.8 19.7 
% that own a television 23.2 24.3 
% that owned ITNs prior to the trial 86.3 85.5 
Animals: % owning buffalo 56.7 58.4 
% owning pigs 57.4 60.1 
% owning goats 11.2 11.4 
% owning chickens 70.4 73.4 
% owning dogs 47.2 46.3 
Median PCA1 score (IQR) -0.23 (-1.14, 1.09) -0.23 (-1.23, 1.24) 
Median PCA2 score (IQR) -0.07 (-0.78, 0.66) -0.07 (-0.89, 0.80) 
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Table 5.3 Baseline parasite rates per treatment arm with prevalence ratio and p-values to compare 
arms. 
Repellent Placebo 
Number of malaria cases 27 33 
P. falciparum 21 27 
P. vivax 4 6 
Mixed infections 2 0 
Number of participants 3956 3984 
Parasite rate (%) 0.68 0.83 
Prevalence ratio (95% c.i.) 0.82 (0.5-1.37), p=0.454 
Table 5.4 Baseline parasite rates by age, children aged 6-10 years used as comparison group. 
Age group Number Total malaria Prevalence (%) Prevalence ratio p 
(years) cases (95% CI.) 
6-10 1859 25 1.34 
11-15 1447 10 0.69 0.51 (0.25-1.07) 0.103 
16-20 879 6 0.68 0.51 (0.19-1.39) 0.190 
21-30 1340 9 0.67 0.50 (0.18-1.40) 0.119 
31-40 1084 3 0.28 0.21 (0.06-0.76) 0.015 
41-50 798 6 0.75 0.56 (0.14-2.23) 0.270 
51-60 533 1 0.19 0.14 (0.02-1.16) 0.064 
Total 7940 60 0.76 
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5.4.2 Trial Progress 
Follow-up visits were carried out every month, finishing in December both years. Table 5.5 
shows the number of households and participants surveyed at each monthly follow-up visit. 
No folloW-Ups were carried out in September 2009 due to widespread flooding in the study 
area, although households did receive replacement lotion as necessary. Therefore there were 
a potential 59,023 person-months, a loss to follow-up of 14.2% with no difference between 
treatment arms (repellent users 14.2%, placebo users 14.1%). A further 11.3% of participant-
months were excluded from the intention to treat analysis due to incomplete data. Therefore 
in total 1,398 households and 44,024 person-months at risk (PMAR) entered the intention to 
treat analysis (Table 5.6 and Figure 5.4). 
Table 5.5 Attendance of households and participants to follow-up surveys throughout the trial. 
Month 
0 1 2 3 4 5 6 7* 8* 
Repellent Surveyed 795 776 740 645 673 719 659 545 371 
Households Missing 0 19 55 150 122 76 136 101 275 
Placebo Surveyed 802 779 753 657 677 738 654 546 377 
Households Missing 0 23 49 145 125 64 148 105 274 
Repellent Surveyed 3972 3893 3776 3148 3304 3555 3158 2705 1721 
Participants Missing 0 79 196 824 668 417 814 522 1506 
Placebo Surveyed 4008 3890 3824 3201 3314 3659 3107 2696 1718 
Participants Missing 0 118 184 807 694 349 901 558 1536 
* 300 households were surveyed in 2009 for 6 months after baseline and 1,297 households 
were follow-up during 2010 for 8 months after baseline, giving a total of 1,597 households 
for months 0-6 and 1,297 households for months 7 and 8. 
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Table 5.6 Person-months at risk entering intention to treat analyses. 
Repellent Placebo 
Participants 3,972 4,008 
Excluded by age 16 24 
Person-months at risk 29,413 29,610 
Person-months lost to follow-up 4,184 (14.2%) 4,170 (14.1%) 
Person-months excluded by incomplete data 3,084 (10.49.9%) 3,561 (12.0%) 
Person-months entering In 22,145 (75.3%) 21,879 (73.9%) 
Ran d 0 m i sed Con t r 0 I led T ria I I 104 
Recruitment of 1,597 households and 7,980 participants 
Randomisation stratified at the village level 
I 
795 households and 3,972 participants 802 house holds and 4,008 participants 
allocated to 15% DEET allocated placebo 
Median household size = 5 (range : 3-5) Median household size = 5 (range: 3-5) 
Monthly follow-up surveys: 5 visits July-December 2009 (September missed due to floods) 
and 8 visits May-December 2010 
29,413 participant follow-ups 29,610 participant follow-ups 
Withdrew, lost to follow-up or excluded Withdrew, lost to follow-up or excluded 
for incomplete data : for incomplete data: 
93 households (11.7%) 106 households (13.2%) 
7,268 PMAR (24.7%) 7,731 PMAR (26.1%) 
, 1 
Households and PMAR entering analysis: Hou seholds and PMAR entering analysis: 
In: 702 households & 22,145 PMAR In: 696 hou seholds & 21,879 PMAR 
ATP 90% compliance: 651 households & ATP 90% compliance : 660 households & 
9,522 PMAR 9,845 PMAR 
ATP 75% compliance : 673 households & ATP 75% compliance : 669 households & 
10,938 PMAR 11,099 PMAR 
ATP 50% compliance: 685 households % ATP 50% compliance: 683 households & 
16,466 PMAR 16,426 PMAR 
Figure 5.4 Progress of households from recruitment to analysis. 
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5.4.3 Intention to treat analysis 
During follow-up there were 47 P. /a/ciparum cases, 16 P. vivax cases and 11 mixed infections 
from 44,024 participant-months (Table 5.6). No cases were excluded due to concurrent 
positive results within a month. Our sample size calculation required 633 households per arm 
with an annual parasite rate of 0.015 to measure a 50% intervention effect at 95% significance 
with 80% power. Despite the drop in malaria rates following baseline the trial actually 
recorded an annual parasite rate of 0.020. The loss to follow up resulted in 696 households in 
the placebo arms and 702 households in the treatment arm. Therefore the trial was 
sufficiently powered to detect an intervention effect of at least 50%. 
Table 5.7 Individual and household malaria incidence by treatment group. 
Repellent Placebo 
Person-months at risk (PMAR) 22,145 21,879 
Malaria cases 36 38 
P. /a/ciparum cases 22 25 
P. vivax cases 7 9 
P. Jalciparum & P. vivax 7 4 
Incidence 0.002 0.002 
After exclusions for missing data a total of 44,024 person-months were entered into a multi-
level mixed effects Poisson regression to account both for repeated measures over time and 
household clustering. Age, LLiN use and nights spent away from the village were not included 
in any models as they were not significantly related to the outcomes in univariate analysis (full 
results in Appendix D). The second socio-economic score, PCA2, was also dropped from the 
final models as it showed no effect. After accounting for socio-economic score and gender 
there was no difference between the placebo and repellent arms for overall malaria incidence 
(rate ratio 0.96, 95% CI 0.54-1.71, p=0.886, Table 5.7), P. Jalciparum incidence (rate ratio 0.86, 
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95% CI 0.45-1.67, p=0.665) or P. vivax (rate ratio 0.91, 95% CI 0.33-1.47, p=0.0.850). The 
models showed that a higher PCAl score was associated with a reduced malaria risk in all 
models. Being female decreased the risk of overall malaria infection and P. !alciparum 
infection by 40-50% (overall malaria rate ratio 0.62, 95% CI 0.39-1.00, p=0.051, P. !alciparum 
rate ratio 0.54,95% CI 0.31-0.92, p=0.025). 
Table 5.8 Incidence rate ratios and 95% confidence intervals from In Poisson regressions on counts of 
overall malaria and P. Jalciparum infections. 
Variable Overall malaria P. falciparum P. vivax 
Placebo 1 1 1 
Repellent 0.96 (0.54-1.71 0.86 (0.45-1.67) 0.91 (0.33-2.47) 
p=0.886 p=0.665 p=0.850 
PCAl 0.76 (0.62-0.92) 0.76 (0.60-0.96) 0.71 (0.49-1.02) 
p=0.006 p=0.016 p=0.65 
Male 1 1 
Female 0.62 (0.39-1.00) 0.54 (0.31-0.92) 
p=0.051 p=0.025 
Ran d 0 m i sed Con t r 0 I led T ria I I 107 
5.4.4 According to protocol analysis 
A primary according to protocol (ATP) analysis excluded participant outcomes with less than 
90% compliance (self-reported lotion and LLiN use <27 evenings per month and volume of 
lotion used <270ml per month). Secondary analyses were also run using compliance cut-offs of 
75% (self-reported lotion and LLiN use <22 evenings per month and volume of lotion used 
<225m I per month) and 50% (self-reported lotion and LLiN use <15 evenings per month and 
volume of lotion used <150ml per month). This resulted in the exclusion of 25-56% of 
participant months (Table 5.8). 
Table 5.9 Participants-months entering ATP analysis. 
Compliance cut-off Repellent Placebo Total 
0% (ITI) 22,145 21,879 44,024 
50% 16,466 (74.4%) 16,426 (75.1%) 32,892 {74.7%} 
75% 10,938 (49.4%) 11,099 (50.7%) 22,037 {50.1%} 
90% 9,522 {43.0%} 9,845 {45.0%} 19,367 {44.0%} 
Age, gender, net use and nights spent away from the village were not included in any models 
as they were not significantly related to the outcome by univariate analysis (see Appendix D). 
The results of the ATP analyses were in line with the outcomes of the In analysis. After 
accounting for socio-economic scores there was no difference between the placebo and 
repellent arms in the overall malaria, P. falciparum or P. vivax models {Tables 5.9-5.11}. PCAl 
was again associated with a decrease in malaria risk and PCA2 was associated with an 
increased risk of P. falciparum infections. 
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Table 5.10 Incidence rate ratios (95% confidence intervals) and p-values for predictors in Poisson 
regressions for overall malaria incidence excluding participants with lower than 50%, 75% and 90% 
compliance. 
Placebo 
Repellent 
PCAl 
PCA2 
>50% 
1 
1.13 (0.55-2.32) 
p=0.730 
0.79 (0.63-1.00) 
p=0.048 
1.41 (1.05-1.91) 
p=0.025 
Compliance 
>75% >90% 
1 1 
1.36 (0.53-3.51) 1.45 (0.53-3.99) 
p=0.525 p=0.467 
0.55 (0.37-0.82) 0.58 (0.38-0.88) 
p=0.004 p=O.Oll 
Table 5.11 Incidence rate ratios (95% confidence intervals) and p-values for predictors in Poisson 
regressions for P. Jalciparum incidence excluding participants with lower than 50%, 75% and 90% 
compliance. 
Placebo 
Repellent 
PCAl 
PCA2 
>50% 
1 
0.96 (0.43-2.16) 
p=0.920 
1.51 (1.12-2.04) 
p=0.007 
Compliance 
>75% >90% 
1 1 
1.25 (0.38-4.13) 1.56 (0.45-5.39) 
p=0.710 p=0.482 
0.57 (0.36-0.91) 0.56 (0.34-0.92) 
p=0.017 p=0.024 
2.00 (1.18-3.41) 1.99 (1.12-3.53) 
p=0.010 p=0.019 
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Table 5.12 Incidence rate ratios (95% confidence intervals) and p-values for predictors in Poisson 
regressions for P. vivax incidence excluding participants with lower than 50% and 75% compliance. 
Compliance 
>50% >75% >90% 
Placebo 1 1 1 
Repellent 1.01 (0.32-3.16) 1.92 (0.48-7.68) 1.65 (0.39-6.90) 
p=0.993 p=0.356 p=0.494 
PCA1 0.65 (0.42-1.02) 0.51 (0.28-0.94) 0.61 (0.33-1.11) 
p=0.062 p=0.031 p=0.105 
S.4.S Compliance 
Participants aged over 12 years were provided with 300ml of lotion per month and median 
volume of lotion used was 260ml (IQR: 200-300ml). Children under 12 years were provided 
with 200ml per month and median volume used was 160ml (IQR: 133-200ml). Almost half of 
participants had used all lotion supplied each month and about 60% self-reported full 
compliance with daily lotion use. 
Although compliance and malaria rates were broadly similar in the two treatment arms, a 
closer examination showed some differences. After adjusting for household clustering, higher 
observed compliance was significantly associated with a lower odds of malaria in both 
treatment arms (placebo group odds ratio: 0.14, 95% CI 0.05-0.41, p<O.OOl; repellent group 
odds ratio 0.27, 95% CI 0.10-0.77, p=0.015). Figure 5.5 shows malaria rates decline with 
increasing compliance in the repellent group. In the placebo group the relationship is similar 
between compliance and malaria rates, but is less clear cut. 
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Figure 5.5 Malaria incidence in different repellent and placebo-use groups. 
A linear regression accounting for household clustering showed a weak but statistically 
significant relationship between observed and reported lotion use (r2=O.194, p<O.OOl). 
Compliance with LLiN use was much higher than lotion use regardless of treatment group 
(repellent users 97.0%, placebo users 97.4%, p=0.547). Linear regression showed a significant 
relationship between compliance to the two types of interventions (p<O.OOl). As shown in 
Table S.13, participants who were non-compliant with LLiN use were more likely to be non-
compliant with lotion use (logistic regression accounting for household clustering, p<O.OOl). 
Ran d 0 m i sed Con t r 0 I led T ria I I 111 
Table 5.13 Relationsh ip between compliance with LLiNs and compliance with lotions, compliance with 
lotion defined as both self-reported and observed lotion use of 100%. 
Repellent or placebo lotion use 
<100% 100% Total 
LLiN use <100% 1,280 (90.0%) 142 (10.0%) 1,422 
100% 36,264 (73 .6%) 12,983 (26.4%) 49,247 
Total 37,544 (74.1%) 13,125 (25.9%) 50,669 
Travel away from the village was more common in men (males 43.0%, females 38.8%, X2=95.6, 
p<O.OOl) and during September (Figure 5.5) . However no correlation was found between 
increased time away and increased lotion use (r2=0.002). 
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Figure 5.6. Percentage of participants each month who slept away from the village each month with 
corresponding lotion use. 
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5.4.6 Adverse Events 
Approximately one in ten part icipants reported one or more allergic reactions during the trial 
(repellent users 10.9%, placebo users 10.1%). A logistic regression accounting for household 
level clustering indicated reports of allergies were not associated with treatment group 
(p=0.518). However, women were about 30% more likely to report an adverse reaction than 
men (odds ratio=1.38, p<O.OOl) and there was no effect from age on the likelihood of allergies 
(p=O.101). 
5.4.7 Long-lasting insecticide nets 
All households in both treatment arms were provided with LLiNs at baseline. There was an 
overall reduction of 73 .8% (95% C.I : 44.3-103.4%) in malaria prevalence between baseline and 
the first month of follow-up. This effect persisted throughout the trial with malaria rates 
between 52-90% lower than baseline and low prevalences recorded over the peak of the wet 
season from June to September (Figure 5.6). 
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Figure 5.7. Monthly parasite rates at baseline and follow-up during 2009 and 2010. 
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5.5 Discussion 
5.5.1 Summary 
A randomised placebo controlled trial of 15% DEET repellent lotion used by agricultural 
communities in southern Lao PDR was carried out over two wet seasons in 2009-2010. The 
trial was powered to detect an intervention effect of 50% on malaria incidence. No significant 
reduction in malaria incidence was found from the use of the topical repellent. 
The regression analysis identified socio-economic scores as being the most important risk 
factors for malaria. The first score produce from the PCA was influenced mostly by housing and 
possessions. An increase of 1 in this score could represent having a tiled roof compared to a 
thatched one, ownership of 1.5 more motorbikes or 1 more television and corresponded with 
a 20-45% reduction in the risk of household malaria. Although malaria researchers in the Lao 
PDR have not previously looked for a link between malaria risk and wealth, our results are 
consistent with the findings of other studies where lower socio-economic status is associated 
with increased malaria risk [176,177]. 
The second PCA component related to animal ownership and an increase of 1 in this score 
could represent owning 12 more buffalo or 10 more pigs, and also corresponded with an 
approximate doubling in the risk of P. Jalciparum malaria. This variable had less association 
with overall malaria and P. vivax incidence. Participants in households owning more animals 
may spend more time outside and experience a higher level of biting, raising their risk of P. 
Jalciparum malaria. 
There was a sustained drop of over 50% in monthly malaria prevalence from baseline when all 
households were provided with LLlNs. Although this effect could be a result of changes in 
malaria as there was no control group, the fact that lower prevalences continued to be 
recorded throughout the wet season when they would have been expected to increase does 
support the effect of the intervention. In addition the baseline rates in 2009 and 2010 were 
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similar suggesting there had been no overall drop in malaria rates in the area between the two 
years. In conclusion this trial shows no additional protection from malaria from topical 
repellent above that provided by LLiNs the current best practice in the study area. 
5.5.2 Limitations 
The use of 15% DEET was chosen based on human landing catches in a village setting in rural 
Lao PDR (Chapter 2). This meant that the protection measured would accurately reflect the 
perception of biting pressure experienced by the participants of the trial. However the major 
malaria vectors in the area An. minimus and An. maculatus were very rare in entomological 
collections, so the level of protection by 15% DEET from these species was not tested. 
Anophelines show less response to repellents than other genera, including Stegomyia and 
Culex mosquitoes that made up the majority of catches in the local area [115, 118]. Therefore 
the recorded 98.9% protection against biting from15% DEET is potentially an overestimate for 
the protection from malaria vectors. 
While this gap in the efficacy testing of the intervention should be acknowledged, it is probably 
not as important as the variation in the dosage of DEET applied to the skin that would result 
from variation between user applications. A participant applying only 5ml of the repellent 
lotion, would achieve the same DEET dosage as 10ml of a 7.5% DEET lotion. Even two 
participants applying the same volume of lotion would end up with different dosages 
depending on their relative body size. This variability is a major limitation with topical insect 
repellents as an intervention tool, but this does not rule out other forms of repellent such as 
impregnated fabrics that can be better standardised. 
The trial was double-blinded and unblinding was only carried out after data analysis was 
complete. Landing catches in a village setting found a reduction in mosquito biting of over 95% 
from the trial repellent compared to the placebo indicating repellent users might easily be able 
to distinguish which group they had been assigned to after a short period of use. All 
households in one treatment arm from a particular village withdrew from the trial after three 
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months because they believed they had the placebo rather than repellent lotion, and 
unblinding found that they were correct. This meant the blinding while as good as it could be 
was not perfect. An alternative that could prevent the two lotions being directly compared 
would be to assign separate batch numbers to each household's supply meaning there was no 
easy way for participants to separate the two treatment groups. This method was not 
implemented in this trial as distribution of lotion was made each month by village health 
workers with limited education and it was judged that the system should work as simply as 
possible to avoid confusion. 
In order to avoid artificially increasing malaria rates in the placebo group through diversion of 
biting from repellent users, a maximum of 25% of any village were recruited to the trial. 
However although all members of a household were randomised to the same arm, there was 
no way to enforce repellent use by all members of a household at all times. Therefore, 
diversion of mosquitoes from participants using the repellent to participants within the same 
household not using the repellent could increase malaria risk for those individuals. Individual 
compliance could have a large impact on this household randomised trial, and the ability to 
accurately measure this could also have an important impact on the outcome. Participants 
were not compelled to use repellent during this trial, a demonstration of how much, where 
and when to apply the lotion was given at the start of the trial. Participants self-reported the 
number of evenings per month they used the lotion and as a second measure the amount of 
lotion returned was recorded. Random checks were also carried out in the evenings on a small 
sample of villages. Self-reported data on compliance is notoriously unreliable, so these data 
were combined with the volume of lotion used in order to filter non-compliers out of the ATP 
analysis. However uncertainty remained over the actual daily use of the lotion, in particular 
whether all members of a single household had used the lotion supplied equally. 
Compliance was lower in this trial than in previous repellent trials. Self-reported and observed 
data gave estimates of full compliance from 48-60%, other trials have reported compliance 
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levels from 68-98% [129-131, 178]. Only one repellent trial, in Ecuador and Peru, reported 
compliance around 50%, but this was because not enough repellent had been provided [128]. 
A mathematical model has suggested that compliance would be the most important influence 
on the success of repellent interventions [137], so this low level of compliance may explain at 
least some of the lack of effect found in our results. 
This trial was focused on agricultural populations and the results may not be applicable to one 
important malaria risk group within the GMS. Forestry workers spend much more time in the 
forest potentially without good access to healthcare, and live in more temporary 
accommodation meaning they may be more exposed to vector biting. They often come from 
elsewhere in the region and their movement between endemic and non-endemic areas has 
been linked to the spread of antimalarial resistance in the region [18]. 
5.5.3 Conclusions 
Southern Lao PDR shares similarities in malaria vectors, environment and the human 
population with much of the GMS and the results of this trial are likely to be applicable across 
this region. Topical repellents are not likely to be a suitable intervention for agricultural 
populations in this region already using LLiNs who require long-term protection throughout 
the wet season. The lIT and ATP analyses produced similar results meaning that non-use of 
the lotions is most likely not responsible for the lack of effect observed. But variability 
between individual dosages, inherent in the use of topical repellent may have confounded the 
results. In addition to this variability in dosage topical repellents require application every day 
relying on a large behaviour change for full protection. Therefore the longer the intervention 
needs to last, the lower the probability of full compliance. Therefore further work to test the 
effectiveness of repellents that can be better standardised, such as impregnated fabrics are 
recommended as a next step. 
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5.6 Additional Information 
5.6.1 Trial Registration and Study Protocol 
This trial is registered with ClinicalTrials.gov number NCT00938379. The full study protocol is 
described in Chapter 2. 
5.6.2 Funding and Support 
This trial is supported by the PSI Innovations Fund. Both the 15% DEET and the placebo 
formulations were donated by SC Johnson, who had no part in the design and analysis of this 
study. 
5.6.3 Ethical Approval 
Ethical Approval for this study was obtained from the Lao Ministry of Health and the Ethics 
Committee of the London School of Hygiene & Tropical Medicine (Appendix A). 
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Chapter 6: Attitudes of agricultural populations in southern Lao 
PDR to the use of topical insect repellent used to reduce 
malaria. 
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6.1. Abstract 
A cluster randomised trial was started in southern Lao PDR in 2009 to determine whether the 
use of 15% DEET and long-lasting insecticidal nets (LLlNs) could reduce malaria cases compared 
to those using a placebo and LLiNs. Following the first year of the trial focus group discussions 
were held to establish the opinion of the repellent users to the lotions used and explore 
reasons for non-compliance. Questionnaires administered throughout the trial collected 
similar information. A comparison between self-reported lotion use and the amount of lotion 
returned to health staff was also made. Only 20.2% of placebo users complained that the 
lotion was failing to reduce biting, although this was significantly higher than repellent users 
(13.1% p<0.001). Repellent users were more likely to complain about the smell of the lotion 
(repellent users 49.5%, placebo users 44.1%, p=0.003) however this did not affect compliance 
(smell given as reason for non-compliance in repellent users 12.3%, placebo users 12.1%, 
p=0.600). A weak but consistent relationship was found between self-reported lotion use and 
the amount of lotion that was observed to have been used (R2=0.21). An important finding 
from the FGDs was that many men and young children are outdoors fishing and hunting 
throughout the night, when it had previously been presumed people were protected by LLiNs. 
Adult men also spent more time sleeping away from home in the forest, in contrast to their 
wives who spent time away from the village at the family's rice fields. Previous village-based 
studies in southern Lao PDR found no difference between malaria risk in men and women, 
which was in contrast to the pattern in the rest of Southeast Asia where adult men are usually 
at greatest risk. Our findings showed adult men in southern Laos are carrying out high risk 
behaviours making them more susceptible to malaria. 
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6.2. Background 
Vector borne diseases are a significant problem in Southeast Asia where almost 700,000 
disability-adjusted life years (OALYs) were lost to malaria, dengue and Japanese Encephalitis in 
2004 [179]. Of these malaria currently causes most deaths, although within the Greater 
Mekong Sub-region (GMS) malaria cases fell by almost a quarter between 1998 and 2007 [18]. 
In this region malaria is a rural disease, disproportionately affecting poor and remote 
populations found along forested, mountainous border areas [18, 141]. In the Lao POR, this 
means malaria is most prevalent in the south-east, where in the two provinces of Attapeu and 
Sekong, 90% of the population are rural and about half of villages have no road access during 
the wet season [43]. A risk analysis in Attapeu found that malaria cases were associated with 
sleeping without a net or under an untreated net, sleeping away from home, visiting the forest 
and living within 2km of a suspected mosquito breeding site [45]. 
Local malaria vectors are Anopheles dirus, An. minimus and An. maculatus with An. dirus likely 
to be the major vector [44,49-51]. Members of the An. dirus complex are strongly associated 
with forest habitats which provide dry season larval sites allowing year round malaria 
transmission cycles to persist [52]. Biting behaviour in the An. dirus complex varies with sibling 
species, early evening feeding is observed in An. cracens and An. scanloni with others feeding 
later at night [54]. It is not yet clear which sibling species are present in southern Lao POR, to 
date sibling identification has only been successfully carried out in one central-Laos site which 
found An. dirus s.s. [52]. An. minimus is also recorded biting in the early evening across 
Southeast Asia [55, 145, 180]. All three bite outdoors as well as indoors, with only An. 
maculatus showing a marked preference for exophagy [44,49,50,56, 143-147, 150, 151]. This 
is important since current malaria control policy in the Lao POR is for the entire population at 
risk, estimated to be 70% of the country, to receive long-lasting insecticide treated nets (LLlNs) 
[162]. LLiNs are highly effective against mosquitoes indoors, and may reduce the overall vector 
density lowering both the indoor and outdoor biting populations. Nevertheless, where vectors 
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bite outdoors there is a need for additional measures of protection. A trial was designed to 
determine whether mosquito repellent applied daily in the early evening could protect against 
malaria vectors that bite outdoors in the early evening before subjects were asleep under 
LLiNs (Chapter 3). 
The present study aimed to find out more about the attitudes of the local people to insect 
repellent. The main aim was to identify any problems users experienced with the repellent and 
to explore reasons for non-compliance. Further issues concerning local people's perceived 
exposure to mosquitoes and their use of repellents or other methods of personal protection 
against mosquito biting outside the trial were also explored. A behaviour change like daily use 
of insect repellent would require the perception of biting or malaria to be an important 
problem. To examine the reliability of self reported data on lotion use a comparison was made 
between this and the amount of lotion left in the bottle as reported by health staff. 
6.3. Methods 
6.3.1. Questionnaires 
Questionnaire surveys were administered to each household (300 households for 5 months 
and 1,297 households for 8 months = 11,876) every month they participated in the trial. Forms 
were written and designed in English and translated into Lao (Appendix B). Training and 
consultations with local health staff were then used to check the questions, multiple choice 
answers and translations before the start of the trial. These forms were simple as they were 
often completed by workers with a low level of literacy. Therefore most questions could be 
answered by numbers, where responses were in words, they were entered into the database 
in Lao and translated into English by an independent team. Compliance with lotion use was 
measured by self-reported evenings per month. As self-reported data are unreliable, health 
staff also estimated the amount of lotion participants had used each month. As health staff 
visited participants' villages for follow-up and were therefore unable to carry weighing scales 
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or other equipment, a scoring system was used to estimate the lotion returned. Three 100mi 
bottles were given to each participant each month and the amount of lotion left in each bottle 
was scored out of 5, giving a total score 0-15. Both measures were compared to determine the 
level of accuracy in the self-reported data. Participants were also asked about any problems 
they experienced using the repellent, such as itching or headaches. 
6.3.2. Focus Group Discussions 
Four focus group discussions (FGDs) each involving a 6-7 participants were carried out in 
Layaokao and Kasom villages in Samackixay District, Attapeu Province, the Lao PDR in April 
2010. Participants were volunteers from each village who had taken part in the repellent trial 
the previous year aged 13-60 years. They were divided into two groups and separate 
discussions were held with each group. The first group were those who had reported good 
compliance with repellent use and the second group were made up of participants who had 
reported not using the repellent during the trial. Question lines were developed around 
problems with the repellent, where and when repellent was used, exposure to mosquito biting 
particularly any differences between age groups and genders and other forms of personal 
protection used. Discussions were carried out in the Lao language and run by a moderator who 
was fluent in both Lao and English, the trial manager (VCH) sat outside the discussion circle 
close to the moderator [181]. Discussions were also recorded on digital recorder. A Lao 
government observer and two local health staff were also present and made notes at each 
FGD. 
6.3.3. Data Analysis 
Analysis of FGD data started in the field. Following each session a discussion of the main 
themes that had emerged was held by trial staff and observers. The FGDs themselves were 
also reviewed to ensure all question lines had been addressed and that participants had not 
been lead into answering in a particular way. Following each discussion digital recordings and 
field notes were used to produce transcripts in English (Appendix). Discussions stopped when 
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both trial staff and observers agreed that no new information was being gathered. Transcripts 
were analysed according to the methods described by Dawson and Manderson [181]. 
Differences in compliance and opinions of the lotion between the two treatment groups were 
analysed using rate ratios. A correlation was performed between self-reported and health staff 
observed compliance using pairwise deletion of missing data. Data analysis was carried out in 
STATA 12 and all charts produced in Excel. 
6.3.4. Ethical Considerations 
Ethical approval for the repellent trial was provided by the London School of Hygiene & 
Tropical Medicine Research Ethics Committee and by the Lao Ministry of Health. The aim and 
procedure of the FGD were explained to participants, village elders and district health staff 
prior to the start of discussions. Participants were identified by codes to protect their 
identities. 
6.4. Results 
6.4.1. Study Population 
Over the course of the intervention trial 10,513 household questionnaires (11.5% lost to 
follow-up) were administered to 1,597 households, involving a total of 7,980 participants 
(Table 6.1). There were no differences between the age structure and gender balance of each 
treatment arm (Chapter 5). The repellent trial needed to ensure ethnic minorities were 
included as these groups are disproportionately affected by malaria in Southeast Asia and Lao 
PDR [18, 41]. The Lao PDR is incredibly ethnically diverse and the Lao ethnic majority only 
make up 54.6% of the total population [43, 182]. Amongst trial participants Lao only made up 
9.9% of households, the remainder coming from sixteen ethnic groups in the Katuic and 
Bahnaric-Khmer ethno-linguistic categories (Table 6.1). More than half of all trial households 
belonged to the four ethnic groups: Triang, Brao, Halak and Kriang which make up 1.6% of the 
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general population (full data in Appendix F). There were a total of 25 FGD participants, of 
which 14 (56%) were women, and the median age was 36 (IQR: 21-47). 
Table 6.1 Age, gender and ethnicity of the study population 
Repellent Placebo Total 
Participants (households) recruited 3,972 (795) 4,008 (802) 7,980 (1,597) 
Household follow-up visits 5,913 5,963 11,876 
Questionnaires returned 5,225 (88.4%) 5,288 (88.7%) 10,513 (88.5%) 
Median age in years (IQR) 19 (11-35) 20 (11-35) 20 (11-35) 
Female 2,193 (55.2%) 2,196 (54.8%) 4,389 (55.0%) 
Ethno-linguistic category Lao 396 (10.0%) 396 (9.9%) 792 (9.9%) 
Katuic 712 (17.9%) 726 (18.1%) 1,438 (18.0%) 
Bahnaric-Khmer 2,154 (54.2%) 2,106 (52.5%) 4,260 (53.4%) 
No or incomplete data 710 (17.9%) 780 (19.5%) 1,490 (18.7%) 
6.4.2. Opinions and problems reported with trial lotions 
Both lotions were well liked, over 90% of participants reported after 6-8 months that they 
enjoyed using the lotions, with no significant preference for either lotion (repellent users 
92.5%, placebo users 91.8%, Table 6.2). Although only requested to use the lotion in the 
evening, almost all participants also applied the lotions voluntarily during the day as well 
(repellent users 96.9%, placebo users 96.7%) and about 40% did this every month throughout 
the trial (repellent users 40.2%, placebo users 38.2%). 
Complaints about the lotions were most commonly to do with the smell (44.0%), followed 
about equally by no reduction in biting (16.5%), allergies (15.4%) and headaches (14.9%). 
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There were differences between the treatment arms as to the problems reported. After 
accounting for household clustering, it was found that there were no significant differences in 
reports of smell (p=0.314), allergic reactions (0.988) or headaches (0.565) between the two 
treatment groups (Table 6.2). However repellent users were significantly less likely to complain 
of mosquito bites whilst using the lotion (Table 6.2, p=0.002). Participants who did not use the 
lotion every evening were given a second opportunity to report problems with the lotion, 
when asked about their reasons for non-compliance. After accounting for household 
clustering, no differences between the two treatment groups were found in the reasons given 
for non-compliance (Table 6.3). 
Age and gender were also included in the models and it was found that men were significantly 
less likely to report problems with the lotions (odds ratio: 0.79, 95% CI: 0.74-0.85, p<O.OOl). 
Women were more likely to report problems with the smell (odds ratio: 1.30, 95% CI: 1.18-
1.44, p<O.OOl), allergies (odds ratio: 1.30, 95% CI: 1.12-1.52, p=O.OOl) and headaches (odds 
ratio: 1.39, 95% CI:1.20-1.61, p<O.OOl), although they were not any more likely than men to 
find the lotion had failed to repel mosquitoes (odds ratio: 0.95, 95% CI: 0.85-1.07, p=0.383). 
Age was also found to affect the reporting of problems, with older people complaining more 
frequently of the smell (p=0.035), allergies (p=O.OOl) and headaches (p<O.OOl), but age had no 
effect on the failure of the lotions to repel biting (p=0.368). 
Problems with the smell also emerged from FGDs where some users found the fragrance 
overpowering to the point of headaches and nausea. Allergic reactions to the lotions were also 
reported in the FGDs, although this was sometimes linked to using the lotion contrary to 
directions for example getting it into wounds or the eyes. Others reported adverse effects 
after using large doses of the repellent, although one participant used it every day for cosmetic 
reasons believing it to soften the skin. 
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Table 6.2 Problems reported about the repellent and placebo lotions at monthly follow-up visits. 
Repellent Placebo Odds Ratio 
P 
users (%) users (%) (95% c.i.) 
No problems reported 90.4% 89.95% 1.05 (0.90-1.23) 0.540 
Unpleasant smell 5.08 4.62 1.10 (0.91-1.34) 0.314 
Allergy 1.70 1.70 1.00 (0.76-1.30) 0.988 
Headache 1.58 1.71 0.93 (0.72-1.20) 0.565 
Biting not reduced 1.37 2.26 0.60 (0.43-0.83) 0.002 
6.4.3. Self-reported lotion use 
Participants were asked to use their lotion every evening, and lotion use was assessed at the 
end of each month. Participants over 12 years were given 300ml of lotion per month, allowing 
10ml per day for an adult. A single application of 10ml was used during landing catches 
(Chapter 4) and volunteers reported this volume to be more than enough with most having to 
reapply to already treated areas to use the full amount. Median lotion use was 86.7% per 
month, which equated to 260ml or 8.7ml per day. Approximately 60% of participants self-
reported full compliance with lotion use each month with no difference between treatment 
arms (repellent users 61.3%, placebo users 62.2%, p=0.588). Health staff also observed the 
volume of lotion that was returned and found less than half of participants had used all the 
lotion (repellent users 47.4%, placebo users 48.1%). A comparison of full compliance from 
these two measures showed the false positive rate, self-reported full compliance with non-
lotion use was 46.7%, much higher than the false negative rate, complete lotion use with self-
reported non-compliance 28.5% (Table 6.3). The relationship between self-reported and 
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observed lotion use was very similar between the two treatment arms (Figure 6.1). A weak 
positive correlation was found between the two measures (r2=0.19). 
Table 6.3 Observed and self-reported lotion use per participant-month . 
Observed lotion use per month 
<100% 100% Total 
Self-reported lotion <100% 14,122 (72.9%) 5,259 (27.1%) 19,381 
use per month 100% 12,339 (39.1%) 18,949 (60.6%) 31,288 
Total 26,461 (52.2%) 24,208 (47.8%) 50,669 
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Figure 6.1. Median and IQR for self-reported lotion use with observed lotion use for repellent and 
placebo users. 
The most common reason for non-compliance in both repellent and placebo users was 
forgetting to use the lotion (repellent users 68.8%, placebo users 69.1%, p=0.402). During FGDs 
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some participants said that they only used the repellent when they perceived mosquito biting 
to be bad, for example in the forest rather than the village. Although seasonal mosquito 
density for the study area is not available, malaria rates were highest between August and 
November when lotion use was highest (Figure 6.2). Other reasons for non-compliance 
included disliking the smell (repellent users 12.9%, placebo users 12.3%, p=0.212), and 
allergies which were slightly higher in repellent users (repellent users 3.8%, placebo users 
3.2%, p=0.029). Fourteen percent of participants gave no reason for non-compliance. 
Compliance with LLiN use was much higher than for lotion use regardless of treatment group 
(repellent users 97.0%, placebo users 97.3%, p=0.711). But a relationship was found between 
compliance with LLlN use and compliance with lotion use, and those participants who did not 
sleep under their LLiN every night were much less likely to use the lotion every day (X2=316.1, 
p<O.OOl). 
Table 6.4 Problems reported about the repellent and placebo lotions non-compliers. 
used the lotion every evening 
Forgot to use the lotion 
Did not use the lotion because of the 
smell 
Did not use the lotion because of an 
allergic reaction 
Did not use the lotion because it did 
not stop bites 
Repellent 
users (%) 
61.29 
28.25 
5.30 
1.55 
0.28 
Placebo Odds Ratio 
P 
users (%) (95% c.i.) 
62.21 0.96 (0.84-1.10) 0.559 
27.76 0.92 (0.76-1.12) 0.402 
4.95 1.04 (0.85-1.27) 0.731 
1.28 1.17 (0.86-1.59) 0.332 
0.43 0.63 (0.34-1.15) 0.131 
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Figure 6.2 Percentage of participants who self-reported full compliance and those who used over 200ml 
per month, bars show P. !alciparum rates in both treatment groups. 
6.4.4. Perception of biting and methods of personal protection 
Evening outdoor activity was revealed in the FGDs: people reported that at this time they 
could be walking from the rice fields or to the river, mending nets, eating, watching television 
or drinking and socialising. People would be exposed to outdoor biting mosquitoes during all of 
these activities as even those that take place in and around the house would either be in the 
open area underneath a stilted house, or on the veranda if the stilts were not high enough. But 
what also emerged in the FGDs was that people in this area are often active and outside their 
house at night. Men reported that they would start fishing in the river at around llpm using 
lights to attract fish. During the peak of the wet season young children would also be collecting 
frogs as a supplement to their diet from flooded rice fields at around the same time. The In 
analysis found that men had almost twice the risk of P. falciparum infection compared to 
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women (men 1.8 cases per 1,000, in women 0.9 per 1,000, rate ratio: 0.54, 95% CI: 0.32-0.93, 
p=0.027). Visiting the forest is known to be a risk factor for malaria in Southeast Asia [183], 
and might explain the difference between infection rates between the genders. When asked 
whether the forest or the rice field had highest biting, 86% people chose the forest. Both men 
and women spent similar amounts of time away from the village during the day, but men were 
more likely to sleep away from the village (Table 6.4). FGDs suggested that while both men and 
women visited the forest, longer overnight trips were usually undertaken by groups of adult 
men whereas couples or family groups would only visit during the day and in general women 
who slept away from the village would be at their rice fields. 
Table 6.5. Time spent away from the village by men and women. 
Men Women p 
Mean days away from village per month 15.3 15.1 0.368 
Spent >20 days away from village per month 35.0% 34.77% 0.705 
Mean nights away per month 7.1 6.7 0.007 
Spent >7 nights away from village per month 32.1% 29.9% <0.001 
Participants were asked whether they thought they had suffered malaria in the previous year 
regardless of RDT test results and if they knew how it had been transmitted. It should be noted 
here that the word for malaria in Lao language actually translates as 'mosquito fever' so the 
link to mosquitoes is clear. But with the high proportion of ethnic minorities in this trial it was 
desirable to see whether mosquito bites were still linked to malaria. Almost 40% of people 
believed that LLiNs would protect from malaria, and this was unaffected if the person had 
previously had malaria (malaria 39.1%, no malaria 39.6%). Whereas the belief that repellents 
could protect from malaria was significantly lower amongst participants who thought they had 
caught malaria in the previous year (malaria 12.2%, no malaria 21.7%, p=0.014). Another 
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method of reducing insect biting described during the FGDs was to wear long clothing and 
even cover the face when visiting the forest or rice fields. Smoke, produced by a variety of 
methods, was used to drive away insects. Cooking fires kept mosquitoes away from the house 
or forest camps in the evening. Ropes can be made of tissue or rice leaves (from seedlings 
before transplantation) which are then burnt close to the body when travelling through the 
forest. One FGD participant even said that smoking cigarettes would reduce biting. Citronella 
was also mentioned during FGD, simply crushed and mixed with water and applied to the skin, 
although there were complaints that this was not effective for more than two hours. The trial 
repellent was generally thought to be more convenient than these methods. 
6.5. Discussion 
6.S.1. Compliance 
The repellent was popular and acceptance was high although there was little history of topical 
repellent use in the area prior to the trial. There is a tradition of insect repellents, but as found 
our FGDs and by other researchers these are usually burnt as torches or incense rather than 
applied to the skin [81]. The compliance with repellent or placebo lotion use was around 60%, 
which compares well with other trials. Compliance of over 85% has recorded in Thailand but 
this trial used a product that was already well accepted by the user group and compliance of 
over 98% in a Bolivian trial was achieved by stringent nightly checks [131]. A much lower level 
of compliance, around 20%, was recorded in a trial of repellent soap where the intervention 
was on sale rather than provided free of charge [132]. In our study we found a weak but 
consistent relationship between self-reported and observed data for compliance. About 30% 
of participants presented inconsistent data, where they had reported using the repellent every 
evening in a month whilst actually using less than 200ml of lotion. These results suggest an 
adjustment of the inclusion criteria for the clinical trial analysis may be advisable, perhaps 
excluding participants with these inconsistent data. 
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Comparisons between self-reported and objectively measured data have been made in 
antiretroviral therapy studies where patients are required to take medication daily over the 
long-term and patient recall over several weeks or months make their findings relevant to this 
study [184-186]. Self-reporting always overestimates the compliance as there is social pressure 
to appear to comply with treatment. One study ranked patients by their likelihood to give a 
'socially desirable response' and found this significantly improved predictions of clinical 
response to self-reported treatment [186]. Other trials have found consistent results, pre-
operative physical activity in bariatric patients was identical when measured by self-reporting 
and objective measurements from an accelerometer, but self-reported post-operative physical 
activity was 11 times higher than that measured by the accelerometers [187]. There was great 
similarity in our study between self-reported full-compliance and full compliance as defined by 
use of at least 200m I of lotion. Comparison with similar trials suggests that this cut off may be 
too low and could be overestimating true compliance. 
Although LLlN use was much higher than use of either lotion, the compliance with both 
interventions was closely related and the percentage of participants who were fully compliant 
with lotion use was twice as high amongst participants who were also fully compliant with LLiN 
use as those who were not. The trial was carried out in an area of low malaria transmission, so 
people may have chosen not to use an LLiN or repellent because they believed they were not 
at risk of malaria. There is some indication that this could be the case from raw malaria figures 
(LLIN compliant 1.3 P. fa/ciparum cases per 1000, LLiN non-compliant 0.7 cases per 1000), but 
a more in depth study of village level malaria and compliance would make this clearer. 
6.5.2. Social acceptability of repellent 
The smell of the repellent was found more offensive than the placebo lotion, suggesting that 
the smell of DEET itself was what participants objected to, although this did not translate to a 
reduction in compliance. However it may be that higher concentrations would be less 
acceptable, particularly for long term use. Allergies were reported by about 16% of 
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participants and there was no difference between repellent and placebo groups, meaning 
DEET was not responsible for all adverse reactions. This was high when compared to the 
proportion who gave an allergy as the reason for non-compliance, less than 4% in both groups. 
FGDs suggested there may have been some confusion over the definition of an allergic 
reaction. Allergies were defined with local health staff prior to the trial as a rash, redness or 
swelling of the skin where lotion was applied or breathing difficulties. But FGD participants 
reported 'allergic reactions' when the lotions were misused such as applying to wounds or 
accidently getting into the eyes. This kind of accidental exposure to wounds might be 
commonly experienced by participants carrying out agricultural work, but as it was recognised 
that the misuse rather than the lotion was to blame this had little effect on overall compliance. 
Safety directions were given at the start of the trial during demonstration of lotion use and 
enforced by posters in villages and by illustrated directions on the bottle labels. However, as 
participants were reporting adverse effects from misuse and over-use it was clear that 
participants were not always following these instructions. Not all over use resulted in adverse 
reactions and observations from FGDs found women using lotions for cosmetic rather than 
insect repellent reasons, this is echoed in other trials where repellent use was found to be 
highest amongst women and unrelated to malaria knowledge [188]. LLiN use is promoted in 
southern Lao PDR by interactive educational shows, and it may be necessary to use this type of 
communication to promote appropriate use of repellent. 
6.5.3 Malaria exposure 
Across Southeast Asia young men are usually found to be at greater risk of malaria and this is 
often explained by men making more visits to the forest and thereby coming into greater 
contact with An. dirus, the major malaria vector of the region [20-22, 155]. However in the Lao 
PDR village trials have mostly found no difference between male and female infection rates 
[45-47]. This discrepancy could have been explained by the exclusion of forestry workers from 
these village-based surveys, these are often young male immigrants and are at high risk both 
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through exposure and because they may have come from malaria-free areas and have no 
natural immunity. However, our trial also excluded this group but still found malaria rates 
more in line with the rest of Southeast Asia with men at greater risk of infection. Differences in 
study methodology are most likely to explain the differences. Local people spend much of the 
rainy season away from their villages living nearer to their rice fields. Participants in the 
repellent trial were recruited before the wet season and asked to return to the village once a 
month for follow-up surveys throughout the rains. Other trials have recruited participants 
present in the village when researchers turned up, which could have excluded those living 
away who are potentially at greater risk. Control programmes in the Lao PDR need therefore 
to focus more on this behaviour for example by supplying single man LLiNs that can be taken 
into the forest. 
The intervention trial used repellent in the evening and LLiNs at night, but evidence from FGD 
suggests that the repellent would be useful at night as well. Men and children were outdoors 
at night carrying out activities such as fishing or catching frogs. This night time exposure is 
likely to be an important risk factor for malaria and consideration of this is recommended in 
future control programmes. 
6.5.4. Conclusion 
The trial repellent and placebo lotion were generally well liked and use was high, but 
improvements could be made to make them more accepted. Spray formulations or repellent 
wipes that could be easily transported or a water resistant formulation that could protect 
during fishing might be well appreciated. Overall, topical repellents were successfully 
introduced in the study area despite the lack of their traditional use. Control programmes that 
include repellents would need to address education, particularly focusing on appropriate and 
safe use, to maximise their uptake. 
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Chapter 7: A meta-analysis of randomised controlled trials of 
topical insect repellent to reduce malaria. 
7.1 Abstract 
Background: Malaria is major cause of mortality and morbidity in developing countries. The 
vector control strategies currently recommended by the World Health Organization (WHO) are 
long-lasting insecticidal nets (LLlNs) and indoor residual spraying (IRS). Both these strategies 
target mosquitoes that rest and feed indoors. But in Southeast Asia and South America local 
vectors are primarily outdoor biting. Therefore there is a real need for tools such as insect 
repellents that can prevent outdoor biting. 
Objectives: To assess the impact of topical insect repellents on malaria cases. 
Methods: Published and unpublished trials were sought using CAB Abstracts, Cochrane library, 
EthoS, LILACS, Open Grey, Pubmed, Web of Science, the WHO Library, ClinicalTrials.gov and 
Current Controlled Trials. Reference lists of papers were checked and researchers contacted 
for unpublished data. The search criteria were cluster and randomised trials of topical insect 
repellent compared to placebo or no treatment to reduce malaria. Trials were assessed for 
inclusion, checked for bias and data extracted and analysed. 
Main results: Four trials including the Lao PDR repellent trial met the inclusion criteria. The 
average protection from Plasmodium /alciparum malaria by the use of topical insect repellents 
was 30% although this was not significant (rate ratio: 0.70,95% Confidence interval: 0.42-1.16, 
p=0.16). Similarly the 38% average protection against P. vivax infections did not reach 
significance (rate ratio: 0.62, 95% CI 0.18-2.16, p=0.45). 
Conclusions: In comparison with other repellent trials, the results from the Lao PDR showed 
generally lower protection from repellent use. However the effect was within the scope of 
other trial results and in fact only one trial showed a significant decrease in P. !alciparum 
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infections. The variation between trials was very high, which could be explained by different 
background malaria rates, different compliance levels or variation between intervention 
formulations. There was also suggestion of publication bias that excluded trials showing low 
effect from repellent. Overall the results show that topical insect repellent is not a suitable 
wide-scale intervention against malaria. 
7.2 Background 
The World Health Organization reported 655,000 confirmed deaths from malaria in 2010 [1], 
but the actual figure could be about twice as high, with a recent study estimating around 1.2 
million deaths [2]. The Roll Back Malaria initiative [189] recommends attacking malaria on 
three fronts: (1) vector control through long-lasting insecticidal nets (LLlNs) and indoor residual 
spraying (IRS), (2) preventative therapy for high risk populations and (3) accurate diagnosis 
with appropriate treatment. LLiNs reduce malaria mortality and morbidity by approximately 
50% in a range of settings [67]. However, LLiNs and IRS both work best against indoor biting 
mosquitoes. The most important malaria vectors in the Greater Mekong Subregion (GMS) are 
Anopheles dirus, An. minimus and An. maculatus which often bite in the early evening and 
outdoors before people can be protected by LLiNs [51, 56]. There is also evidence that the 
indoor biting African vector An. gambiae s.s. is being replaced by the outdoor biting vector An. 
arabiensis [136, 190, 191]. This change has been linked to the use of indoor insecticides in 
LLiNs and IRS, but whatever the cause the effect is the same, increasing the need for new tools 
to protect people against outdoor biting vectors. 
It is likely that people have been using repellents to prevent insect bites since pre-history [79]. 
Early repellents were largely plant derived and include some still in use today such as citronella 
(oil derived from plants of the Cymbopogon genus), neem (leaves from Azidarachta indica) and 
lemon eucalyptus (Eucalyptus maculata citriodon). Synthetic insecticides were first developed 
during the twentieth century, and N,N-diethyl-m-toluamide (DEET) the most effective repellent 
to date was developed in the 1950s [77]. Topical insect repellents are very successful at 
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reducing outdoor biting at any time of the day from a wide range of insects, but this protection 
is short-lived. The current 'gold standard' repellent, DEET, applied topically will provide up to 
six hours of protection under field conditions [125, 1271. This short period of effect means 
topical insect repellents are not suitable as a sole intervention, but they might be an effective 
complementary tool to LLiNs. 
7.3 Objectives 
To assess the impact of topical insect repellent on Plasmodium falciparum and P. vivax cases. 
The hypothesis is that insect repellent used in areas of outdoor biting will provide additional 
protection above that provided by LLiNs alone. 
7.4 Methods 
7.4.1 Literature search and study selection 
A literature search was performed to find randomised controlled trials of insect repellents 
used to prevent malaria. The search terms "insect repellent" and "malaria" were entered into 
more focused databases: CAB Abstracts, Cochrane library, EthoS and LILACS. Grey literature 
was also sought using the same search terms in the Open Grey database. Additional terms 
"trial" or "randomised controlled trial" were used to narrow the results from more general 
databases: pubmed, Web of Science and the WHO Library. Unpublished studies were searched 
for in clinical trials databases ClinicalTrials.gov and Current Controlled Trials and results 
requested from the authors. 
The results were checked for duplicates and the resulting references screened for inclusion in 
the qualitative and quantitative analyses. Trial interventions included any topical insect 
repellent regardless of active ingredient or concentration used. Repellent impregnated 
clothing was excluded as this would involve a different level of behaviour change from users. 
Space repellents were also excluded as the effect would be difficult to directly compare to 
topical applications. Outcomes reported had to include parasite rates of P. falciparum or P. 
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vivax malaria measured by blood smears or rapid diagnostic tests. Trials involving travellers 
from developed countries were also excluded as the compliance and trial duration would be 
very different to trials involving local populations. Trials had to be randomised controlled trials 
to be included in the quantitative analysis, but other studies such as case-control studies were 
also included for discussion in the qualitative analysis. 
7.4.2 Data collection and analysis 
Standard forms were used to collate trial location; study population; randomisation; blinding 
methods; repellent formulation; estimated coverage or compliance and method of estimation; 
type of control; co-interventions; outcome measures and length of follow-up from each trial. If 
not presented in the report, the trial location was used to infer malaria endemicity, 
Plasmodium species and Anopheles vectors present. 
Review manager 5.1 was used to calculate rate ratio, rate difference, summary rate ratio and 
summary mean difference. If the model 12 value was >50% indicating significant heterogeneity 
between studies random effects were used to calculate confidence intervals. 
7.4.3 Risk of bias 
Randomised controlled trials were assessed for risk of bias through recruitment bias, 
generation of allocation sequences, allocation concealment, blinding, baseline imbalance, 
missing data and selective reporting. Recruitment bias would arise when recruitment 
procedures exclude groups of participants, a common example would be the exclusion of 
certain age groups, which means that the findings of the trials may not apply to these excluded 
groups. Trials were given an assessment of 'A' meaning the recruitment process was fair and 
representative, 'B' indicating the recruitment process was unclear or not described, and 'e' if 
the recruitment process was clearly biased. The generation of the allocation sequence 
describes the method of randomisation. Good randomisation ensures the treatment groups 
are comparable and each individual or cluster should have an equal chance of ending up in 
each group. Trials were assessed as 'A' acceptable randomisation method, 'B' if trial described 
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as randomised but method not described or '(' poor randomisation. Allocation concealment 
and blinding are closely related but slightly different. In a blinded trial the participants do not 
know which treatment or placebo they have been given, in a double-blinded trial the people 
assigning the intervention also do not know the identities of the treatment. Allocation 
concealment means that steps have been taken to ensure nobody concerned with the data 
collection or analysis know or can find out which treatment they have been given, so usually 
the key to identifying the treatments is kept securely until the all data analysis had been 
completed. Therefore trials were rated 'A' if the were double-blinded and had taken step to 
conceal the allocation sequence from investigators, 's' if stated as blinded but not clear who 
was blinded and allocation concealment not fully described or '(' if the blinding or allocation 
concealment were not acceptable. Imbalances in baseline measurements show that the 
randomisation may not have worked well, and that there are significant differences between 
the two groups. Trials were rated 'A' if treatment groups were similar across a range of 
measurements, 's' if treatment groups are similar only for baseline malaria rates or 'e' if 
treatment groups showed significant differences at baseline. Trials with a high level of missing 
data that was likely to be related to the outcome or was unbalanced between treatment 
groups were given a '(' assessment, if missing data is not reported clearly a'S' and low missing 
data or balanced missing data between groups an 'A'. Trials were also checked for selective 
reporting, so a trial reporting all pre-specified outcomes was assessed as 'A', if outcomes were 
not clearly pre-specified 's' or not all pre-specified outcomes were reported a 'e'. 
7.5 Results 
7.5.1. Study selection 
Fifty-six references were identified from the literature search, but 48 were excluded from both 
quantitative and qualitative analyses because they concerned the wrong intervention (10), 
wrong outcome (16), wrong study population (1) or wrong trial type (13) or a combination (8). 
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7.5.2 Study characteristics 
Eight studies of insect repellent against malaria were identified, including seven randomised 
control trials which were carried out in Bolivia, Ecuador and Peru, India, Lao PDR, Pakistan, 
Tanzania and Thailand and a case-control study in Afghanistan. The study characteristics of 
these trials are summarized in Table 7.1. Four of these studies were excluded from 
quantitative analysis. Two, the trials in Ecuador and Peru, and Thailand could not be entered 
into the meta-analysis because they did not report full data on cases and person time at risk 
[128, 129]. The Indian trial also failed to report separate incidence rates for P. falciparum and 
P. vivax [192]. The case-control study was could not be included in the meta-analysis, however 
it was included in the qualitative analysis as it was a well-run study giving informative results 
[132]. 
Table 7.1. Study characteristics of randomised controlled trials of insect repellent against malaria. 
Location Trial characteristics 
Afghanistan Trial type: Case-control study 
[132] Study population: Fever patients from two clinics in eastern Afghanistan. 
Cases were confirmed by microscopy. 
Repellent: Repellent soap containing 20% DEET and 0.5% permethrin was 
promoted by ministry of health staff in the year prior to the study. 
Other behaviours recorded: Age, gender, insecticide treated net use. 
Bolivia [131] Study popUlation: 860 households recruited from rural and peri-urban 
communities. Up to 20% of households per village were recruited. Participants 
were aged >10 years and 45.2% were female. 
Randomisation: Sequential alternate system used to randomise households. 
Blinding: Field staff and study participants were blinded to allocation. 
Intervention: 30% PMD lotion. 
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Coverage: Compliance measured by questionnaires, observed volume of 
lotion used and random sniff checks. 98.5% of participants used lotions >90% 
of the time. 
Control: 0.1% clove oil 
Co-intervention: Treated nets 
Outcome: P. falciparum incidence as measured by active monthly detection 
by RDT and P. vivax incidence passively detected by blood slide at a local 
clinic. 
Length of follow-up: 4 months 
Ecuador and Study population: 18 rural communities on the north coasts of Ecuador and 
Peru [128] Peru. 
India [192] 
Randomisation: Simple randomisation of matched pairs. 
Blinding: None 
Intervention: Repellent soap containing 20% DEET and 0.5% permethrin 
Coverage: 50-70% when soap was distributed free, 6% when soap was sold. 
Control: Untreated 
Co-intervention: None 
Outcome: Self-reported malaria episodes. 
Length of follow-up: 7 months 
Study population: 2 rural villages. 
Randomisation: Not described 
Blinding: None 
Intervention: Insect repellent, proprietary name Enteemosq, active ingredient 
not given. 
Coverage: Not estimated 
Control: Untreated 
Lao PDR 
Pakistan 
[130] 
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Co-intervention: None, but chemotherapy guidelines changed halfway 
through the trial possibly triggering large decreases in malaria incidence. 
Outcome: Malaria cases diagnosed by microscopy 
Length of follow-up: Two years 
Study population: 1,597 households recruited from agricultural communities. 
Up to 25% of households per village were recruited. Participants were aged 6-
60 years and 54.8% were female. 
Randomisation: Equal groups allocation of households stratified by village. 
Blinding: Data analyst, trial manager, field staff and study participants were 
blinded to allocation. 
Intervention: 15% DEET lotion 
Coverage: Compliance measured by self-reporting, observed volume of lotion 
used and random infrequent sniff checks. 58% of participants used lotions 
>90% of the time. 
Control: Placebo lotion 
Co-interventions: LLiNs 
Outcome: Active detection of P. falciparum and P. vivax cases by monthly 
RDTs 
Length of follow-up: 5-8 months (average 6.3) 
Study population: 127 households recruited from a refugee camp on Afghan 
border. 25% of households in camp were enrolled. Participants were aged >5 
years and 49.2% were female. 
Randomisation: Simple random allocation of households. 
Blinding: Study participants were blinded to allocation. 
Intervention: 20% DEET and 0.5% permethrin soap 
Coverage: Twenty (16%) households interviewed at end of study, 19 (95%) 
Tanzania 
[1781 
Thailand 
[1291 
reported using the repellent 'regularly'. 
Control: placebo lotion 
Co-interventions: None 
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Outcome: Passive detection of P. falciparum and P. vivax cases diagnosed by 
microscopy. 
length of follow-up: 5 months 
Study population: 937 households recruited from a rural village. 50% of 
households in a village were recruited. Participants were aged >6 months and 
55.3% of household heads were female. 
Randomisation: Sequential alternate allocation of clusters of 47 households. 
Blinding: Not described. 
Intervention: 15% DEET lotion 
Coverage: Compliance measured by self-reporting and compliance with 
repellent reported at 89% and placebo 68% 
Control: Placebo lotion 
Co-intervention: LLI Ns 
Outcome: Passive detection of malaria cases confirmed by RDT at local 
dispensary. 
Length of follow-up: 14 months 
Study population: 897 women 3-7 months pregnant recruited from Karen 
refugee camps in western Thailand. 
Randomisation: Method not described 
Blinding: Method not described 
Intervention: Repellent lotion containing 20% DEET and thanaka (Limania 
acidissima) 
Coverage: Compliance self-reported at 90.5% and actively detected at 84.6% 
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Control: A placebo formulation containing thanaka 
Co-interventions: None 
Outcome: Active case detection by weekly blood smears 
Length of follow-up: 18 weeks (median) 
7.5.3 Outcomes of individual studies 
The outcomes of the four studies excluded from the meta-analysis are described here, and 
Tables 7.2 and 7.3 show reported outcomes from included trials. In India, no effect was found 
on malaria rates following distribution of repellent for two years [192]. Again no significant 
reduction was found in malaria rates in Ecuador and Peru where repellent soap (20% DEET and 
0.5% permethrin) was distributed or sold [128]. In Thailand reductions in malaria rates were 
recorded in repellent users, but the lower than expected overall malaria rates meant that 
samples were to low for these reduction to reach significance [129]. A case-control study in 
Afghanistan found that the use of repellent soap reduced the odds of malaria by 45% even 
after accounting for confounders such as LLiN use [132]. 
Table 7.2. Outcomes (cases/person time at risk) of randomised controlled trials of repellent against P. 
!alciparum and resulting rate ratios with 95% CI between trial arms. 
Study Repellent Control Rate Ratio (95% CI) 
Bolivia [131] 1/7,706 6/7,468 0.16 (0.02-1.34) 
Lao PDR 29/22,145 29/21,879 0.88 (0.45-1. 71) 
Pakistan [130] 23/618 47/530 0.42 (0.26-0.68) 
Tanzania [178] 122/2,586.25 138/2,549.12 0.87 (0.69-1.10) 
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Table 7.3. Outcomes (cases/person time at risk) of randomised controlled trials of repellent against P. 
vivax and resulting rate ratios with 95% (I between trial arms. 
Study 
Bolivia [131] 
Lao PDR 
Pakistan [130] 
7.5.4. Meta-analysis 
Repellent 
14/7,673 
13/22,145 
103/618 
Control 
66/7,336 
14/21,879 
62/530 
Rate Ratio (95% CI) 
0.20 (0.11-0.36) 
0.96 (0.54-1.71) 
1.42 (1.06-1.91) 
The combined summary rate ratio for P. falciparum infection rates was 0.67 (95% CI 0.42-1.09, 
p=O.l1), giving a protective effect of 30% from repellent use although this did not reach 
statistical significance (Figure 7.1). The overall effect on P. vivax infection rates was similar to 
that for P. fa/ciparum but was again not statistically significant (rate ratio: 0.65, 95% CI 0.18-
2.34, p=0.51). Heterogeneity was very high (1 2=70% in the P. falciparum analysis and 12=94% in 
the P. vivax analysis) so random effects were used to calculate confidence intervals for the 
overall effect. 
• I Bolivia 
• I Lao PDR 
• I Pakistan 
............... Tanzania 
Total 
• 
0.01 0.10 Risk Ratio 1.00 10.00 
Figure 7.1. Rate ratios and 95% confidence intervals from randomised controlled trials of insect 
repellent against P. falciparum malaria. 
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Figure 7.2. Rate ratios and 95% confidence intervals for from randomised controlled trials of insect 
repellent against P. vi vax. 
7.5.5 Risk of bias 
An overall comparison of the risk of bias in each trial is shown in Table 7.4. Recruitment bias 
was low in three of the four studies, in the Lao PDR study, the use of village elders to choose 
trial households may preferentially have selected individuals whose compliance with the 
intervention and malaria monitoring was higher than in general. All trials used a fair system to 
generate allocation sequences, either simple randomisation or lottery systems. Bias from a 
lack of allocation concealment was less easy to assess. In Pakistan the placebo was a lotion 
which was compared to a repellent soap formulation, meaning that field workers may have 
known the treatment allocations throughout the trial. The other three trials used similar 
placebo and intervention products, but only the Lao PDR trial reported that the treatment key 
was kept away from researchers. Baseline imbalance was generally low, with some minor 
differences reported in the Bolivian and Tanzanian trials. Loss to follow-up and missing data 
were low in the Bolivian and Tanzanian trials, however the loss to follow-up was over 10% in 
the Lao PDR and this information was not reported from Pakistan. All trials reported the pre-
determined outcomes of P. !alciparum and P. vivax cases. Blinding was attempted in all trials, 
but with repellents, the possibility always remains that participants using the placebo quickly 
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notice that they continue to be bitten. This problem would particularly apply to trials where 
there were only two treatment codes for repellent and placebo, and participants were able to 
compare the efficacy of the two products. The Tanzanian trial may have reduced the likelihood 
of this comparison by randomising groups of geographically close households to the same 
treatment. All trials provided results of statistical analysis that took the effect of clustering into 
account. 
Table 7.4. Methodological bias in trials included in quantitative analysis. 
Potential source of bias Bolivia Lao PDR Pakistan Tanzania 
[131] [130] [178] 
Recruitment A B A A 
Generation of allocation sequences A A A A 
Allocation concealment B A B B 
Baseline imbalance A A A A 
Missing data A B B A 
Selective reporting A A A A 
Blinding B B B A 
Analysis allows for clustering A A A A 
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7.6 Discussion 
7.6.1 Summary of evidence 
The combined effect of repellent use from four randomised controlled trials was a 33% 
reduction in P. falciparum and a 35% reduction in P. vivax, although these differences were not 
statistically significant. There have only been four fully reported trials and any attempt to 
compare the results is confounded by varying background rates of malaria, user compliance 
and co-interventions. 
7.6.2 Limitations 
Heterogeneity was very high in the meta-analysis indicating substantial variance between the 
studies. As there were so few studies, it was not thought appropriate to create subgroups to 
account for some of the important differences between studies that could contribute to this 
high heterogeneity. The most obvious difference is in study location which would lead to 
varying background malaria rates. Malaria rates in the control groups ranged from 0.1-11.7 
cases per person per year. and mathematical modelling suggests that lower background 
malaria rates mean the repellent intervention could have a greater effect [137]. The 
interventions also varied; DEET, permethrin and PMD were all used at different concentrations 
and formulations. The formulation will have a large impact on dosage applied, so it is difficult 
even to make a judgement on a 15% DEET lotion being a less efficacious repellent than a 20% 
DEET soap. Compliance varied greatly between studies from 98% in Bolivia to 58% in the Lao 
PDR. Compliance is very difficult to assess in large trials as direct observation is only 
practicable in a small number of participants. Most of the trials used a combination of self-
reported data confirmed by a small number of direct observations. The mathematical model 
mentioned above suggests that compliance is the most influential component on a repellent's 
potential to reduce malaria. All of these factors made combining the studies to create an 
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overall figure for protection difficult, although with more studies it may have been possible to 
take factors such as malaria endemicity and compliance into account. 
It was also evident that publication bias may have affected the meta-analysis. Two trials were 
excluded from the meta-analysis because full data could not be found in the literature for case 
numbers. These were trials that did not find any effect and their publications may have been 
compressed because of this rather than any lack of methodological quality. Therefore despite 
not finding any significant value for repellent protection it is likely that the overall protection 
has still been overestimated. 
Despite vector control having a major role in current malaria control and elimination policies, 
very few meta-analyses have yet been carried out on vector control interventions. Two 
Cochrane reviews have been produced examining the effectiveness of LLiNs at reducing 
malaria, one of which concentrates on malaria in pregnancy. The general review found only 
fourteen studies to include in analysis [67]. A single meta-analysis has been produced on IRS, 
which included six studies and found that there was too little high quality data to establish an 
overall effect [193]. Mosquito larval source management and mosquito control using 
larvivorous fish are both awaiting a full meta-analysis, although a protocols have been 
published for both [194, 195]. One other Cochrane review has been published on electronic 
mosquito repellents which found no protective effect [87]. The scarcity of these meta-analyses 
and the small number of studies that are included illustrate how urgent the need is for further 
well-designed trials of vector control interventions. 
7.6.3 Conclusions 
The randomised controlled trial of 15% DEET against malaria in southern Lao PDR found no 
evidence of an effect on malaria. When put in the context of the results of other repellent 
trials, the measured effect is low but not significantly different from other outcomes, and 
much lower than the 50% effect that the trial in the Lao PDR hoped to detect. 
Met a - A n a I y sis 150 
Although LLiNs do work well, outdoor biting in South-east Asia means they are unlikely to be 
sufficient as a sole intervention method in this region. Signs of changes in mosquito behaviour 
in Africa also suggest protection against outdoor biting might be needed in other areas too. 
Repellents can protect against outdoor biting, but further trials of topical repellent aimed at 
developing a wide-scale malaria control tool are not recommended based on these results. 
What is needed now are trials of alternative modes of repellents delivery such as long-lasting 
repellent impregnated into clothing as well as trials that can measure the impact of repellents 
on other vector-borne diseases. 
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Chapter 8: Assessing the efficacy of topical insect repellents to 
reduce malaria in southern Lao PD R. 
8.1. Abstract 
Malaria remains a serious threat in the Greater Mekong Sub-region (GMS), not just from the 
direct impact on human health, but also from the emergence and spread of resistance to 
artemisinin, the last remaining effective antimalarial. Therefore malaria control in this region is 
a high priority on a global as well as local scale. In southern Lao PDR, as across much of the 
GMS, malaria vectors bite outdoors in the early evening before people are protected by their 
bed nets. Lotions containing 10-20% N,N-diethyl-m-toluamide (DEET) were shown to protect 
users from 96-99% of biting by mosquitoes between 17.00 and 22.00h in a village in southern 
Lao PDR. 15% DEET was found to be the best choice of intervention as it provided the most 
reliable protection at the lowest dose. A randomised controlled trial was designed to test the 
effect of 15% DEET against malaria. A total of 1,597 households were recruited and 
randomised to either a 15% DEET or a placebo lotion. All households were also provided with 
long-lasting insecticide treated nets (LLlNs). Intention to treat analysis found no difference 
between treatment arms after accounting for gender, socio-economic status and observed 
lotion use (rate ratio 0.96, 95% CI 0.54-1.71, p=0.886). According to protocol (ATP) analyses of 
participants who used the lotions over 90% of the time also found no effect from repellent use 
after other factors had been taken into account (rate ratio 1.45, 95% CI 0.53-3.99, p=0.467). 
The most important predictor of malaria incidence was a socio-economic score based on a 
combination of factors including housing materials, access to services such as electricity and 
ownership of key possessions like motorbikes. Lower wealth resulted in higher risk of malaria 
in both In and ATP models for outcomes of P. !alciparum, P. vivax and overall malaria. While 
the repellent was well received and over 90% of participants said they liked using both the 
lotions, compliance was still low with fewer than 60% of participants using the lotions more 
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than 90% of the time. However, the results of the ATP analyses suggest that low compliance 
was not responsible for the lack of observed effect from the trial. The size of the effect on P. 
ja/ciparum was lower than in other randomised controlled trials of repellent carried out in 
Bolivia, Pakistan and Tanzania. A combined rate ratio from all four trials found that repellent 
use was associated with a 33% reduction in P. /alciparum incidence and a 35% reduction in P. 
vivax incidence. Two trials were excluded from this analysis as full data were not reported; 
both had non-significant results. 
The outcome of this trial shows that topical insect repellent is not a suitable wide-scale 
intervention against malaria and does not provide significant protection over and above LLiNs 
in an area of outdoor biting. However, repellents do undoubtedly reduce biting and therefore 
their potential to be effective intervention tools remains. Smaller-scale interventions could be 
more effective, such as targeting high-risk groups such as children, pregnant women or non-
immune migrants. Alternatively repellent impregnated clothing could provide outdoor 
personal protection which requires much less of a behaviour change from the user than topical 
formulations. 
8.2. Background 
Malaria is a major health problem across the tropics, but the nature of the challenge varies 
between different regions. Malaria in Africa accounted for 78% of the 225 million cases and 
91% of the 780,000 deaths caused by the parasites in 2009 [48]. In the Greater Mekong Sub-
region (GMS) the major concern is the development of antimalarial resistance as genetic 
studies suggest this region is where strains resistant to chloroquine and pyrimethamine 
emerged previously, before spreading to other endemic areas [5,1961. At present artesunates 
are the only remaining effective antimalarials and the first cases of artesunate-resistance have 
already been detected on the Thai-Cambodian border [197]. 
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The current best method of malaria prevention is the use of long-lasting insecticidal nets 
(LLlNs), but these have a major limitation in the GMS. The most important malaria vectors in 
the GMS are Anopheles diru5, An. minimu5 and An. maculatu5, which bite in the early evening 
and outdoors before people are protected by their bed nets [51, 56]. Outdoor biting behaviour 
also makes control methods such as indoor residual spraying or house screening less effective. 
Larval control is limited as larval habitats are normally small water bodies found in the forest 
or forest fringe, challenging to access and identify [52, 55]. There is also evidence that vector 
behaviour in Africa is shifting towards outdoor and evening biting, perhaps in response to 
indoor insecticide use such as LLlNs and indoor residual spraying [136, 190, 191], increasing 
the need for tools to protect against outdoor biting. Topical insect repellents seem to answer 
these issues with LLiNs. They can protect against outdoor biting as easily as indoors, and are 
suitable for use at any time of the day. 
One of the most obvious limitations with insect repellents is the duration of protection. The 
current 'gold standard' repellent, N,N-diethyl-m-toluamide (DEET), applied topically will 
provide up to six hours of protection under field conditions [125, 127]. In comparison, LLiNs 
last up to five years and can be permanently suspended over the bed space further reducing 
the effort required by the user. This also means that topical repellents cannot provide all-night 
protection whilst people are asleep as this would require the user to wake and reapply during 
the night. The solution to this would be a more permanent repellent formulation, such as 
impregnated clothing. 
Repellents can have an insecticidal effect in the laboratory, but under normal field conditions 
the repellent prevents direct contact and any lethal effects. LLiNs have the advantage here 
too, as the insecticide reduces the mosquito population in the local area, reducing disease 
transmission for both net-users and non-users. Repellent users may actually increase the risk 
to nearby non-users by diverting biting pressure [121]. However, these disadvantages of 
repellents and advantages of LLiNs do not necessarily apply to the outdoor biting scenario in 
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the GMS. The community effect of LLiNs is likely to be diluted as fewer mosquitoes enter the 
house and come into contact with the insecticide. If the LLlN is carried into the forest for the 
night, killing a small number of mosquitoes here will likely have no impact on human health at 
all. Diversion of biting away from repellent users might not increase disease risk for other 
people as many of the GMS mosquito vectors will readily bite animals as well as humans [56]. 
Therefore while repellents are not suitable as a sole control method, when used in conjunction 
with LLiNs they have the potential to provide more complete protection in areas of outdoor 
biting. A randomised controlled trial was therefore designed to test the hypothesis that 
repellents could provide additional protection against malaria when used alongside LLiNs in 
southern Lao PDR. 
8.3. Entomology Surveys 
Entomological surveys were carried out in Gueng Makheua, Saysettha District, Attapeu 
Province as a typical lowland village, surrounded by a mix of open woodland and rice fields. 
The village was approximately 30km from the district hospital, but was the site of a local health 
centre servicing four villages. Routine entomological surveys using light traps and larval 
sampling were carried out in July 2009 to gather background information on the species found 
in the study area. In July 2010 human landing catches with 10%, 15% and 20% DEET and a 
control lotion were carried out over sixteen evenings between 17.00h and 22.00h in a Latin-
square rotation to compare the efficacy of these concentrations. 
The most common mosquito species in both landing and light trap collections included 
members of the Culex vishnui subgroup known to be vectors of Japanese Encephalitis (JE) as 
well as members of the Stegomyia and Armigeres genera which feed early in the evening. On 
average light traps caught 50 mosquitoes per trap-night and all-night landing collections 15 
mosquitoes per person-night. About three times as many species were also recorded from the 
light traps, but these would represent mosquitoes attracted indoors which may only be to rest 
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rather than feed on humans sleeping indoors. Therefore in a region with such high mosquito 
species diversity such as Southeast Asia, landing catches are necessary to establish the species 
that are actually biting humans and therefore of potential importance for disease 
transmission. 
All DEET concentrations tested gave significant protection from biting compared to the 
placebo over the five hours of testing. After controlling for night and collector variation, 10% 
DEET gave 96.1% protection (95% CI. 92.4-99.0%), 15% DEET provided 9S.9% protection (95% 
CI. 96.0-100%) and 20% DEET gave 98.1% protection (95% CI. 95.0-100%). The greater 
variation found in the protection from 10% DEET means that 15% would be a safer 
recommendation for use in the repellent trial, where environmental conditions will be much 
more variable and repellent use will be mostly unsupervised. 
8.4 Randomised controlled trial of topical repellent against 
malaria 
A double blind, household randomised, placebo controlled trial of insect repellent to reduce 
malaria was carried out in southern Lao PDR to determine whether the use of repellent and 
LLlNs could reduce malaria more than LLiNs alone. Three hundred household were recruited in 
June 2009 and a further 1,297 in April 2010 giving a total of 1,597 households which included 
7,979 participants. In total 795 households (3,972 participants) were assigned to use a 15% 
DEET lotion and S02 households (4,007 participants) a placebo lotion. Randomisation was 
stratified by village and participants, field staff and data analysts were all blinded to the group 
assignment. All households received new long lasting insecticidal nets (LLlNs) the current best 
practice. Participants were asked to apply their lotion to exposed skin every evening from 
lS.00h until retiring, adults were provided with 300ml per month and children under 12 years 
with 200ml. Plasmodium falciparum and P. vivax cases were actively identified by monthly 
rapid diagnostic tests. Five rounds of follow-ups were completed in 2009 and eight in 2010. 
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An initial intention to treat (ITI) analysis was performed on all data. Household socio-economic 
scores, age, gender, nights slept under an LLlN, nights spent away from the village, self-
reported lotion use and observed volume of lotion used were tested using non-parametric 
univariate tests for inclusion in the model. Those with a significant association with the 
outcome at p<O.2 were then considered for inclusion in a multi-level mixed effects Poisson 
regression model adjusted for intra-cluster variation by random effects methods. Variables 
maintaining their association in the multivariable model at p<O.05 were kept in the final 
model. According to protocol (ATP) analyses were then performed which excluded participants 
who complied with LLiN and lotion use less than 90%, 75% and 50% of the month. The effect of 
LLiN use on malaria was estimated by comparison of malaria rates before and after baseline. 
Intention to treat analysis included 1,398 households followed up for a maximum of eight 
months. No effect from the use of repellent was found on malaria incidence (IRR: 0.96, 95% CI: 
0.54-1.71, p=0.886). A higher household socio-economic score indicating higher wealth was 
found to decrease the risk of malaria. Women were found to have approximately half the risk 
of P. !alciparum malaria compared to men (IRR: 0.54, 95% CI: 0.31-0.92, p=0.02S), although 
gender was not significant in P. vivax models. ATP analysis produced consistent results, no 
effect from the use of repellent was found, while lower wealth increased malaria risk. 
8.5 Acceptance of topical repellents as an intervention tool 
Compliance with LLiN use and lotion use were first compared separately between treatment 
arms and then a chi-squared analysis of the relationship between compliance with each 
intervention was performed. Focus group discussions were held to establish the opinion of the 
repellent users to the lotions used and explore reasons for non-compliance. Questionnaires 
administered throughout the trial collected similar information. Reports of adverse events 
were compared between treatment groups using a chi-squared test. A logistic regression was 
run to examine treatment group, age and gender as predictors for the reports of allergic 
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reactions. A comparison between self-reported lotion use and the amount of lotion returned 
to health staff was also made. 
Almost two-thirds of participants reported that they had used the lotion at least 90% of the 
time (repellent users 65.5%, placebo users 66.2%, X2=2.47, p=0.116). However less than half of 
participants used more than 90% of the lotion supplied each month (repellent users 47.4%, 
placebo users 48.1%, X2=2.31, p=0.129). There was a weak but consistent relationship found 
between self-reported lotion use and the amount of lotion that was observed to have been 
used (pair-wise correlation r2=O.19) and 61.9% of paired observations were within 10% of each 
other. The most common reason for not using the lotions every night was forgetfulness, with 
no difference between treatment groups (repellent users 68.8%, placebo users 69.1%, X2=0.18, 
p=0.675). Only 20.2% of placebo users complained that the lotion was failing to reduce biting, 
although this was significantly higher than repellent users (13.1%, p<0.001). Repellent users 
were more likely to complain about the smell of the lotion (repellent users 49.5%, placebo 
users 44.1%, p=0.003) however this did not affect compliance (smell given as reason for non-
compliance in repellent users 12.3%, placebo users 12.1%, p=0.600). 
8.6 Meta-analysis of randomised controlled trials of insect 
repellent against malaria 
A meta-analysis was carried out to assess the impact of topical insect repellents on malaria. A 
literature search identified four trials including the Lao PDR study that met the inclusion 
criteria. The average protection from malaria through the use of topical insect repellents was 
33% for P. falciparum infection (rate ratio: 0.67, 95% CI: 0.42-1.09, p=O.l1) and 35% for P. 
vivax infections (rate ratio: 0.65, 95% CI 0.18-2.34, p=0.51). However neither of these figures 
reached statistical significance. The variation between trials was very high, which could be 
explained by different background malaria rates, different compliance levels or variation 
between intervention formulations. There was also suggestion of publication bias that 
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excluded trials showing low effect from repellent. Overall the results show that topical insect 
repellent is not a suitable wide-scale intervention against malaria. 
In comparison with other repellent trials, the results from the Lao PDR showed generally lower 
protection from repellent use. However the effect was within the scope of other trial results 
and only one of the trials showed a significant decrease in P. /alciparum infections. 
8.7 Conclusions and future work 
The randomised controlled trial of 15% DEET against malaria in southern Lao PDR found no 
evidence of an effect on malaria. When put in the context of the results of other repellent 
trials, the effect is low but not significantly different from other outcomes. Overall the 
combined effect of repellent use from four randomised controlled trials was a 33% reduction 
in P. !alciparum and a 35% reduction in P. vivax. These figures are much lower than the 50% 
effect that the trial in the Lao PDR hoped to detect. However, there have only been four fully 
reported trials and any attempt to compare the results is confounded by varying levels of 
malaria endemicity, user compliance and co-interventions. 
Compliance with daily or nightly repellent use is very difficult to assess as direct observation is 
only practicable in a small number of participants and most of the trials used a combination of 
self-reported data confirmed by a small number of direct observations. There did seem to be a 
relationship between higher compliance and greater intervention effect. This relationship has 
also been suggested by a mathematical model built to explore a repellent's potential to reduce 
malaria. The model found that a drop in compliance from 98% to 80% would result in an even 
larger reduction in effect from 89% to 48% [137]. Coverage in a control programme is likely to 
be lower than within the highly controlled conditions of a clinical trial, meaning repellents used 
as a wide-scale intervention would have very little impact. In the Lao PDR compliance with use 
every evening was less than 60% although over 90% of participants claimed to like using the 
repellent and adverse reactions were rare. The most common reason for not using the lotion 
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was forgetfulness rather than not liking the lotion. This suggests that topical repellents are 
limited as an intervention tool as they require too great a behaviour change in users. 
Repellents applied to clothing could be a suitable alternative to protect against outdoor biting, 
but at present there is little data on their effectiveness and none on their efficacy to reduce 
disease transmission. Traditional clothing in the Lao PDR tends to leave the lower legs and 
feet, favourite feeding locations for mosquitoes, uncovered. Trials are required to determine if 
repellent clothing can protect the whole person against biting rather than just the covered 
skin. In addition while it has been shown that mosquitoes can be diverted from repellent users 
to non-users over a distance of 1m, it is not known whether mosquitoes can be diverted to 
another part of the body. Mosquitoes tend to prefer biting around the feet and ankles, so it 
would be useful to know if this can be changed by the use of repellents on the ankles. 
Although An. minimus and An. maculatus were captured in entomological collections, most 
biting pressure came from vectors of Japanese Encephalitis (JE) rather than malaria vectors. 
Very little is known about JE in the Lao PDR as until recently there has been no national 
diagnostic programme. However the arbovirus is confirmed in neighbouring China, Thailand 
and Vietnam, where vaccine programmes appear to have helped reduce cases and may be on 
the increase in Cambodia and Myanmar, where like the Lao PDR there are no vaccine 
programmes or diagnostic centres [154]. This trial aimed to assess the impact of repellents on 
malaria, but repellents also have the potential to prevent other vector-borne diseases. As 
arboviruses like JE and dengue can be epidemic problems, repellents could be targeted to 
vulnerable populations at high-risk times. This avoids possible health risks from long-term use 
and might result in higher compliance as users would have to modify their behaviour for a 
much shorter time. 
Repellents have low lethal effects in the field as insects are repelled before they come into 
contact with the chemical. Therefore there is much lower probability of the emergence of 
resistance. However if the mode of action of a repellent overlaps with an insecticide used in 
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the area, then repellent resistance could be driven into the population. The modes of action of 
repellents are not completely established, and like insecticides may vary with the chemical 
family. However with strongly anthropophilic vectors there may be a fitness cost associated 
with widespread repellent use, which could lead to the emergence of resistance. Research in 
this area would be required if repellents were adopted into control programmes. 
The entomology studies for this trial, found that most biting in a village setting in the study 
area actually comes from JE vectors. Given the high ownership of pigs, amplifying intermediate 
hosts for the virus, and the lack of any national vaccination programme in the Lao PDR, there a 
real risk that JE is well established in the study area. These results argue strongly for 
monitoring of this potentially fatal disease in both the human population and the livestock 
reservoir. 
There remains a real urgency to find novel control tools to address the malaria problem in the 
GMS in order to control the spread of artemisinin-resistance. Although LLiNs work well in this 
region, outdoor biting means they are unlikely to be sufficient as a sole intervention method. 
Signs of changes in mosquito behaviour in Africa also suggest protection against outdoor biting 
might be needed in other areas too. Repellents can protect against outdoor biting, but further 
trials of topical repellent aimed at developing a wide-scale malaria control tool are not 
recommended based on these results. What is needed now are trials of alternative modes of 
repellents delivery such as impregnated clothing as well as trials that can measure the impact 
of repellents on other vector-borne diseases. 
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Consent Form 
Clinical evaluation of mosquito repellent 
Study Co-ordinator 
Study Principle Investigator 
Vanessa Chen-Hussey 
c/o PSI Laos, House No. 268/18, 
Saphanthong Tai Village, Sisattanak District, 
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Mobile 0204292769 
Steve Lindsay 
LSHTM, Keppel Street, London, WC1 E 7HT, 
UK 
Tel: +44 (0)207 927 2674 
Fa)(: +44 (0)207 927 2675 
I have attended the village meeting where details of the study were presented 
and have read the information sheet concerning this study and I understand what 
will be required of me and what will happen to me if I take part in it. 
My questions concerning this study have been answered by the local health 
worker. 
I understand that at any time I may withdraw from this study without giving a 
reason and without affecting my normal care and management 
I agree to provide blood spots at the start and end of the study that can be stored 
for up to 12 months for diagnostic use directly associated with this study. 
I agree to take part in this study 
Signed ..... Date .. 
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Information sheet for participation in trial (in Lao only, English translation provided here) 
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Information for Volunteers 
Clinical evaluation of mosquito repellent 
Introduction 
Mosquitoes can carry many different diseases including malaria & Dengue in 
many parts of Asia. People working outdoors, particularly in the evening, are at 
particular risk of mosquito bites. Mosquito repellents are used in many parts of 
the world to reduce mosquito bites. We need to find out if people using mosquito 
repellents can be protected from getting diseases carried by mosquitoes. 
Why are we doing this study? 
We know that mosquito repellents can reduce mosquito bites. However, there is 
very little evidence that using repellents can prevent diseases carried by 
mosquitoes. We think that using repellents may help reduce diseases like 
malaria but we need to be sure before we can use them as part of a malaria 
control method. This study will provide information to help us decide if repellents 
can be effective. The study has been approved by the ethics committee in Laos. 
What is the study? 
To see if repellents are effective we need to compare people using repellents 
with those who are not to see if fewer people get diseases like malaria. The best 
way to do this is to get a large number of people in different villages to take part 
in our study. We will then give half of these people a repellent, and the other half 
will get a similar liquid but that does not repel mosquitoes. We will then record 
how many people get diseases like malaria over the next 9 months. At the end 
of the study we will see if fewer people using repellent got malaria or if there was 
no difference. 
What will happen if I take part in the study? 
Everyone in the village will be given information about the study at a village 
meeting. Those people who would like to take part in the study will be given this 
information sheet and can discuss it with the local health staff who will answer 
any questions you have. We will also ask you some questions to be sure you are 
able to take part. Everyone who takes part in the study can drop out at any time 
without giving a reason. At the start of the study the local health worker will take 
a small amount of blood from the tip of your finger. This blood spot will be used 
in a test to see if you have malaria. Another blood spot will be taken on paper 
which we will dry and store to test for other mosquito carried diseases at the end 
ofthe study. You will need to give one blood drop in the same way every month 
for 9 more months to see if you have malaria each month during the study. If the 
test ever finds you have malaria we will be sure that you get the best treatment 
as soon as possible. Everyone taking part in the study will be given a new 
mosqUito bed net to protect them against mosquitoes while they are in bed. We 
want you to remember to sleep under your net every night, but if you forget you 
can let us know when we visit you each month. As well as the bed net, everyone 
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will be given 3 bottles of liquid to rub onto their bare legs & arms every evening 
when the sun goes down. We will show you how to put on this liquid and there 
will be enough in the 3 bottles to use it every night for 1 month. Each month 
when we return to take the blood spot we will also give you 3 more bottles of 
liquid for the next month. We would like you to remember to use the liquid every 
evening, but if you forget you can tell us when we visit. Half of the people taking 
part in the study will have liquid that has a mosquito repellent, and the other half 
will have a liquid with no mosquito repellent. You will not know which one you 
have and the health worker coming each month will not know which one you 
have. At the end of the study we will take a final blood spot from your finger to 
test for malaria and one to store on paper to look for other mosquito carried 
diseases. We will not bring any more repellent but you will be able to keep all the 
bed nets we gave to you and your family as these will still be effective for several 
more years. Remember, if you no longer want to continue in the study you can 
drop out at any time without giving a reason. At the end of the study we will 
compare the results of the blood tests to see if there is a difference between 
those using the repellent of those who did not. After the tests are complete we 
will store no samples and we will only keep records with numbers, not your 
names. 
Will it be painful and is it safe? 
Wlen the health worker takes the blood spot from your finger it will sting for a 
little while. Only one or 2 small spots of blood are taken and this will be very 
quick. We will give you a small tissue to keep the finger clean. This way of 
taking blood drops to test for malaria is exactly the same as the one used in your 
village by the health workers and in your local clinic a hospital, it is very easy, 
very fast and very safe. 
The bed nets we will give you are the same as those used in Laos and many 
other parts of the world where there are mosquitoes carrying malaria. They are 
safe and will help prevent you get bitten at night in bed. 
The liquid mosquito repellent we will give you is a very common product sold in 
most Countries in the world including America and Europe. It is used by many 
people around the world and sold in most Countries. It has passed safety testing 
in all Countries and is already sold in Laos. A very few people may be allergic to 
the lotion, and we will ask you if you have any problems. If you use it and you 
think it is making you unwell, or if you get red skin or itching you should stop 
using it and tell the health worker or study manager (contact details below). It is 
very rare for people to have problems using mosquito repellents, but you must 
always follow the instructions on the bottle or given to you by the health worker at 
the start of the study. 
How to contact us 
Your local health worker is •.•••..•...•••. - Contact; 
The study manager is Vanessa Chen Hussey - Mobile: 020 4292769 
ll'nl't 
i~~rlJonun~~Bl~mOQe,n~~~~v~m~n~~, 
lJ'tQue~IJ~IJ~.un 
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Consent form for participation in human landing catches (in English and Lao) 
Project Informed Consent form for Human Landing Catch Collector 
I, (name of collector) agree 
to participate in the following study: Survey of local species of anthropophilic mosquitoes and 
the effectiveness of di-ethyl toluamide (DEEl) as a repellent for early evening hours. I agree 
that I will participate as a landing catch for collecting mosquitoes and the repellent effects of 
DEET. 
I have been given the opportunity to ask questions concerning this study. Any such questions 
have been answered to my full satisfaction. Should any further questions arise concerning this 
study I may contact Sarah DeRaedt or Vanessa Chen-Hussey. I understand that I may revoke 
this consent at any time without penalty or loss of pay. 
Signature of participant Date 
ID number ___ _ 
Fieldworkers initials Date 
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Information sheet for participation in trial (in Lao only, English translation provided here) 
Information for Volunteers 
Study of Repellent Efficiency 
Survey of local species of anthropophilic mosquitoes and the effectiveness of di-ethyl toluamide 
(DEEl) as a repellent for early evening hours. Masters' project thesis. Sarah DeRaedt 
Introduction 
Mosquitoes can carry many different diseases including malaria and Dengue in many parts of 
Asia. People working outdoors, particularly in the evening, are at particular risk of mosquito 
bites. We need to find out if people using different concentrations of mosquito repellents will 
be protected from getting diseases carried by mosquitoes. 
Why Are We pplng This Study? 
We know that mosquito repellents can reduce mosquito bites. We think that different strengths 
(concentrations) of repellents will last different times and reduce biting differently. This study 
will tell us how long different strengths of repellents last and how much they reduce biting. 
This study has been approved by the Lao Ministry of Health National Ethics Committee for 
Health Research. 
Whit II The Study? 
In order to test the different strengths of repellents we need to put them on people. Human 
landing catches are the best way to test the repellents as they are as close to real life as 
possible. We will give each collector a different strength of repellent or similar liquid which 
does not repel mosquitoes each night for 16 nights. It is important that you and we do not 
know which strength of repellent or non-repellent you have been given. This makes sure that 
the study gets rid of as much human bias as possible. The number of mosquitoes caught at the 
end of the study will show us the strength of each repellent. 
Whit Will Hippen If I Tlke part In Thll Study? 
Those people who want to take part in this study will be given this information sheet and can 
discuss it with the local health staff who will answer any questions you have. We will also ask 
you some questions to see if you are able to take part. Anyone who takes part in the study can 
stop at any time without giving a reason. At 4:30 PM each evening of the study you will be 
given a place to sit and a liquid to rub on your bare arms and legs. We will show you how to 
put on this liquid. You will not know which liquid has been given and the entomology trial 
supervisor giving you the liquid will not know which one you have. You will also be given a light 
and a tool for catching the mosquitoes called and aspirator. When you catch a mosquito you 
will put it into a container for us to count later. This catching will go on for SO minutes with a 
ten minute break from 5 PM until 11 PM. At every ten minute break we will collect the 
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containers and give you new ones. At the end of the study a local health worker will take a 
small amount of blood from the tip of your finger. This blood will be used in a test to see if you 
have malaria. Remember, if you no longer want to continue in the study you can drop out at 
any time without giving a reason. When the study is finished we will only keep records with 
numbers not your names. 
Wj!I It Be painful And Is It Safe? 
There may be some pain if you get bitten by a mosquito before it is caught. When the blood 
from your finger gets taken it will sting for a little while. Only 1 or 2 small drops of blood are 
taken and this will be very quick. We will give you a small tissue to keep your finger clean. 
This way of taking blood drops to test for malaria is exactly the same as the one used in your 
village by the health workers and in your local clinic at hospital, it is very easy, very fast and 
very safe. The blood test will tell us if you have gotten malaria during the study, but if you feel 
like you have a fever, headache, or tiredness up to 15 days after the study finishes or at any 
point during the study, you should let us know or go to your local clinic for testing and you will 
be given medicine. The liquid mosquito repellent we will give you is a very common product 
sold in most Countries in the world including America and Europe. It is used by many people 
around the world and sold in most Countries. It has passed safety testing in all Countries and is 
already sold in Laos. A very few people may be allergic to the lotion, and we will ask you if you 
have any problems. If you use it and you think it is making you unwell, or if you get red skin or 
itching you should stop using and tell the health worker or study manager (contact details 
below). It is very rare for people to have problems using mosquito repellents, but you must 
always follow the instructions on the bottle or given to you by the health worker at the start of 
the study. 
Will I Be paid? 
If you are able to take part in the study you will be paid 40,000 Kip and evening for 16 
evenings totaling 640,000 Kip. 
How to Contact Us 
The study manager is Vanessa Chen Hussey - mobile: 020 4292769 
English language baseline survey form (page 1/3) 
Part 1: Basic Identification Information 
1. Interviewer Name 
2. Date 
3. Province 
4. District 
5. Village 
6. Name of Head of Household 
7. Household Number 
8. Group (258/305) 
Part 2: Questions to Head of Household Onlv 
9. How many people are there in 
your household? 
10. What is your main occupation? 
11. How many years of education 
have you had? 
12. What is your house made from? 
(Circle) 
13. What is the roof of your house 
made from? 
(Circle) 
Bamboo (1) 
Brick (4) 
Bamboo (1) 
Wood (4) 
None (0) 
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nopeople 
occupation 
education 
Mesh & leaves (2) Wood (3) 
housemat 
Other 
---
Tile (2) Thatch (3) 
roofmat 
Metal (5) Other 
Continuous power supplv (1) 14. What type of electricity supply do 
you have? Evening power supply (2) Own generator (3) electric (Circle) 
Other 
English language baseline survey form (page 2/3) 
15. How is your water supplied? 
16. What type of cooking fuel do you 
use? 
17. Do you own a motorcycle? 
Yes (I" No (0) 
18. Do you own a tractor? 
Yes (1), No (0) 
19. Do you own a radio? 
Yes (I" No (0) 
20. Do you own a television? 
Yes (1), No (0) 
21. How many insecticide treated bed 
nets are there in your house? 
22. Bed net ownership verified by 
interviewer 
Yes (1), No (0) 
23. Do you use other types of personal 
protection against mosquito bites? 
(Circle) 
24. How many animals do you own? 
2S. Where are they kept over night? 
Out of village (1), By house (2) 
Under house (3), Inside house (4) 
Free roaming (5), Other (state) 
Pipe (1) 
Spring/Stream (3) 
Wood fire (1) 
Untreated nets (1) 
Burning a fire (3) 
Insecticide spray (5) 
Buffalo 
Pigs 
Goats 
Chickens 
Dogs 
Buffalo 
Pigs 
Goats 
Chickens 
Dogs 
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Well/pump (2) 
water 
Lake/River (4) 
Charcoal (2) Gas (3) fuel 
mbike 
tractor 
radio 
tv 
itn 
itnverify 
Coils (2) 
Burning herbs (4) persprotec 
Other 
piB-no 
goat no 
buffalo )ocatio 
goaUocation 
chick)ocation 
English language baseline survey form (page 3/3) 
Part 3: Questions to ALL participants 
26. How old are you? 
27. Are you male or female? 
Male (0), Female (1) 
28. What relation are you to the head of the household? 
Head (1), Spouse (2), Child (3), Parent (4), Sibling (5), 
Grandchildren (6), Other relative (7), Non-relative (8) 
29. Did yOu sleep under a bed net last night? 
Yes (1), No (0) 
30. Do you use any kind of insect repellent? 
Yes (1), No (0) 
31. Do you work in fields or forests? 
Yes (1), No (0 & Go to Question 37) 
32. Do you sleep in the fields/forest when working there? 
Yes (1), No (0 & Go to Question 37) 
33. How many nights last month do you sleep there? 
1-2 Nights (1), 3-6 Nights(2), 7-14 Nights (3),15-21 
Nights (4) 22-28 Nights (5), More than 28 nights (6) 
34. Do yOu use a bed net when sleeping in the 
fields/forest? 
Yes (1), No (0 & Go to Question 37) 
35. Is it an insecticide treated net? 
Yes (1), No (0) 
36. Is it the same bed net that you use at home? 
Yes (1), No (0) 
37. ROT results for Pf 
Positive (1), Negative (0) 
38. ROT results for Pv 
Positive (1), Negative (0) 
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Household Member 
1 2 3 4 5 
age 
female 
relation 
net 
repel 
forst 
fsleep 
fsnpm 
fsnet 
fSitn 
hmitn 
pfrdt 
pvrdt 
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Lao language baseline survey form (completed example) 
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English language monthly follow-up form 
I Household I Date 
Participant 10 
1 
How many nights did you sleep under a bed net this 
month? 
netnts 
If did not sleep under bed net every night, why not? 
2 Not applicable (99), Forgot (1), Did not hove a net whynonet 
(2), Too hot (3), Other (state) 
3 
How many nights did you sleep in the fields/forest 
this month? ffnts 
When you slept in the fields/forest did you use a bed 
4 net? ffnetnts 
Yes (1), No (0) 
5 
How many days did you work in the fields/forest this 
month? 
ffdoys 
Did you have any problems using the lotion? 
6 No problems (0), Bod smell (1), Allergy (2), Headache Itnprob 
(3), Daes not stop bites (4), Other (state) 
7 How many evenings did you use the lotion? Itnnts 
8 
If NO, why did you not use the lotion? 
Forgot (1), Smell (2), Allergy (3), Other (state) whynoltn 
9a 
Did you use the lotion during the day? 
Yes (1), No (0) Itndoyuse 
9b If lotion used during the day, how many days? Itndays 
9c 
If lotion used during the day, how many times per 
day? 
Itnxdoy 
10 
How much lotion is left? 
None (0) to All (15) bottle 
10 ROT results for PI Positive (1), Negative (0) RDTPf 
11 
ROT results for Pv 
Positive (1), Negative (0) RDTPv 
12 
Did you have a fever this month? 
None (0), One (1), More than one (2) fever 
13 
If had a fever, did you have an ROT? 
Yes (I), No (0) feverRDT 
What treatment did you receive? 
14 None (0), CQ (I), ACT (2), Received treatment but no fevertmt 
sure which (3) 
Lao language monthly follow-up form (completed example) 
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English language exit survey form 
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Lao language exit survey form (completed example) 
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Bottle Labels 
SAMPLE 258 
100 
Inoredients: May contan 
Insect repellent (DEET) 
DIRECTION S: 
Apply on arms 
and leos 
Do not apply 
~ ~ near mouth E3 and eyes 
~_ Do not apply on plastiC spectades , and watches 
PRECAUTIONS: 
• May cause eye Irritation 
• Harmful r swalowed 
• Do not apply on cuts 
. If in eyes flush wth plenty 
ro. water, if i-ritation persists 
~medlcal assistance 
• Keep away from ctliidren 
SAMPLE 305 
100 mI 
Ingredients: May contan 
Insed repellent (DEET) 
DIRECTIONS: 
Apply on arms 
and legs 
Do not apply 
~ ~ near mouth 
~ and eyes 
~ Do not apply on plastic spectades and watches 
PRECAUTION 5: 
• May cause eye Inltation 
• Harmful r swalo.ved 
• Do not a",ly on cuts 
·If In eyes fkJsh ~ plenty 
~ water: if Jritation persists 
s.e.e.k medical assistance 
.Ke~ep away from ctliidren 
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SAMPLE 258 
l ooml 
I.:l.,\t (DEET) 
3>ii ' ;';.ti ta3. r.ttiJ ~f"~ • .:t ~~ 
k4)"~: 
• .:Ill;!.:1t;)'" f 'l& 
• ~~I,. ttUiil..ffl),J" • ~!l 
· f ~'l('i'1 rOllQ,,~;;n.~~' ~I'I 
v~rw :1"\l.In.' .f QU" tJtJt4, nruef 
SAMPLE 305 
looml 
f Oli tl'l.· : ;'l.~' 'lti'l~ 
I.:l.';';: (DEET) 
~Jt,., -a ~ l.:1 IIIQ. t'p;J !M~ ~Qr • ~ 
" ~: 
• ;".n"rrw"'rl'llir.Jn'l 
· iJlJ;li. t~ tI ~",fbJ 
.~U1 a~~",o 
• ~'l~'lr. rOlJ~ :l;;ru\Jt/l.', :'1'"rl 
ii,rw'l:i'llirud.rQlJ\z.J-.Ju~l.I nruf. 
• ;:;:;~'I t6'\nwlJ!m 
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Appendix C: Entomology Survey Data 
Table Cl. Average mosquito catch by CDC light trap night (CDC, n=301 nights) and man-hour from 
landing collections (HLC, n=784 hours). 
Genus 
(Subgenus) 
Anopheles 
(Anopheles) 
Anopheles 
(Cellia) 
Species 
baezai Gater, 1933 
barbirostris van der Wulp, 1884/ campestris Reid, 1962 § 
hodgkini Reid, 1962 
peditaeniatus (Leicester, 1908) 
pursati Laveran, 1902 
roperi Reid, 1950 
umbrosus (Theobald, 1903) 
annularis van der Wulp, 1884 
culicifacies Giles, 1901 
dirus Peyton & Harrison, 1979 
dravidicus Christophers, 1924 
indefinitus (Ludlow, 1904) 
jamesii Theobald, 1901 
jeyporiensis James, 1902 
kochi Donitz, 1901 
maculatus K / sawadwongporni Rattanarithikul & Green, 1987 
§ 
minimus Theobald, 1901 
nemophilous Peyton & Ramalingam, 1988 
nivipes (Theobald, 1903) 
notanandai Rattanarithikul & Green, 1987 
pamapanai BOttiker & Beales, 1959 
philippinensis Ludlow, 1902 
Average catch 
CDC HLC 
0.003 0.000 
0.003 0.000 
0.007 0.000 
0.023 0.000 
0.013 0.001 
0.007 0.000 
0.003 0.000 
0.130 0.003 
0.030 0.001 
0.007 0.000 
0.007 0.000 
0.003 0.000 
0.040 0.000 
0.173 0.001 
0.016 0.000 
0.146 0.000 
0.053 0.003 
0.033 0.000 
0.027 0.000 
0.003 0.000 
0.003 0.000 
0.010 0.000 
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subpictus Grassi, 1899 0.003 0.000 
tessellatus Theobald, 1901 0.010 0.000 
vagus Donitz, 1902 0.007 0.000 
Anopheles Unidentified 0.143 0.000 
Armigeres Not identified to species 0.907 0.056 
Coquilettidia Not identified to species 0.120 0.001 
atis Theobald, 1903 0.047 0.000 
barraudi Edwards, 1922/ edwardsi Barraud, 1923 § 0.090 0.000 
fuscocephala Theobald, 1907 O.OlD 0.000 
gelidus Theobald, 1901 1.728 O.OlD 
hutchinsoni Barraud, 1924 0.375 0.000 
perplexus leicester, 1908 0.259 0.000 
Culex (Culex) pseudovishnui Colless, 1957 0.017 0.000 
quinquefasciatus Say, 1823 10.179 0.042 
sitiens Wiedemann, 1828 0.017 0.000 
tritaeniorhynchus Giles, 1901 0.003 0.000 
vishnui Theobald, 1901 2.203 0.001 
whitei Barraud, 1923 14.319 0.284 
whitmorei (Giles, 1904) 0.116 0.001 
Culex 
nigropunctatus Edwards, 1926 0.047 0.000 
(Cuticiomyia) 
foliatus Brug, 1932 0.010 0.000 
Culex 
malayi (leicester, 1908) 0.213 0.029 
(Eumelanomyia) 
tenuipalpis Barraud, 1924 3.601 0.089 
Culex 
bitaeniorhynchus Giles, 1901 0.003 0.000 
(Oculeomyia) 
Culex Unidentified 13.987 0.023 
Lutzia fuscanus (Wiedemann, 1820) 0.017 0.000 
(Metalutzia) halifaxii (Theobald, 1903) 0.007 0.000 
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scan/oni Bram, 1967 0.532 0.046 
sinensis Theobald, 1903 0.013 0.000 
Mansonia Not identified to species 0.196 0.000 
Mimomyia Not identified to species 0.007 0.000 
Och/eratatus niveus Edwards, 1926 0.023 0.001 
Orthopodomyia Not identified to species 0.017 0.000 
a/bopicta (Skuse, 1895) 0.140 0.027 
Stegomyia 
Unidentified 0.037 0.068 
Topomyia Not identified to species 0.007 0.000 
Tripteroides Not identified to species 0.276 0.060 
Uranotaenia Not identified to species 0.173 0.000 
Total 50.595 0.749 
§ Not distinguishable by morphology 
A p pen d i x E 210 
Appendix D: Poisson regression STATA outputs 
Intention to Treat Analysis 
. spearmdn mdldrla fdlci~drum VIVdX p~dl pca2 age female net forest, stats(p) pw 
(ob.'3=varles) 
+-----------------+ 
1 Key 
1-----------------1 
1 Sig. level 1 
+-----------------+ 
malaria 
falciparum 1 C.C2CC 
VI'Iax 1 C:.C22C 
peal C.CCC3 
pca2 0.0364 
age C • 2 C 15 
female 0.0166 
net C. 31 99 
forest C. g.; 15 
::.sse::. pp::. Da::.e 
pane: variab~e: 
::.ime variable: 
de:~a: 
VIVdX pca2 age female 
C. '::;CCC' 
C. CC 13 C.1136 
C.0337 0.3255 0.0000 
C.3C77 0.2740 0.0000 0.1226 
0.0179 0.2084 0.0000 0.0001 0.0001 
0.4787 0.3363 0.0009 0.0000 0.0000 0.0000 
C.8987 0.2753 0.0109 0.0000 0.0000 0.0000 
pp::. (unbalanced) 
Date, 27 Ju~ 09 to 22 Jan 11, but with gaps 
: day 
net furest 
0.4261 
xtmepoi sson ma:'ar ia tmt pca1 pca2 female, I I household:, covariance (independen t) I I 
ppt:, covariance (independent) irr 
Note: sing:e-variable random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variab:'e random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting values: 
Iteration 0: 
Iteration 1: 
Itera-:ion 2: 
:'og ~ike:'ihood 
log likelihood 
log like:'ihood 
-562.65099 
-520.02699 
-515.33894 
Performing gradient-based optimization: 
Itera'Cion 0: log '..ike::'ihood -515.33894 
Iteration 1: log ~ikelihood -511.653 
Iteration 2: log ::'ike:'ihood -511.41733 
Iteration 3 : ::'og likelihood -511.41107 
Iteration 4 : log likelihood -511.41104 
Mixed-effects Poisson regression Number of obs 44024 
--------------------------------------------------------------------------
Group variable 
No. of 
Groups 
Observations per Group 
Minimum Average Maximum 
Integration 
Points 
----------------+---------------------------------------------------------
household I 
ppt I 
1398 
6945 
2 
1 
31.5 
6.3 
40 
8 
7 
7 
--------------------------------------------------------------------------
Log likelihood = -511.41104 
malaria I IRR Std. Err. z 
Wald ehi2(4) 
Prob > ehi2 
P>lzl [95% Conf. 
12.80 
0.0123 
Interval] 
-------------+----------------------------------------------------------------
tmt .961611 .2844l74 -0.13 0.895 .5385649 1. 716963 
peal .765376 .076445 -2.68 0.007 .6292999 .9308764 
pea2 1.138898 .1483198 1. 00 0.318 .8823317 1.470068 
female .6237954 .1513094 -1. 95 0.052 .3877685 1.003487 
cons .0004593 .0001785 -19.78 0.000 .0002145 .0009837 
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Random-e::ec~s Farame:ers Es:.ima:.e S:.d. Err. [95% Conf. In~ervall 
househo~d: Idenci~y 
sd( :::ons) .2113262 1. 33973 2.176262 
ppc: Idencicy 
sd ( ::ons) .44560:6 o 
LR ~es~ vs. Poisscn regression: chi2(2) ~ 50.04 Prob > chi2 = 0.0000 
No~e: ~R cesc is conserva~ive and provided only for reference . 
. x~mepoisson ma':'aria cm·_ pca: ::ema~e, hO:.Jsehold:, covariance (independent) II ppt:, 
covariance (independen:) irr 
Note: sing!e-variab:e random-effects specification in household equation; covariance 
str:.Jct:.Jre set cO identity 
Note: sing':'e-variab':'e random-e:fec~s specification in ppt equation; covariance structure 
sec to identicy 
Refining starcing va~jes: 
Itera:.ion 0: 
Iteration -. 
Iteration 2: 
':'og ':'ike~ihood 
~og ~ike':'ihood 
':'og ':'ike':'ihood 
-563.2859 
-520.54667 
-515.87283 
performing gradien:-based op:imiza~ion: 
Iteration 0: ':'og ':'ikelihood -515.87283 
Itera:ion - . ':'og .i.ike':'ihood -5:2.:6255 
Iteration 2: ~og like':'ihood -511.90611 
Itera:ion 3 : ~og ':'ike':'ihood -51:.89979 
Itera:ion 4 : ':'og ':'ike.i.ihood -51:.89976 
Mixed-effects Poisson regression Number of obs 44024 
No. 0: 
Group Variable I Groups 
Observations per Group 
Minimum Average Maximum 
Integration 
Points 
----------------+---------------------------------------------------------
household 
ppt 
:398 
6945 
2 31. 5 
6.3 
40 
8 
7 
7 
----------
----------------------------------------------------------------
Log likelihood ~ -511.89976 
Wald chi2(3) 
Prob > chi2 
11.72 
0.0084 
-----------
-------------------------------------------------------------------
malaria i IRR Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
t.mt I 
pcal 
female 
cons 
.95823:2 
.7559783 
.6232583 
.0004562 
.2839289 
.0765574 
.1512416 
.0001776 
-0.14 
-2.76 
-1.95 
-~9.76 
0.886 
0.006 
0.051 
0.000 
.5361ll2 
.6198815 
.3873586 
.0002127 
1.712717 
.9219555 
1.00282 
.0009783 
------------------------------------------------------------------------------
------------------------------------------------------------------------------
Random-effects Parameters Estimate Std. Err. [95% Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identi:y 
sd ( cons) 1.71624 .2ll4379 1.348066 2.184965 
-----------------------------+------------------------------------------------
ppt: Identity 
sd ( cons) .0000103 .4454839 o 
------------------------------------------------------------------------------
LR test vs. Poisson regression: chi2(2) = 50.72 Prob > chi2 = 0.0000 
Note: LR test is conservative and provided only for reference . 
. xtmepoisson falciparum tmt peal pca2 female, I I household:, covariance (independent) I I 
ppt:, covariance (independent) irr 
Note: single-variable random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variable random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting values: 
Iteration 0: log likelihood -454.72452 
I:.era~icn _. 
Itera~ion 2: 
:09 :ike:ihcod -4':7.98489 
:og :ike:ihood - -412.56714 
Performing gradient-based optimization: 
Iteration J: ':og :ike:ihood - -4:2.567:4 
Iteration - . log :ike:ihood -410.06261 
Itera~ion 2 : ':og ':ike':ihood - -409.99:76 
Iteration 3 : ':og like:ihood -409.99044 
Iteration 4 : :og ':ike':ihood -489.99044 
Mixed-effects Poisson regression 
A P pen d i x E 212 
Number of obs 44024 
GroClp Variab:e 
No. of 
Groclps 
Observations per Group 
Minimum Average Maximum 
Integration 
Points 
----------------+---------------------------------------------------------
hOJseho':d 
PP"-
:398 
6945 
Log :ike:ihood = -409.99044 
2 3l.5 
6.3 
40 
8 
Wald chi2(4) 
Prob > chi2 
7 
7 
13 .16 
0.0105 
---------------------------------------------------------------------------
fal.ciparum IRR Sed. Io:rr. z P>,zl [95% Conf. Interval) 
------------------------------------------------------------------------------
t.mt .8673835 .2927589 -0.42 0.673 .4476246 1.68077 
pea: .7688484 .0867979 -2.33 0.020 .616234 .9592588 
pca2 ;'.232207 .1788878 l. 44 0.150 .9270627 l. 637791 
:emale .5365387 .1490326 -2.24 0.025 .3112903 .924776 
cons .000327 .0001476 -17.77 0.000 .000135 .0007923 
-------------
--------------------------------------------------------------
Random-effects Parameters Estimate Std. Err. [95% Conf. Interval) 
-----------------------------+------------------------------------------------
househo~d: Idencity 
sd ( cons) 1.815903 .2383784 1.403955 2.348725 
-----------------------------+------------------------------------------------
ppt: Identity 
6.42e-09 .3770199 o 
------------------------------------------------------------------------------
LR test vs. Poisson regression: chi2(2) = 46.3: Prob > chi2 = 0.0000 
Note: LR test is conservative and provided only for reference. 
xtmepoisson falciparum tmt peal female, i I household:, covariance (independent) I I 
ppt:, covariance (independent) irr 
Note: single-variable random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variabie random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting values: 
Iteration 0: log likelihood -455.87171 
Iteration 1 : log likelihood -419.0271 
Iteration 2 : log likelihood -413.84429 
Performing gradient-based optimization: 
Iteration 0: log likelihood -413.84429 
Iteration 1 : log likelihood ~ -411.08138 
Iteration 2 : log likelihood -411.0025 
Iteration 3 : log likelihood -411.0009 
Iteration 4 : log likelihood -411.0009 
Mixed-effects Poisson regression Number of obs 44024 
--------------------------------------------------------------------------
No. of Observations per Group Integration 
Group Variable I Groups Minimum Average Maximum Points 
----------------+---------------------------------------------------------
household I 1398 2 31.5 40 7 
ppt I 6945 1 6.3 8 7 
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Wald chi2(3) 
Prob > chi2 
11.18 
8.0108 
fa~ciparJm lRR Sed. Err. z P>lzl [95% Conf. Interval] 
erne .8642:07 .29:5873 -0.43 0.665 .4460891 1. 67424 
pea: .7559833 .0877263 -2.4l 0.016 .6021159 .9489697 
:ema:e .5363298 . :49007 -2.24 0.025 .3111322 .9245255 
cons . :):)J3296 .:)00:486 -:7.78 0.000 .000l362 .0007976 
Random-ef:ec~s Parame~ers Es~imace Std. Err. ,95% Conf. Interval] 
hOJsehc:d: Identity 
sd ( cons) :.822188 .238557 1.409795 2.355216 
ppt: Iden'_ity 
sd ( cons) 6.0:e-08 .3764874 o 
~R ~es: vs. Poisson regression: chi2(2) ~ 46.6: Prob > chi2 = 0.0000 
No:e: ~R ~es: is conserva:ive and provided on:y for reference. 
xemepoi sson vi vax :m: pea: female, household:, covariance (independent) ppt: , 
covariance (independene) irr 
Note: sing:e-variab:e random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variab:e random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting va:ues: 
Iteration 0: :og likelihood -232.59288 
Iteration 1 : log like::'ihood -208.45415 
Iteration 2 : log likelihood -206.21637 
performing gradient-based optimization: 
Iteration 0: log likelihood -206.21637 
I:eration 1 : log ::'ikelihood -204.24192 
I~eration 2 : log likelihood -203.66292 
I:eration 3 : log likelihood -203.65385 
Iteration 4 : log likelihood -203.65384 
Mixed-effects Poisson regression Number of obs 44024 
--------------------------------------------------------------------------
Group Variable I 
No. of 
Groups 
Observations per Group 
Minimum Average Maximum 
Integration 
Points 
----------------+---------------------------------------------------------
househo:d i 
ppt I 
1398 
6945 
2 
1 
31.5 
6.3 
40 
8 
7 
7 
--------------------------------------------------------------------------
Log likelihood = -203.65384 
vivax I IRR Std. Err. z 
Wald chi2(3) 
Prob > chi2 
3.55 
0.3140 
P>lzl [95~ Conf. Interval] 
-------------+----------------------------------------------------------------
tmt 
peal 
female 
cons 
.9059417 
.7126458 
.8758515 
.0000485 
Random-effects Parameters 
.4630505 
.1315281 
.3483744 
.0000402 
-0.19 
-1.84 
-0.33 
-11 . 97 
0.847 
0.066 
0.739 
0.000 
Estimate Std. Err. 
.3326816 
.4963333 
.401662 
9.53e-06 
2.467014 
1.023232 
1.909854 
.0002466 
[95~ Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd( cons) 2.244755 .3585104 1.641433 3.069832 
-----------------------------+------------------------------------------------
ppt: Identity 
sd ( cons) 2.52e-06 .4224303 o 
LR test vs. Poisson regression: chi2(2) = 40.73 Prob > chi2 = 0.0000 
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Nc:e: ~k :es: 1S ccnserva:ive and provided only for reference. 
xtmepcisscn vivax :m: pca~, hC..lsehold:, covariance (independent) II ppt:, 
covariance (lndependen:) irr 
Note: sing~e-variab~e random-effects specification in household equation; covariance 
s:r..lc:..lre set :c identity 
No:e: sing~e-variab~e randcm-e:fec:s specification in ppt equation; covariance structure 
set. :0 iden'~i'~y 
Re~ining s~ar:ing va:~es: 
I:eraticn 0: ~og ~ike~ihcod -232.69522 
Iteration - . :og ~ike~ihood -208.46453 
Iteracion 2: ~og ~ikelihood -206.44294 
Performing gradient-based optimization: 
Iteraticn 0: ~cg ~ike:ihood -206.44294 
Iteraticn - . ~og ~ike~ihood -204.75617 
I:era'cion 2: ~og like:ihood -203.76174 
Iteration 3 : ~cg ~ike:ihood -203.70995 
Iteration 4 : ~og ~ike~ihood -203.70941 
I:eration 5 : ~og ~ike~ihood -203.70941 
Mixed-e:!ec:s Poisson regression Number of obs 44024 
----------------------------------------------------------------------
No. 0: 
Group variable Groups 
Observations per Group 
Minimum Average Maximum 
Integration 
Points 
--------------------------------------------------------------------------
hOClseho:d 
ppt 
:398 
6945 
2 
1 
31.5 
6.3 
40 
8 
7 
7 
----------------------------------------------------------------------
Log like:ihood ~ -203.70941 
Wald ch12(2) 
Prob > chi2 
3.43 
0.1799 
------------------------------------------------------------------------------
vivax IRR Std. Err. z P>lzl [95% Conf. Interval] 
-------------~---------------------------------------- ------------------------
tmt .9076742 .4643015 -0.19 0.850 .333055 2.473683 
pca1 .7109188 .1313506 -1.85 0.065 .4949377 1.02115 
cons .0000447 .0000357 -12.55 0.000 9.36e-06 .0002138 
------------
---------------------------------------------------------- --------
------------------------------------------------------------------------------
Random-effects Parameters Estimate Std. Err. [95% Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd(_cons) 2.249136 .3586687 1.645413 3.074372 
-----------------------------+------------------------------------------------
ppt: Identity 
1.86e-08 .4269282 o 
------------------------------------------------------------------------------
LR test vs. Poisson regression: chi2(2) = 41. 05 Prob > chi2 = 0.0000 
Note: LR test is conservative and provided only for reference. 
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According to Protocol Analysis: 50% Compliance 
. spedrmdfJ ITid;drld tdl_'l:'d;lJnl 'Jl\"dX ~),-'al p·=a'? d,le female net forest, stats(p) pw 
(ObS=Vd r 1 L'S) 
+-----------------+ 
Ke"/ 
1---------- -------1 
S i J. 1 L'".·C 1 
+-----------------+ 
mdldr Id fdl':lp-m VIVdX peal pca2 age female net forest 
-------------+---------------------------------------------------------------------------------
rnd Idr I d 
fdlcl~~arurn 
VIVdX 
p_'d 1 
rCd~ 
female 
ne: i 
fares':. 
, C 
C. CCC~' 
'~' . :: :: 3·~ 
C. 
~' .. ~ ~ 5 9 
C . ·;2 e 1 
. 31 .;.; 
C . 5 - b 1 
lsse:' pp~ Da~e 
~' .CCCO 
C . C 183 0.0630 
~' • C 1 C .1341 :I.OOJO 
': . 61'~ e 0.5849 J.OOJO 
C • ~,.2 8 4 C.5299 0.0001 
.:: . 3794 C.5876 C.CCCC 
C.8121 C .4279 C.OOOO 
pp:. (Jnba:anced) 
0.0279 
0.0006 0.1917 
C.OOOO 0.0000 
O.UOOO 0.0000 
0.0000 
0.0000 0.0008 
pane~ valiab~e; 
cime variab:e: 
de:~a: 
Dace, 27 Jul 09 to 22 Jan 11, but with gaps 
: day 
xtmepoisson ma:aria ::m:. pca: pca2, I I household:, covariance (independent) I I ppt:, 
covariance (independenc) irr 
Note: sing:e-variab~e random-effects specification in household equation; covariance 
struc:Jre sec :'0 idenci:y 
Nole: sing:e-variable random-effects specification in ppt equation; covariance structure 
set cO iden:.icy 
Refining s::ar::ing values: 
Iteration 0: 
Iteration _. 
Iteration 2: 
log :ikelihood 
:og like':'ihood 
log like':'ihood 
-350.31557 
-323.08596 
-321.57024 
Performing gradient-based optimization: 
Iteration 0: log likelihood -321. 57024 
Iteration 1 : log like':'ihood -319.26394 
Iteration 2 : log likelihood -319.21788 
Iteration 3 : log likelihood -319.21732 
Itera::ion 4 : log ':'ikelihood -319.21731 
Mixed-effec:.s Poisson regression Number of obs 32892 
--------------------
------------------------------------------------------
Group Variable I 
No. of 
Groups 
Observations per Group 
Minimum Average Maximum 
Integration 
Points 
----------------+---------------------------------------------------------
household 1 
ppt 
1368 
6627 
Log likelihood = -319.21731 
1 24.0 
5.0 
40 
8 
Wald chi2(3) 
Prob > chi2 
7 
7 
8.54 
0.0360 
------------------------------------------------------------------------------
malaria I IRR Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
tmt 1.134405 .4146221 0.35 0.730 .554':'868 2.322096 
pca1 .7918374 .0934416 -1.98 0.048 .6283319 .9978907 
pca2 1.413918 .2179861 2.25 0.025 1.045185 1.912738 
cons .000236 .0001424 -13.84 0.000 .0000723 .00077 
Random-effects Parameters Estimate Std. Err. [95% Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd( cons) 1.73299 .2893351 1.249344 2.403866 
-----------------------------+------------------------------------------------
ppt: Identity 
sd ( cons) 
.3244254 1.328297 .0001062 991.2737 
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~R ~es~ vs. F2issc~ regression: chi2(2) ~ 25.54 Prob > chi2 = 0.0000 
Note: ~R :es~ is conserva~ive and provided only for reference . 
. xemepcisscn :a~ciparJm em: pca: pca2, II hO:.Jsehold:, covariance (independent) II ppt:, 
ccvariance(independent) irr 
Note: sing~e-variab~e random-effects specification in household equation; covariance 
struc::.Jre set to identity 
Note: sing:e-variab~e random-effeces specification in ppt equation; covariance structure 
set to identity 
Refining s:arting va:Jes: 
Itera~icn 0: :og :ike:ihood - -275.09296 
Ileraticn ~ . :cg ~ike:ihood -253.77508 
Itera~ion 2 : :og :ike:ihood ~ -252.05l64 
Performing gradient-based optimi"ation: 
Itera:.ion J: :og likelihood -252.05164 
Iteration - . :og likelihood -250.80553 
H.eration 2 : log :ike:ihood -250.7l789 
Iteration 3 : :og likelihood -250.70766 
Iteration 4 : ~og :ike:ihood -250.70753 
Iteration 5 : :og :ike:ihood -250.70753 
Mixed-effects Poisson regression Number of obs 32892 
-----------------
---------------------------------------------------------
Observa~ions per Group 
GroCJp Variable 
No. of 
Gro:.Jps Minimum Average Maximum 
Integration 
Points 
----------------+---------------------------------------------------------
household 
ppe I 
1368 
6627 
1 
1 
24.0 
5.0 
40 
8 
7 
7 
----------------------------------------------------------------------
Log likelihood = -250.70753 
Wald chi2(3) 
Prob > chi2 
9.60 
0.0223 
----------------------------------------------------------------------------
falcipar:.Jm IRR Std. Err. z P>lzl [95% Conf. Interval] 
_____________ T ________________________________________ ------------------------
tmt 
pcal 
pca2 
cons I 
.9474088 
.8058672 
1. 594853 
.000199 
.3886486 
.1025238 
.2641839 
.00011 77 
-0.13 
-1.70 
2.82 
-14.41 
0.895 
0.090 
0.005 
0.000 
.4239896 
.6280182 
1.152713 
.0000625 
2.116994 
1.034082 
2.206583 
.000634 
-----------------
----------------------------------------------------------
----------------
--------------------------------------------------------------
Random-effects Parameters Estimate Std. Err. [95% Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd (_"cons) 1.720907 .3423673 1.165238 2.541561 
-----------------------------+------------------------------------------------
ppt: Identity 
sd(_cons) 1.o8e-07 .7711505 o 
---------------------------------------------------------------------------
LR test vs. Poisson regression: chi2(2) = 16.38 Prob > chi2 = 0.0003 
Note: LR test is conservative and provided only for reference. 
xtmepoisson falciparum tmt pca2, I I household:, covariance (independent) II ppt:, 
covariance (independent) irr 
Note: single-variable random-effects specification in household equation; covariance 
structure set to identity 
Note: Single-variable random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting values: 
Iteration 0: log likelihood -277.62989 
Iteration : : log likelihood -255.74821 
Iteration 2: log likelihood -253.5642 
Performing gradient-based optimization: 
Iteration 0: log likelihood = -253.5642 
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I~era:.icn - . ~cg ~ike~ihcod -252.37354 
I:..era~.ion 2 : ~og ~ike~ihcod - -252.298:6 
I:era:ion 3 : ~og ~ike~ihcod - -252.25:43 
Itera~ion 4 : :og :ike~ihood -252.25"4 
Mixed-e::ec:s Poisson regression Number of obs 32892 
Gro'Jp \far iab~e 
NO. of 
GroJps 
Observations per Group 
MinimJm Average MaximJm 
Integration 
Points 
:368 
6627 
~og :ike:ihood ~ -252.25l4 
24.0 
5.0 
40 
8 
Wald chi2(2) 
Prob > chi2 
7 
7 
7.34 
0.0255 
:a~ciparJm IRR Std. Err. z P>'ZI [95% Conf. Interval) 
·~m·,-
pca2 
cons 
.95902c 
:.5::952 
.000:823 
Random-effeccs Parameters 
.3974457 
.23::626 
.000:072 
-0.10 
2.70 
-14.64 
0.920 
0.0:)7 
0.000 
Estimate Std. Err. 
.425663 
1.120464 
.0000576 
2.160679 
2.040227 
.0005773 
[95% Conf. Interval) 
-----------------------------+------------------------------------------------
househo:d: Identity 
sd ( cons) 1.815313 .3213352 1.28315 2.568182 
-----------------------------+------------------------------------------------
ppt: Identity 
sd (cons) .0000192 .7613616 o 
LR test vs. Poisson regression: chi2(2) = 20.43 Prob > chi2 = 0.0000 
Note: LR test is conservative and provided only for reference. 
xtmepoisson vivax tmt pca: pca2, II hOJsehold:, covariance (independent) II ppt:, 
covariance (independent) irr 
Note: sing:e-variab:e random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variab::'e random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting values: 
Iteration 0: log likelihood -128.72024 
Iteration 1 : log likelihood -119.45524 
Iteration 2 : log Ii ke::' ihood -119.10847 
Performing gradient-based optimization: 
Iteration 0: log likelihood -119.10847 
Iteration 1 : log likelihood -118.79147 
Iteration 2 : log likelihood -118.73531 
Iteration 3: log likelihood -118.72919 
Iteration 4 : log likelihood -118.72791 
Iteration 5: log likelihood -118.72791 
Mixed-effects Poisson regression Number of obs 32892 
No. of 
Groups 
Observations per Group Integration 
Points Group Variable I Minimum Average Maximum 
----------------+---------------------------------------------------------
household I 
ppt I 
1368 
6627 
Log likelihood = -118.72791 
vivax I IRR 
1 
1 
Std. Err. z 
24.0 
5.0 
40 
8 
Wald chi2(3) 
Prob > chi2 
7 
7 
3.81 
0.2823 
P>lzl [95% Conf. Interval) 
-------------+----------------------------------------------------------------
tmt I 1.013961 .5901457 0.02 0.981 .3240447 3.172764 
pca: 
pca2 
cons 
.662968 
:. :48737 
.0000824 
Random-e::ec~s Parame~ers 
ho~seho:d: Identity 
sd( cons) 
.:499:35 
.3:H042 
.0000939 
-1.82 
0.52. 
-8.25 
0.069 
0.612 
0.000 
Estimate Std. Err. 
:.704536 .6394128 
.4256129 
.6718:66 
8.83e-06 
A P pen d i X E 218 
1.032691 
1.964223 
.0007688 
[95% Conf. Interval] 
.817146 3.555597 
-----------------------------+------------------------------------------------
pp::: IdenLity 
sd (_ cons) 4.:6e-07 :.505006 o 
LR test vs. Poisson regression: chi2(2) = 2.67 Prob > chi2 = 0.2627 
No::e: ~R tese is conservative and provided only for reference. 
xcmepoisson vivax tmt peal, i I household:, covariance (independent) I I ppt:, 
covariance (independent) irr 
Note: sing:e-variab:e random-effects specification in household equation; covariance 
str~c:ure set to identity 
Note: sing:e-variable random-e:fects specification in ppt equation; covariance structure 
set La identity 
Refining starting values: 
Iteration 0: :'og like:ihood -:28.8805'-
Iteration - . log likelihood -119.62821 
Itera:.ion 2 : :og :ikelihood -1:.9.26836 
Performing gradient-based optimization: 
Iteration 0: log likelihood -119.26836 
IteraLion : : log like:ihood -118.9432 
Iteration 2 : log :ikelihood -118.88511 
Iteration 3: log likelihood -118.85591 
Iteration 4 : :og likelihood -118.85317 
Iteration 5 : log likelihood -118.85288 
Iteration 6 : log likelihood -118.85288 
Mixed-effects Poisson regression Number of obs 32892 
Group Variable I 
No. of 
Groups 
Observations per Group 
Minimum Average Maximum 
Integration 
Points 
----------------+---------------------------------------------------------
household ; 
ppe I 
1368 
6627 
Log likelihood = -118.85288 
vivax i IRR 
1 
Std. Err. z 
24.0 
5.0 
40 
8 
Wald chi2(2) 
Prob > chi2 
7 
7 
3.48 
0.1753 
P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
tmt 
pca1 I 
cons ! 
1. 005379 
.6522806 
.0000782 
Random-effects Parameters 
.5870387 
.1494446 
.0000897 
0.01 
-1. 86 
-8.24 
0.993 
0.062 
0.000 
Estimate Std. Err. 
.3201215 
.4163082 
8.25e-06 
3.157509 
1.022007 
.0007412 
[95% Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd(_cons) 1.739135 .6332697 .8518953 3.550427 
-----------------------------+------------------------------------------------
ppt: Identity 
sd(_cons) 2.03e-07 1.491323 o 
LR test vs. Poisson regression: chi2(2) = 2.83 Prob > chi2 = 0.2429 
Note: LR test is conservative and provided only for reference. 
A P pen d i x E 219 
According to Protocol Analysis: 75 0/0 Compliance 
. spearman ma~aria :a~ciparJm vivax pcal pca2 age female net forest, stats(p) pw 
(Obs-"Vdfles) 
+-----------------+ 
1 Key 
1-----------------1 
1 Si~. level 1 
+-----------------+ 
Vlvax peal pca2 age female net forest 
-------------+---------------------------------------------------------------------------------
mdlarid 
fdlcl~drum 
ViVdX 
temale 
ne':: 
fore s t 
C.Cf~\CC 
C.0':03 
C • C II e 
,--'. bi. /2 
C.33';C 
C.5;'e~ 
C. 8 ~ C 1 
lsse~ ppt Date 
pane~ variab~e: 
:.ime variab:e: 
delta: 
,'.9312 
C'. OC J I 0.0471 
2. eel 4 C. 9762 0.0000 
C.5619 0.9482 o.cooe 0.5972 
C.2027 C. 9646 0.0057 0.0002 0.3250 
2.6~3C 0.5925 0.C249 0.OCC7 0.0000 0.0000 
0.9721 C.7150 0.0000 0.0000 0.0000 0.0006 
ppt (~nbalanced) 
Date, 27 J~l 09 to 31 Dec 10, but with gaps 
: day 
0.3209 
xtmepoisson malaria tmt.. pca1 pca2, !: household:, covariance (independent) II ppt:, 
covariance (independent) irr 
Note: sing:e-variab':'e random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variable random-effecls specification in ppt equation; covariance structure 
set to iden~ity 
Refining starting va:~es: 
Iteration 0: 
Iteration 1: 
Iteration 2: 
log likelihood 
log likelihood 
log ':'ikelihood 
-183.15296 
-168.93313 
-168.53804 
Performing gradient-based optimization: 
Iteration 0: log likelihood -168.53804 
Iteration i.: log likelihood -168.13258 
Iteration 2 : log likelihood -168.1114 
Iteration 3 : log likelihood -168.10808 
Iteration 4 : log likelihood -168.10756 
Iteration 5 : log ':'ikelihood -168.10753 
Iteration 6 : log likelihood -168.10753 
Mixed-effects Poisson regression Number of obs 22037 
----------------------------------------------------------------------
Group Variable I 
No. of 
Groups 
Observations per Group 
Minimum Average Maximum 
Integration 
Points 
----------------+---------------------------------------------------------
household i 
ppl I 
1342 
6147 
1 
1 
16.4 
3.6 
40 
8 
7 
7 
----------------------------------------------------------------------
Log likelihood = -168.10753 
Wald chi2(3) 
Prob > chi2 
11.11 
0.0111 
--------------------------------------------------------------------------
ma:aria , IRR Std. Err. z P>lzl [95% Conf. Interval) 
-------------+----------------------------------------------------------------
tmt 
pca1 
pca2 
cons 
1.40835 
.5756266 
1.361821 
.0001947 
.6680392 
.1125831 
.311694 
.0001687 
0.72 
-2.82 
1. 35 
-9.86 
0.470 
0.005 
0.177 
0.000 
.5558402 
.3923374 
.8695548 
.0000356 
3.56838 
.8445433 
2.132767 
.0010638 
------------------------------------------------------------------------------
Random-effects Parameters Estimate Std. Err. [95% Conf. Interval) 
-----------------------------+------------------------------------------------
household: Identity 
sd(_cons) 1.489954 .528589 .74335 2.986431 
-----------------------------+------------------------------------------------
A P pen d i x E 220 
ppe: Iden~i:y 
sri (cons) .::14021 5.232334 1.17e-41 1.06e+39 
~R tes: vs. Poisson regression: chi2(2) = 4.96 Prob > chi2 = 0.0838 
Note: :R tese is conservaeive and provided only for reference. 
xtmepoisson ma':'aria tmt peal. I I household:. covariance (independent) I I ppt:. 
covariance (independent) irr 
Noee: single-variab~e random-e:fects specification in household equation; covariance 
structure set to identity 
Note: single-variable random-e:fects specification in ppt equation; covariance structure 
set to identity 
Refining starling values: 
Iteration 0: ':'og likelihood - -184.26471 
Iteration .. log likelihood -170.12771 
I~erat-ion 2 : ':'og ':'ikelihood -169.52587 
Performing gradient-based optimization: 
Iteration 0: log ':'ikelihood -169.52587 
Iteration 1 : log likelihood -168.99282 
Iteration 2 : ':'og likelihood -168.9619 
Iteration 3 : ':'og likelihood -168.95867 
Iteration 4 : log likelihood -168.95792 (not concave) 
Iteration 5 : log ':'ikelihood -168.95786 
Iteration 6 : log likelihood -168.9578 
Iteration 7 : log likelihood -168.9578 
Mixed-effects Poisson regression Number of obs 22037 
Observations per Group 
Group Variable i 
No. of 
Groups Minimum Average Maximum 
Integration 
Points 
hO;Jsehold I 
ppt I 
1342 
6147 1 
16.4 
3.6 
40 
8 
7 
7 
Log likelihood = -168.9578 
Wa1d chi2(2) 
Prob > chi2 
9.04 
0.0109 
malaria ' IRR Std. Err. z P>!zl [95% Conf. Interval] 
_____________ T ________________________________________ ------------------------
tmt I 
pca1 
cons 
1.360049 
.5517356 
.0001612 
Random-effects Parameters 
.6572281 
.1124133 
.0001295 
0.64 
-2.92 
-10.87 
0.525 
0.004 
0.000 
Estimate Std. Err. 
.5274982 
.3700864 
.0000334 
3.506614 
.8225436 
.000778 
[95% Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd(_cons) 1.653499 .4813497 .9345677 2.925479 
-----------------------------+------------------------------------------------
ppt: Identity 
.0005069 6.157531 o 
LR test vs. Poisson regression: chi2(2) = 7.13 Prob > chi2 = 0.0283 
Note: LR test is conservative and provided only for reference . 
. xtmepoisson falciparum tmt pcal pca2 female. I I household:. covariance (independent) I I 
ppt:. covariance (independent) irr 
Note: single-variable random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variable random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting values: 
Iteration 0: log likelihood 
-1l5.59597 
Iteration 1 : log likelihood 
-106.48128 
Iteration 2 : log likelihood 
-106.40968 
A P pen d i x E 221 
Per:orming gradien~-based 0Plimization: 
Iteration 8 : :og :ike':'ihood - -186.40968 
l::.eracion 1 : log ':'ike:ihood -105.75536 
Iteration 2 : log :ikelihood ~ -105.71027 
Iteration 3 : :og .i.ike::'ihood -105.69933 
llera:ion 4 : :og like.i.ihood -:85.69933 
Mixed-ef:ec:s Poisson regression Number of obs 22037 
Gro'Jp Var iable ' 
No. of 
GroJps 
Observations per Group 
Minimum Average Maximum 
Integration 
Points 
hOJseho::'d 
ppt ! 
1342 
6147 
Log like:ihood = -105.69933 
1 
1 
16.4 
3.6 
40 
8 
Wald chi2(4) 
Prob > chi2 
7 
7 
12.26 
0.0155 
fa2.ciparClm I lRR Std. Err. z P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
tmt 1.276856 .7775206 0.40 0.688 .387094 4.211795 
peal .5E6::'971 .134491 -2.39 0.017 .3554499 .9018968 
pca2 2.002911 .5406937 2.57 0.010 1.179985 3.399749 
female 2.053022 1.224236 1.21 0.228 .6379908 6.60652 
cons .0000586 .0000698 -8.17 0.000 5.66e-06 .0006062 
Random-effects Parameters Estimate Std. Err. [95% Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd ( cons) 1.538643 .7506904 .5913494 4.003424 
ppt: Identity 
sd (cons) 6.45e-06 .9075495 o 
LR test vs. Poisson regression: chi2(2) = 2.38 Prob > chi2 = 0.3036 
Note: LR test is conservative and provided only for reference. 
. xtmepoisson f alciparum tmt peal pca2, I I household:, covariance (independent) I I ppt:, 
covariance (independent) irr 
Note: single-variable random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variable random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting values: 
Iteration 0: log likelihood -116.43884 
Iteration 1 : log likelihood -107.29601 
Iteration 2 : log likelihood -107.1196 
Performing gradient-based optimization: 
Iteration 0: log likelihood -107.1196 
Iteration 1 : log likelihood -106.55122 
Iteration 2 : log likelihood -106.50144 
Iteration 3 : log likelihood -106.48953 
Iteration 4 : log likelihood -106.48951 
Iteration 5 : log likelihood -106.48951 
Mixed-effects Poisson regression Number of obs 22037 
No. of Observations per Group Integration 
Group Variable I Groups Minimum Average Maximum Points 
----------------+---------------------------------------------------------
household I 1342 1 16.4 40 7 
ppt I 6147 1 3.6 8 7 
Log likelihood -106.48951 
Wald chi2(3) 
Prob > chi2 
10.80 
0.0129 
A P pen d i x E 222 
:a:clpac...:m IRR Sed. Err. z P>iz' r95% Conf. In:erval] 
tmt :.25434 .763255 0.37 0.710 .380598 4.133939 
peal .5696271 .;'347696 -2.38 0.017 .3582635 .9056881 
pca2 2.003694 .543:626 2.56 O. no 1.177842 3.408596 
cons .0000898 .0001008 -8.30 0.000 9.95e-06 .0008102 
------------------------------------------------------------------------------
Random-effects Parameeers Es:imate Std. Err. [95% Conf. In:erval] 
-----------------------------+------------------------------------------------
hOJseho:d: IdenLi:y 
sd (. cons) 1.566382 .7366641 .6231328 3.937449 
-----------------------------+------------------------------------------------
pp:: Idenci':.y 
4.88e-09 .9408947 o 
LR Lest vs. Poisson regression: chi2(2) = 2.58 Prob > chi2 = 0.2755 
Note: LR test is conservative and provided only for reference. 
xcmepoisson vivax tmt peal, househo:d:, covariance (independent) II ppt:, 
covariance (independent) irr 
Note: single-variable random-effects specification in household equation; covariance 
s~ruc~ure set to iden~i~y 
Note: single-variab:e random-effects specification in ppt equation; covariance structure 
set to idencily 
Refining s:arting va:ues: 
Iteration 0: ':'og likelihood -81.781505 
Iteration ' . ':'og likelihood -75.825396 
Iteration 2 : log likelihood -75.724844 
Performing gradient-based optimization: 
Iteration 0: log likelihood -75.724844 
Iteration ~ . log likelihood -75.699682 
Iteration 2 : log likelihood -75.690969 (not concave) 
Iteration 3 : log likelihood -75.690339 
Iteration 4 : log likelihood -75.68865 
Iteration 5 : log likelihood -75.687425 
Iteration 6 : log likelihood -75.686874 
Iteration 7 : log likelihood -75.68679 
Iteration 8 : log :ikelihood -75.68677 
Iteration 9 : log likelihood -75.68677 
Mixed-effects poisson regression Number of obs 22037 
Observations per Group 
Group Variable i 
No. of 
GrOJpS Minimum Average Maximum 
Integration 
Points 
----------------+---------------------------------------------------------
household I 
ppt i 
1342 
6147 
1 16.4 
3.6 
40 
8 
7 
7 
--------------------------------------------------------------------------
Log likelihood = -75.68677 
vivax I IRR Std. Err. z 
Wald chi2(2) 
Prob > chi2 
5.61 
0.0604 
P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
tmt 
peal I 
cons I 
1.920826 
.509808 
.0001795 
Random-effects Parameters 
1. 358741 
.1593142 
.0001211 
0.92 
-2.16 
-12.79 
0.356 
0.031 
0.000 
Estimate Std. Err. 
.4801429 
.276317 
.0000479 
7.68432 
.9406017 
.0006735 
[95% Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd( cons) 3.37e-06 2.61205 0 
-----------------------------+------------------------------------------------
ppt: Identity 
sd( cons) 5.78e-06 5.520397 o 
A P pen d i x E 223 
~R ~est vs. Poisson regression: chi2(2) ~ 0.00 Prob > chi2 = 1.0000 
No~e: LR lest is conservative and provided only for reference. 
A P pen d i x E 224 
According to Protocol Analysis: 900/0 Compliance 
. s~earmdrl maldrid tdl~irarum ViVdX pCdl pea2 age female net forest, stats(pl pw 
(c'G:::;-· ... ar:cs) 
+- ---------------+ 
1 Key 
1-----------------1 
I Sl~. level I 
+-----------------+ 
malaria falci~'m \,lvax peal pea? age female net forest 
-------------+---------------------------------------------------------------------------------
malaria 
fdl-.:1~)drUm 
ViVdX 
p:"dl 
pea2 
d.Je I 
female 
rlC: 
tores: 
C.CCCC 
C.CGCD 
c. 
C.11166 
:' . S 6 3 9 
':.3"295 
C'. :,622 
C.566" 
csse~ pp: Dace 
pane~ variab:e: 
time variab:e: 
de::a: 
0.9323 
C.CC23 C.1385 
0.CC26 0.9672 0.0000 
:;.3' 59 0.7351 0.0000 0.8660 
C.o2848 C.7728 C.OO72 O.OCCI 0.2961 
0.6494 0.7194 0.035" 0.5455 0.0005 0.0000 
C.933: C. 4 132 C.CCCO 0.0086 0.0000 0.0099 
ppt (~nbalanced) 
Date, 27 Jul 09 to 31 Cec 10, but with gaps 
: day 
0.7544 
x~mepoisson ma:aria tm: pca: pca2, 
covariance (independent) irr 
household:, covariance (independent) I I ppt:, 
Note: sing:e-variable random-effects specification in household equation; covariance 
scruccure set to identity 
Note: single-variable random-effects specification in ppt equation; covariance structure 
set to identity 
Re:ining s:ar~ing values: 
Iteration 0: 
Iteration ~: 
Iteration 2: 
~og ~ike::'ihood 
1.og ~ikelihood 
::'og likelihood 
-167.01787 
-153.86475 
-153.38184 
Performing gradient-based optimization: 
Iteration 0: ::'og likelihood -153.38184 
Iteration - . log likelihood -152.94907 
Iteration 2 : log :ike::'ihood -152.91723 
Iteration 3 : log likelihood -152.91187 
Iteration 4 : log likelihood -152.9093 
Iteration 5 : log likelihood -152.90894 
Iteration 6 : :og :ikelihood -152.90878 
Iteration 7 : log likelihood -152.90877 
Mixed-effects Poisson regression Number of obs 19367 
No. of 
Groups 
Observations per Group Integration 
Points Group Variable ! Minimum Average Maximum 
----------------+---------------------------------------------------------
household 
ppt I 
1311 
5810 
Log likelihood = -152.90877 
malaria I IRR 
1 
1 
Std. Err. z 
14.8 
3.3 
40 
8 
Wald chi2(3) 
Prob > chi2 
7 
7 
8.67 
0.0339 
P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
tmt 
peal 
pca2 
cons 
1.489295 
.6047212 
1.325184 
.0001777 
Random-effects Parameters 
.7518178 
.1247683 
.3288408 
.0001525 
0.79 
-2.44 
1. 13 
-10.06 
0.430 
0.015 
0.257 
0.000 
Estimate Std. Err. 
.5537095 
.4035823 
.8148031 
.000033 
4.005711 
.9061045 
2.155259 
.0009559 
[95% Cont. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd( cons) 1.590682 .5447165 .81301 3.112222 
A P pen d i x E 225 
-----------------------------~------------------------ ------------------------
pp::: Identity 
sd ( cons) .0001364 3.770785 o 
-----------------------------------------
-------------------------------------
~R tese vs. Poisson regression: chi2(2) = 5.45 Prob > chi2 = 0.0656 
Note: ~R ~eSe is conservative and provided on':'y for reference. 
xcmepoisson malaria tmt pcal, household:, covariance (independent) I I ppt:, 
covariance (independent) irr 
Note: single-variable random-effects specification in household equation; covariance 
str~ct~re see to iden:i:y 
Note: single-variable random-e::ects specification in ppt equation; covariance structure 
set to identity 
Re:ining starting values: 
Iteracion 0: log :ike:ihood -:;'67.85464 
Iteration 
- . log :ike:ihood -154.81764 
l~erat.ion 2 : :cg :ike':'ihood -154.66896 
Per':orming gradient-based optimization: 
Iteration 0: log :ikelihood -154.66896 
Iteration log likelihood -153.56509 
Itera:ion 2 : :cg :ikelihood -153.51694 
Iteration 3 : ':"og like':"ihood -:53.51262 
Iteration 4 : ':'og :ikelihood -153.51204 
Iteration 5 : log likelihood -153.51174 
Iteration 6 : log likelihood -153.51174 
Mixed-effects Poisson regression Number 0: obs 19367 
No. of 
Groups 
Observations per Group Integration 
Points Group Variable I Minimum Average Maximum 
----------------+---------------------------------------------------------
household 1311 14.8 40 7 
ppt I 5810 3.3 8 7 
Log likelihood = -153.51174 
malaria i IRR Std. Err. z 
Wald chi2(2) 
Prob > chi2 
7.14 
0.0281 
P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
tmt 
peal i 
cons I 
1. 454528 
.5784401 
.0001436 
Random-effects Parameters 
.748689 
.1237898 
.0001246 
0.73 
-2.56 
-10.20 
0.467 
0.011 
0.000 
Estimate Std. Err. 
.5303749 
.3802734 
.0000262 
3.988971 
.8798748 
.0007868 
[95% Conf. Interval] 
-----------------------------+------------------------------------------------
household: Identity 
sd ( cons) 1.744032 .49744 .9971749 3.050266 
-----------------------------+------------------------------------------------
ppt: Identity 
sd ( cons) .0000197 3.059158 o 
LR test vs. Poisson regression: chi2(2) = 7.75 Prob > chi2 = 0.0208 
Note: LR test is conservative and provided only for reference . 
. xtmepoisson falciparum tmt pca1 pca2, I I household:, covariance (independent) I I ppt:, 
covariance (independent) irr 
Note: single-variable random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variable random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting values: 
Iteration 0: log likelihood 
-107.12398 
Iteration 1 : log likelihood -98.525473 
Iteration 2 : log likelihood 
-98.164925 
A P pen d i x E 226 
Per!orming gradien~-based optimization: 
1:er3:ion v • ~og ~ike~ihood -98.:64925 
l~era~ion - . :og :ike:ihood -97.87533 
1:er3:ion 2 : :og :ike:ihood - -97.816448 
1·_er3:ion ' . :og :ike:ihood -97.814:28 
1:er3:ion 4 : :oq :ike:ihood -97.8"4087 
Iteration - . ~og :ike':'ihood -97.814087 
Mixed-e::ec:s Poisson regression Number 0: obs 19367 
No. 0: 
GroJp Variab:e GroJps 
Observations per Group 
Minim:..lm Average Maximum 
Integration 
Points 
hOclseho:d 
pp: 
~og :ike:ihood ~ -97.8:4087 
1 14.8 
3.3 
40 
8 
Wa1d chi2(3) 
Prob > chi2 
7 
7 
9.96 
0.0189 
:a~ciparClm Ikk Std. Err. z P>lzl [95% Conf. Interval] 
:mt. 
pca: 
pca2 
cons 
:.56005: 
.5569636 
:.988774 
.0000927 
Random-ef:eCls Parameters 
.9873801 
.:440143 
.5834757 
.000:031 
0.70 
-2.26 
2.34 
-8.35 
0.482 
0.024 
0.019 
0.000 
Estimate Std. Err. 
.4512321 
.33553 
1.119067 
.0000105 
5.393582 
.9245327 
3.534393 
.0008198 
[95% Conf. Interval] 
_____________________________ T ________________________ -------------------- ___ _ 
household: Identity 
sd (_cons) 1.477231 .766884 .53402l7 4.086372 
-----------------------------+------------------------------------------------
ppt: Identity 
2.23e-08 .936546 o 
------------------------------------------------------------------------------
LR test vs. Poisson regression: chi2(2) = 2.14 Prob > chi2 = 0.3435 
Note: LR test is conservative and provided only for reference. 
xtmepoisson vivax tmt pcal, !, household:, covariance (independent) II ppt:, 
covariance (independent) irr 
Note: single-variable random-effects specification in household equation; covariance 
structure set to identity 
Note: single-variab':'e random-effects specification in ppt equation; covariance structure 
set to identity 
Refining starting values: 
Iteration 0: log likelihood -73.857558 
Iteration 1 : log like::"ihood -68.538169 
Iteration 2 : log like:'ihood -68.46656 
Performing gradient-based optimization: 
Iteration 0: log likelihood -68.46656 
Iteration 1 : log likelihood -68.461834 
Iteration 2 : log likelihood -68.455953 
Iteration 3 : log likelihood -68.447679 
Iteration 4 : log likelihood -68.446131 
Iteration 5 : log likelihood -68.444246 
Iteration 6 : log likelihood -68.443944 
Iteration 7 : log likelihood -68.443634 
Iteration 8 : log likelihood -68.443545 
Iteration 9 : log likelihood -68.443519 
Iteration 10 : log likelihood -68.443518 
Mixed-effects Poisson regression 
(not concave) 
(backed up) 
Number of obs 
No. of Observations per Group Integration 
Group Variable I Groups Minimum Average Maximum Points 
19367 
----------------+---------------------------------------------------------
household I 1311 1 14.8 40 7 
pp:. 5810 3.3 
~og ~ike~ihood - -68.4435:8 
vivax IRR Std. Err. z 
8 
Wald chl2(2) 
Prob > chi2 
A P pen d i X E 227 
7 
3.14 
0.2076 
P>lzl [95% Conf. Interval] 
-------------+----------------------------------------------------------------
:.m~ 
pca: 
cons 
:.647323 
.6062807 
.000237: 
Random-ef:eccs Parameters 
hOJseho:d: Iden:i:y 
sd (cons) 
:.2C'3365 
.:872482 
.0001527 
0.68 
-1.62 
-12.96 
0.494 
0.105 
0.000 
Estimate Std. Err. 
.0000487 3.629l67 
.3935301 
.3309653 
.0000671 
6.895717 
1.110619 
.000838 
[95% Conf. Interval] 
o 
-----------------------------+------------------------------------------------
pp:: Iden:i:y 
sd(_cons) .000164~ 7.899616 o 
LR :.es: vs. Poisson regression: chi2(2) ~ 0.00 Prob > chi2 = 1.0000 
No:e: ~R :es: is conserva:ive and provided only for reference. 
Appendix E 228 
Appendix E: Ethnicity data 
Ethnic groups in the Lao PDR were previously divided into three broad geographically-based 
groups, the Lao Loum (lowland Lao), Lao Theung (midland Lao) and Lao Song (Highland Lao). 
Ethnic groups are now identified more along linguistic lines and the Lao Front for National 
Construction currently recognises 49 ethnic groups. 
Table E1. Ethnicities of participants recruited to the trial according to current categorisations, phonetic 
spellings according to Messerli et 01. (198). 
Ethno- Ethno- Ethnic group Total % of trial %of 
linguistic linguistic (alternative names) recruited population national 
family category population 
Lao Lao 792 9.9 54.6 
Lao-Tai 
Phou Thay, Tai, Lue, 
Tai-Thay Tai Neua, Sek, 0 0 10.2 
Nyouan, Yang,Lao 
Khmou, Phong, Pray, 
Khmuic Ksing Moul, Thene, 0 0 12.0 
Oe Dou, Kri 
Palaungic Lamet, Bit, Sam Tao 0 0 0.5 
Katang (Kasseng) 30 0.4 2.1 
Makong 0 0 2.1 
Tri 0 0 0.05 
Ta Oy 82 1.0 0.6 Katuic Katu 407 5.1 0.4 
Kriang (Ngae) 537 6.7 0.2 
Souay 317 4.0 0.8 
Pacoh 65 0.8 0.03 
Mon- Jrou (Laven) 84 1.1 0.9 
Khmer Triang 1,094 13.7 0.5 
Ye 439 5.5 0.02 
Brao (Lavae) 804 10.1 0.4 
Halak 920 11.5 0.04 
Bahnaric- Oy 422 5.3 0.4 
Khmer Cheng 3 <0.1 0.1 
Sadang (Halang) 40 0.5 0.02 
Nyaheun 22 0.3 0.1 
Lavi 432 5.4 0.02 
Khmer 0 0 0.1 
Vietic 
Toum, Ngouan, 0 0 0.08 Meuang, Kri, Phong 
Sino- Tibeto- Akha, Singsily, Lahu, 0 0 2.9 Tibetan Burman Sila, Hanyi, Lolo, Ho 
Hmong- Hmong Hmong 0 0 8.0 
Mien Mien Lu Mien 0 0 0.5 
Lao Theung 190 2.4 
No data 1,300 16.3 
Total 7,980 100.0 
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Appendix F: Focus Group Discussion Transcripts 
Focus Group Discussion #1 
Location 
Date 
Moderator 
Participants 
Others Present 
Transcript 
Moderator 
A 
B 
G 
Moderator 
B 
E 
Moderator 
C 
E 
o 
Ban Kasom, Samackixay District, Attapeu Province, Lao PDR 
20th April 2010 
Santi Sayarath 
All took part in the trial last year and reported that they did like using the 
lotion 
A - 62 years, F 
B - 52 years, M 
C - 21 years, F 
D - 20 years, F 
E -47 years, M 
F - 13 years, M 
G - 25 years, F 
Vanessa Chen-Hussey - Repellent Trial Manager 
Dr Hongkham Keomanila - CMPE 
Dr Manivone - Samackixay District Hospital Staff 
What do you do in the evening? 
That's when everyone is eating. Everyone comes back from the fields or 
the river and eats at home. 
I make and repair my fishing nets in the evening 
My family all go to the river - we wash and collect water for the next day. 
Do you stay in the house when you eat, or outside or underneath? 
Underneath 
Yes, underneath 
What time do people sleep, is it different for different people? 
I'd say between 9 and 10pm most people will go to bed. But the houses 
far from the village will go to bed earlier. 
Men go to catch fish late at night; maybe 11-12pm 
And the children will catch frogs at the same time 
Moderator 
E 
Moderator 
E 
Moderator 
A 
Moderator 
o 
c 
Moderator 
B 
E 
A 
G 
c 
E 
A 
D 
F 
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Where do you catch fish 
The river, or sometime we walk up to the lake [hydropower dam on 
plateau above village]. It's a long way so that means we will sleep 
overnight in the forest 
How many times a month will you do that? 
Maybe three nights a month 
Does anyone in the village stay up late? 
These days the children all stay up very late - they watch TV. From 6pm 
until late 
Do they sit under the houses? 
No, most people have their TVs upstairs 
And the young men stay up late drinking 
How do you prevent mosquitoes biting? 
The insecticide bed nets 
Older people don't sleep under nets - they say they are protected by phi 
[spirits] 
They don't like to sleep under nets because it is too hot. 
Also they don't wear shirts to protect them from biting when they work in 
the fields 
When we light the fire near the house at night that protects us from 
mosquitoes. 
We also light a fire when we sleep in the forest 
And in the ricefields 
We take the citronella plants and put on the skin, but it only lasts 2 hours 
When we go to collect bamboo shoots in the day there are many 
mosquitoes. 
Focus Group Discussion #2 
Location 
Date 
Moderator 
Participants 
Ban Kasom, Samackixay District, Attapeu Province, Lao PDR 
20th April 2010 
Santi Sayarath 
All took part in the trial last year and reported that they did not like using 
the lotion. 
A -35, F 
Others Present 
Transcript 
Moderator 
F 
A 
D 
E 
C 
B 
Moderator 
B 
Moderator 
E 
A 
D 
B 
C 
F 
B-16, M 
C-40, M 
D - 36, F 
E - 36, F 
F - 57, F 
Vanessa Chen-Hussey - Repellent Trial Manager 
Dr Hongkham Keomanila - CMPE 
Dr Manivone - Samackixay District Hospital Staff 
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You all reported that you did not like using the repellent: what were the 
main problems you found? 
I liked the smell of the repellent to start with, but I got tired of it and in 
the end the smell made me feel sick 
I also didn't like the smell, it gave me headaches 
One time my daughter used the repellent when she had a cut on her leg 
it hurt and made the cut bigger. 
At the beginning I used the repellent and it was fine, but I used often 
and I also got a headache from the smell, it was very bad 
I agree with liE" - when I started using the repellent it was really good 
and I used it every evening before going to sleep. But after 3-5 days I 
started to get headaches from the smell and stopped using it. 
I had a rash from using the repellent 
Do you remember which number you had? 
I think 258 
It seems like the smell of the repellent was a problem for most of you -
can you explain a bit more? What would be a better fragrance? 
Actually I think the smell was good, like a perfume or talcum powder. 
But maybe it was too strong. 
Maybe a fruit smell would be good, like orange 
----------------~ Orange 
I don't know 
I always forgot to use the repellent, that's why I didn't use it much 
The repellent smells like perfume, whatever is the newest brand, that 
D 
F 
Moderator 
F 
A 
C 
Moderator 
C 
Moderator 
D 
E 
C 
A 
E 
Moderator 
o 
B 
Moderator 
F 
Moderator 
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will be the best smell. 
But I liked the smell at first, it was like talcum powder - very good. But 
after 4 days it smelled bad to me. 
It's like when you get the bus and there are many people there all using 
different perfumes and some not using any who smell very bad. Then all 
together the different smells give you a headache. And like durian -
some people like the smell, some don't. 
Did you notice whether you got bitten by mosquitoes when you were 
using the repellent? 
No, it really can protect, 100% 
When you put it on you get no mosquitoes on your body. 
It also worked on other insects and animals that take blood from 
humans, not just mosquitoes. 
What animals? 
Leeches - from the forest 
You all did not use the repellent very much - can you talk about when 
you did, where and why? 
In the evening, and sometimes in the day 
I n the forest 
And the ricefields - because there are many mosquitoes there 
I used it in the ricefields too, but only in the beginning 
Yes, after 4 days I didn't like the smell and didn't want to use it 
anymore. 
Was the smell the only problem with the repellent? 
Only smell was a problem 
The lotion got in my eyes once and made my eye very red and difficult 
to open the next day. 
I was allergic to the lotion and it made me tired . 
How about eating in the evening, was using the lotion a problem then -
maybe you didn't apply the lotion until you finished eating? 
No, that isn't a problem. Just wash your hands before you eat and the 
smell isn't a problem for eating. 
You said earlier that the lotion protected you from mosquitoes biting, 
but you didn't use the repellent much. So is there anything else you do 
to avoid getting bitten? 
F 
C 
Moderator 
C 
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A 
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A 
F 
Moderator 
A 
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Cigarettes can protect you in the forest. It's true! If you smoke cigarettes 
the mosquitoes won' t bite you. 
Some people use the citronella plant. 
How do you use the citronella? 
We crush the plant and mix with water and rub on the skin, but it does 
not kill the mosquitoes and does not last very long. 
In the village; the cooking fires outside the house can protect from 
mosquitoes 
We sometime take tissue and twist it to make a long rope and burn it 
near to the body, to keep all insects, not just mosquitoes, away. 
When the rice is growing, we can use the young leaves [before the rice 
is harvested] the same way - make a rope and burn when we go to the 
forest. 
The best way when you go to the forest to get bamboo shoots is to just 
wear a longer shirt and pants and cover your face. 
For men when we are working directly in the field, we just need to wear 
long clothes. 
In the village many mosquitoes are only in the evening, around 6pm. But 
when you go to the forest, they bite all the time. 
But after the water flood, there were many mosquitoes, even in the 
village and very big mosquitoes. 
Thank you for your time. Before we finish are there any other things 
about the repellent you wanted to talk about? 
I think I would use the repellent if the smell was different - like an 
orange smell 
I think a spray would be good, I have seen other people using it and I 
think it would be easier to use tha n the cream. 
Focus Group Discussion #3 
Location 
Date 
Moderator 
Participants 
Lao Yao Kao, Samackixay District, Attapeu Province, Lao PDR 
21st April 2010 
Santi Sayarath 
All took part in the trial last year and reported that they did like using the 
lotion. 
Others Present 
Transcript 
Moderator 
A 
Moderator 
B 
C 
F 
D 
E 
Moderator 
C 
A 
Moderator 
F 
Moderator 
B 
Moderator 
E 
C 
A-53, M 
B -20, M 
C -44, F 
D -15, F 
E - 46, F 
F - 60, M 
Vanessa Chen-Hussey - Repellent Trial Manager 
Dr Hongkham Keomanila - CMPE 
Dr Manivone - Samackixay District Hospital Staff 
Can you tell me what you do in the evenings? 
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I making fishing nets after I have eaten, probably about 8-9pm 
What time do you sleep? 
I used to stay up late talking after I put the repellent on and usually didn't 
sleep until late - around lOpm 
We prepare the food and eat, usually that would be 5 or 6pm 
People watch TV until 8pm or even later 
I always put the repellent on after eating, so probably around 6pm, then I 
watch TV before I go to sleep. 
I prepare food for everyone from 4pm and only after eating I put the 
repellent on. 
Does everyone in the village sleep at the same time? 
Most people sleep from 8pm 
But depending on the day it can be later 
What groups were sleeping late? 
Younger people like to sleep late and they like to drink and may be 
watching TV. 
Is the TV under the house or inside? 
Sometimes up and sometime underneath, since the water flood, mostly 
up now. 
What is the best way to protect mosquitoes? 
Sleeping in the bednet 
I wear the long clothes to cover the body 
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Moderator 
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When we go out to forest, the repellent was very good 
Anyth ing else? 
Sometimes we use citronella - we mix with water and put on the skin 
Another way is to make a fire when we go to the forest to protect 
mosquitoes. 
When there are lots of mosquitoes in the village, we also make fires here. 
This is especially in July during the raining season. 
Where are t he fires - inside the house? 
Near the house, outside or underneath. 
But the best way is to sleep under a net 
I always sleep under a net - I am used to it. Even in the fields, I sleep 
under a net. It is a habit. If I don't have a net I can't sleep. 
What group like to go to the filed such fo rest? 
Couples and families go to work in the fields together. 
Single people and young people do not go often - only after they are 
married. Then they go girls and boys together. 
I always used a net when I went to the forest, but not lotion. I'm not used 
to using the lotion, so my habit is only to use the net. 
Do you think malaria is a problem in this village? 
In this village, it used to be younger people like children who were sick 
with malaria : 7-10 years old 
Now, it is people in the group of 30 years old who get sick. Because they 
go to work in the forest. 
We have good medicine now in the village, you can take medicine and get 
better. 
But even now in the current situation, children still get malaria. 
Did you have any problems when you used the lotion? 
I had a headache from the smell 
How about when you went to the forest, did you use the lotion? 
There are many mosquitoes in the forest and they cannot bite if you put 
on the repellent. 
I used the repellent in the evening, in the forest and in the village 
The forest has many mosquitoes even during the day, so I use the 
repellent when I went to the forest. 
I like the lotion, it made my skin nice, so I used it all day, every day. 
E 
C 
A 
C 
Moderator 
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Although it made my legs hairy 
I still have some lotion remaining from last year and I use it everyday. 
Do you have any left -I would buy some. 
The raining season is coming soon, will the project come this year and 
give us more repellent or not? 
I need more lotion, if the project gives the lotion to the health centre I can 
buy it from there 
The project is finished now. So this year if you have a fever you should go 
to the health centre and get your blood tested and medicine. 
Focus Group Discussion #4 
Location 
Date 
Moderator 
Participants 
Others Present 
Transcript 
Leader 
E 
Leader 
Lao Yao Kao, Samackixay District, Attapeu Province, Lao PDR 
21st April 2010 
Santi Sayarath 
All took part in the trial last year and reported that they did not like using 
the lotion. 
A-39, M 
B - 39, F 
C-48, F 
D-32, M 
E - 22, F 
F -13, M 
Vanessa Chen-Hussey - Repellent Trial Manager 
Dr Hongkham Keomanila - CMPE 
Dr Manivone - Samackixay District Hospital Staff 
How often did you use the lotion last year? Did you like it, or did you not 
like it? 
I did use it 
Did you like it? 
[no answer] 
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Did you use the repellent? 
I didn't like to use it - it had a bad smell 
[Referring to young girl beside her] At the beginning she used to use 
lotion and finished one bottle. After that she felt itchy, had headaches 
and felt sick from the smell. 
The smell is not that bad, but when I use the lotion I feel sick - I had 
headaches and feel itchy. The district staff told me I should stop using 
the lotion. 
I did not have any problem with the smell but when I used the lotion I 
felt itchy 
Did you th ink the repellent smelt bad from the start 
No, just from 4-5 days 
I had allergic reaction from the first time I used it 
But after two weeks we went to the forest and she used it no problem 
Yes, I only had allergic reaction the first time I used it. Then two weeks 
later I used it again and no problems, so I used it afterward no problems 
Did you use it a lot? 
Yes very often, no problems except at first 
Do you remember which number you had? 
3051 think 
Did everyone use the repellent when they visited the forest? 
I go to the forest to collect bamboo shoots with my mum and I don't use 
the repellent when I go. 
I'm not afraid of malaria, I've never had it. 
What do you think is the best way to prevent mosquito bites? 
Sleeping under a net 
And it should have insecticide 
Is there anything else 
F 
Leader 
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Leader 
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A 
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Leader 
The repellent 
But you didn' t like the smell 
If it had a different smell, I would use it. 
What kind of smell 
Orange 
The best way is to sleep under the bednet 
A P pen d i x F 238 
You should wear the long clothes that cover the body 
Sometimes mosquitoes can bite even if you wear a long shirt. 
Thank you all very much 
